CUMULATIVE SUPPLEMENT 12
JAN'95-DEC'95



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Cumulative Supplement 12

DECEMBER 1995

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 1995

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 15th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 15th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 16th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

The Uruguay Round Agreements Act (URAA), Public Law 103-465, extended the term of patents issued on or after June 8, 1995, from 17 years from date of issue to 20 years from date of filing. Patents in effect on, or based upon applications filed by, June 8, 1995, are entitled to 17 years from date of issue or 20 years from date of filing, whichever is greater. On June 7, 1995, the Patent and Trademark Office (PTO) published a notice in the *Federal Register* (60 FR 30069) that established the method for calculating the patent term expiration date for any patent subject to both the terms of the URAA and the patent term extension provisions at title 35, U.S.C. § 156. FDA published a notice in the *Federal Register* on July 21, 1995, (60 FR 37652) announcing that it would not publish

in this publication patent expiration dates that the NDA applicant submitting the information stated were not calculated in accordance with the PTO method for determining the correct patent expiration date.

Both PTO's determination of the correct relationship between the extension of patents under the URAA and patent term extensions under title 35, U.S.C. § 156, and FDA's refusal to publish patent expiration dates that are not consistent with the PTO determination have been challenged. On October 16, 1995, the U.S. District Court for the Eastern District of Virginia issued an Opinion and Order finding that PTO had misinterpreted the Patent Code, and that PTO's determination of June 7, 1995, is invalid and unenforceable. The court ordered FDA to publish the patent dates it had, by its July 21, 1995, notice, refused to publish. Therefore, because of the court's order, and pending final resolution of appeals from the October 16, 1995, decision, FDA is publishing the patent term expiration dates that NDA applicants have told FDA are not consistent with PTO's June 7, 1995, determination. Because the district court decision may be reversed upon appeal, users of this publication should consult the most recent supplement and are encouraged to confirm that patent information upon which they intend to rely is current.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated

as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BOOTS PHARMACEUTICALS INC (BOOTS)	KNOLL PHARMACEUTICAL COMPANY SUB BASF CORPORATION (KNOLL PHARM)
BRIAN PHARMACEUTICALS INC (BRIAN)	HYGENICS PHARMACEUTICALS INC (HYGENICS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BURROUGHS WELLCOME CO (BURROUGHS WELLCOME)	GLAXO WELLCOME INC (GLAXO WELLCOME)
DORSEY LABORATORIES DIV SANDOZ WANDER INC (DORSEY)	SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS CORP (SANDOZ)
FAULDING HOSPITAL PRODUCTS INC (FAULDING)	FAULDING PHARMACEUTICAL CO (FAULDING)
GLAXO INC (GLAXO)	GLAXO WELLCOME INC (GLAXO WELLCOME)
MARION MERRELL DOW INC (MARION MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MERRELL DOW PHARMACEUTICALS INC SUB DOW CHEMICAL CO (MERRELL DOW)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
MILES PHARMACEUTICAL DIV MILES INC (MILES)	BAYER CORPORATION (BAYER)
PENNEX PHARMACEUTICALS INC (PENNEX)	MORTON GROVE PHARMACEUTICALS INC (MORTON GROVE)
TAP PHARMACEUTICALS INC (TAP PHARMS)	TAP HOLDINGS INC (TAP HOLDINGS)

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1994) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1994	JUN 1995	SEP 1995	DEC 1995
DRUG PRODUCTS LISTED	9141	9221	9221	9286
SINGLE SOURCE	2178 (23.8%)	2186 (23.7%)	2168 (23.5%)	2217 (23.9%)
MULTISOURCE	6963 (76.2%)	7035 (76.3%)	7053 (76.5%)	7069 (76.1%)
THERAPEUTICALLY EQUIVALENT	6330 (69.2%)	6399 (69.4%)	6427 (69.7%)	6437 (69.3%)
NOT THERAPEUTICALLY EQUIVALENT	453 (5.0%)	452 (4.9%)	444 (4.8%)	440 (4.7%)
EXCEPTIONS[1]	180 (2.0%)	184 (2.0%)	182 (2.0%)	192 (2.1%)
NEW MOLECULAR ENTITIES APPROVED	--	10	6	14
NUMBER OF APPLICANTS	534	559	553	586

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACARBOSE

TABLET; ORAL

PRECOSE

	BAYER	50MG	N20482 001	SEP 06, 1995
+		100MG	N20482 002	SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HCL

AB	MYLAN	EQ 200MG BASE	N74288 001	APR 24, 1995
AB		EQ 400MG BASE	N74288 002	APR 24, 1995
AB	WATSON LABS	EQ 200MG BASE	N74007 001	OCT 18, 1995
AB		EQ 400MG BASE	N74007 002	OCT 18, 1995

SECTRAL

AB	WYETH AYERST	EQ 200MG BASE	N18917 001	DEC 28, 1984
AB +		EQ 400MG BASE	N18917 003	DEC 28, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	WEST WARD PHARM	325MG;50MG;40MG	N89718 001	JUN 12, 1995

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	BARRE	120MG/5ML;12MG/5ML	N85861 001	

APAP W/ CODEINE

AA	BARRE	120MG/5ML;12MG/5ML	N85861 001	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	KV PHARM	300MG;30MG	N85288 001	
AA		300MG;60MG	N85365 001	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	KV PHARM	325MG;15MG	N85364 001	
		325MG;45MG	N85363 001	
@		300MG;30MG	N85288 001	
@		300MG;60MG	N85365 001	
@		325MG;15MG	N85364 001	
@		325MG;45MG	N85363 001	
AA	LEMMON	300MG;15MG	N88627 001	MAR 06, 1985
AA		300MG;30MG	N88628 001	MAR 06, 1985
AA		300MG;60MG	N88629 001	MAR 06, 1985
AA	MIKART	650MG;30MG	N89231 001	MAR 03, 1986
+		650MG;30MG	N89231 001	MAR 03, 1986
+	ROXANE	500MG;15MG	N89511 001	APR 25, 1989
+		500MG;30MG	N89512 001	APR 25, 1989
+		500MG;60MG	N89513 001	APR 25, 1989
@		500MG;15MG	N89511 001	APR 25, 1989
@		500MG;30MG	N89512 001	APR 25, 1989
@		500MG;60MG	N89513 001	APR 25, 1989

ACETAMINOPHEN W/ CODEINE #2

AA	LEMMON	300MG;15MG	N88627 001	MAR 06, 1985

ACETAMINOPHEN W/ CODEINE #3

AA	LEMMON	300MG;30MG	N88628 001	MAR 06, 1985

ACETAMINOPHEN W/ CODEINE #4

AA	LEMMON	300MG;60MG	N88629 001	MAR 06, 1985

PHENAPHEN-650 W/ CODEINE

AA	+ ROBINS AH	650MG;30MG	N85856 001	
	@	650MG;30MG	N85856 001	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
	MIKART	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
		500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992
+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
+		500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992

TABLET; ORAL

	ANEXSIA			
AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001	APR 23, 1987
AA	KING PHARMS	500MG;5MG	N89160 001	APR 23, 1987
	ANEXSIA 7.5/650			
AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001	SEP 30, 1987
AA	KING PHARMS	650MG;7.5MG	N89725 001	SEP 30, 1987
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	HALSEY	500MG;5MG	N89554 001	JUN 12, 1987
@		500MG;5MG	N89554 001	JUN 12, 1987
AA	KING PHARMS	500MG;5MG	N40084 002	JUN 01, 1995
AA		750MG;7.5MG	N40084 001	JUN 01, 1995
AA	+ MIKART	650MG;10MG	N81223 001	MAY 29, 1992
AA	WATSON LABS	650MG;7.5MG	N40094 001	SEP 29, 1995
AA		650MG;10MG	N40094 002	SEP 29, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	ROXILOX			
AA	ROXANE	500MG;5MG	N40061 001	JUL 03, 1995

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	OXYCET			
AA	HALSEY	325MG;5MG	N87463 001	DEC 07, 1983
AA	MALLINCKRODT	325MG;5MG	N87463 001	DEC 07, 1983

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX			
+	STORZ OPHTHALM	500MG	N12945 001	
@		500MG	N12945 001	
+		500MG	N12945 003	APR 25, 1995

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
AP	SANOFI WINTHROP	EQ 500MG BASE/VIAL	N40108 001	OCT 30, 1995
	DIAMOX			
AP	+ STORZ OPHTHALM	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	DUPONT MERCK	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	FAULDING	10%	N71364 001	MAY 01, 1989
AN		20%	N71365 001	MAY 01, 1989
AN	LUITPOLD	10%	N72489 001	JUL 28, 1995
AN		20%	N72547 001	JUL 28, 1995

ADENOSINE

INJECTABLE; INJECTION
ADENOSCAN
+ MEDCO RES — 3MG/ML — N20059 001 MAY 18, 1995

ALBUTEROL

AEROSOL, METERED; INHALATION
> ADD > **ALBUTEROL**
> ADD > **AB** NORTON WATERFORD — **0.09MG/INH** — **N73272 001** DEC 28, 1995
> ADD > **VENTOLIN**
> DLT > ~~EN + GLAXO — 0.09MG/INH — N18473 001~~
> ADD > **AB** + GLAXO WELLCOME — **0.09MG/INH** — **N18473 001**

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
> ADD > **AN** BARRE — **EQ 0.083% BASE** — **N73533 001** SEP 26, 1995
> DLT > ~~AN PACO — EQ 0.083% BASE — N73533 001 SEP 26, 1995~~

SYRUP; ORAL
ALBUTEROL SULFATE
AA BARRE — **EQ 2MG BASE/5ML** — **N74454 001** SEP 25, 1995

ALENDRONATE SODIUM

TABLET; ORAL
FOSAMAX
MERCK — EQ 10MG BASE — N20560 001 SEP 29, 1995
+ — EQ 40MG BASE — N20560 002 SEP 29, 1995

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
AB CHELSEA LABS — **0.25MG** — **N74456 001** AUG 31, 1995

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM
AB CHELSEA LABS — **0.5MG** — **N74456 002** AUG 31, 1995
AB — **1MG** — **N74456 003** AUG 31, 1995
> ADD > **AB** GENEVA PHARMS — **0.25MG** — **N74112 001** DEC 29, 1995
> ADD > **AB** — **0.5MG** — **N74112 002** DEC 29, 1995
> ADD > **AB** — **1MG** — **N74112 003** DEC 29, 1995

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT
UPJOHN — 0.01MG/VIAL — N20379 001 JUL 06, 1995
+ — 0.02MG/VIAL — N20379 002 JUL 06, 1995

ALSEROXYLON

~~TABLET; ORAL~~
~~RAUWILOID~~
~~+ 3M — 2MG — N08867 001~~
@ — 2MG — N08867 001

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL
AA PHARM ASSOC — **50MG/5ML** — **N74509 001** JUL 17, 1995

> ADD > AMIFOSTINE

> ADD > INJECTABLE; INJECTION
> ADD > ETHYOL
> ADD > + US BIOSCIENCE — 500MG/VIAL — N20221 001 DEC 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

		AMIKACIN			
	AP	DUPONT MERCK	EQ 50MG BASE/ML	N63350 001	JUL 30, 1993
	AP		EQ 250MG BASE/ML	N63350 002	JUL 30, 1993
	AP	+ ELKINS SINN	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
	AP	+	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992
		AMIKACIN SULFATE			
> ADD >	AP	ASTRA	EQ 50MG BASE/ML	N63167 001	DEC 14, 1995
> ADD >	AP		EQ 250MG BASE/ML	N63169 001	DEC 14, 1995
> ADD >	AP	ELKINS SINN	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
	AP		EQ 250MG BASE/ML	N63275 001	MAY 18, 1992
	AP	FAULDING	EQ 50MG BASE/ML	N63350 001	JUL 30, 1993
	AP		EQ 250MG BASE/ML	N63350 002	JUL 30, 1993
	AP	SANOFI WINTHROP	EQ 250MG BASE/ML	N64098 001	JUN 26, 1995
	AP		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995
		AMIKIN			
	AP	APOTHECON	EQ 50MG BASE/ML	N62311 001	
	AP	+	EQ 50MG BASE/ML	N62311 001	
	AP		EQ 250MG BASE/ML	N62311 002	
	AP	+	EQ 250MG BASE/ML	N62311 002	
		@	EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
		@	EQ 250MG BASE/ML	N62562 002	SEP 20, 1984
		@ BRISTOL	EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
		@	EQ 250MG BASE/ML	N62562 002	SEP 20, 1984
		AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
		@ APOTHECON	EQ 5MG BASE/ML	N50618 002	NOV 30, 1987
		@	EQ 10MG BASE/ML	N50618 001	NOV 30, 1987
		@ BRISTOL	EQ 5MG BASE/ML	N50618 002	NOV 30, 1987

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ BRISTOL	EQ 10MG BASE/ML	N50618 001	NOV 30, 1987

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER	2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 002	OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER	2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 003	OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER	2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 004	OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER	2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 005	OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER	2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML	N20147 001	OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER	4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML	N20147 007	OCT 23, 1995

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER 4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 008 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER 4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 009 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER 4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER 4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML N20147 006 OCT 23, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N20177 001 OCT 23, 1995

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N20173 001 OCT 27, 1995

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N20173 002 OCT 27, 1995

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	FUJISAWA	25MG/ML	N87200 001
AP		25MG/ML	N88407 001
			JAN 25, 1984
@		25MG/ML	N87200 001
@		25MG/ML	N88407 001
			JAN 25, 1984
AP	KING PHARMS	25MG/ML	N86606 001
@		25MG/ML	N86606 001

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

	ABBOTT	100MG/100ML	N88147 002
			MAY 03, 1983
		200MG/100ML	N88147 003
			MAY 03, 1982
+		100MG/100ML	N88147 002
			MAY 03, 1983
+		200MG/100ML	N88147 003
			MAY 03, 1983

TABLET; ORAL
AMINOPHYLLINE

BD	PHOENIX LABS NY	100MG	N85409 001
BD		200MG	N85410 001
@		100MG	N85409 001
@		200MG	N85410 001

AMINOSALICYLATE SODIUM

POWDER; ORAL
P.A.S. SODIUM

AA	CENTURY PHARMS	4GM/PACKET	N80947 001
@		4GM/PACKET	N80947 001

SODIUM AMINOSALICYLATE

AA	HEXCEL	100%	N80097 001
@		100%	N80097 001

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL
NEOPASALATE

+	WALLACE	846MG;112MG	N80059 002
@		846MG;112MG	N80059 002

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
CORDARONE
+ WYETH AYERST — 50MG/ML — N20377 001 AUG 03, 1995

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
AB ROXANE — 150MG — N86090 001
@ — 150MG — N86090 001

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL
CIBA GEIGY — EQ 2.5MG BASE;10MG — N20364 002 MAR 03, 1995
EQ 5MG BASE;10MG — N20364 003 MAR 03, 1995 > ADD >
+ EQ 5MG BASE;20MG — N20364 004 MAR 03, 1995 > ADD >

AMMONIUM LACTATE

LOTION; TOPICAL
LAC-HYDRIN
> DLT > > DLT > > ADD > > ADD > + WESTWOOD SQUIBB — EQ 12% ACID — N19155 001 APR 24, 1985
+ EQ 12% BASE — N19155 001 APR 24, 1985

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN
AB CONSOLIDATED PHARM — 250MG — N62058 001
AB — 500MG — N62058 002
COMOX
AB COPANOS — 250MG — N62058 001
AB — 500MG — N62058 002
POLYMOX
AB APOTHECON — 250MG — N63099 001 MAR 20, 1992 > DLT > > DLT >

AMOXICILLIN

CAPSULE; ORAL
POLYMOX
AB APOTHECON — 500MG — N63099 002 MAR 20, 1992
TRIMOX
AB APOTHECON — 250MG — N63099 001 MAR 20, 1992
AB — 500MG — N63099 002 MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL
AMOXICILLIN
AB CONSOLIDATED PHARM — 125MG/5ML — N62059 001
AB — 250MG/5ML — N62059 002
AMOXICILLIN TRIHYDRATE
AB COPANOS — 125MG/5ML — N62059 001
AB — 250MG/5ML — N62059 002

TABLET, CHEWABLE; ORAL
AMOXICILLIN
AB BIOCRAFT — 125MG — N64013 002 SEP 11, 1995 > ADD >
AMOXIL
AB + SMITHKLINE BEECHAM — 125MG — N50542 002

AMOXICILLIN; CLAVULANATE POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
AUGMENTIN '125'
+ SMITHKLINE BEECHAM — 125MG/5ML; EQ 31.25MG ACID/5ML — N50575 001 AUG 06, 1984 > DLT > > DLT > > ADD > > ADD >
+ 125MG/5ML; EQ 31.25MG BASE/5ML — N50575 001 AUG 06, 1984 > ADD > > ADD >
AUGMENTIN '250'
+ SMITHKLINE BEECHAM — 250MG/5ML; EQ 62.5MG ACID/5ML — N50575 002 AUG 06, 1984 > DLT > > DLT > > DLT >
+ 250MG/5ML; EQ 62.5MG BASE/5ML — N50575 002 AUG 06, 1984 > ADD > > ADD > > ADD >

TABLET; ORAL
AUGMENTIN '250'
+ SMITHKLINE BEECHAM — 250MG,EQ 125MG ACID — N50564 001 AUG 06, 1984 > DLT > > DLT >

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL
AUGMENTIN '250'

> ADD >	+	SMITHKLINE BEECHAM	250MG;EQ 125MG BASE	N50564 001 AUG 06, 1984
> ADD >				

AUGMENTIN '500'

> DLT >	+	SMITHKLINE BEECHAM	500MG;EQ 125MG ACID	N50564 002 AUG 06, 1984
> DLT >				
> ADD >	+		500MG;EQ 125MG BASE	N50564 002 AUG 06, 1984
> ADD >				

TABLET, CHEWABLE; ORAL
AUGMENTIN '125'

> DLT >	+	SMITHKLINE BEECHAM	125MG;EQ 31.25MG ACID	N50597 001 JUL 22, 1985
> DLT >				
> ADD >	+		125MG;EQ 31.25MG BASE	N50597 001 JUL 22, 1985
> ADD >				

AUGMENTIN '250'

> DLT >	+	SMITHKLINE BEECHAM	250MG;EQ 62.5MG ACID	N50597 002 JUL 22, 1985
> DLT >				
> ADD >	+		250MG;EQ 62.5MG BASE	N50597 002 JUL 22, 1985
> ADD >				

AMPHOTERICIN B

INJECTABLE; INJECTION
ABELCET

> DLT >	+	LIPOSOME	5MG/ML	N50724 001 NOV 20, 1995
> DLT >				

AMPHOTERICIN B

AP	GENSIA	50MG/VIAL	N64062 001 MAR 31, 1995

INJECTABLE, LIPID COMPLEX; INJECTION
ABELCET

> ADD >	+	LIPOSOME	5MG/ML	N50724 001 NOV 20, 1995
> ADD >				

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001 FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	APOTHECON	EQ 250MG BASE/VIAL	N62860 002 FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003 FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001 FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004 FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002 FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005 FEB 05, 1988
AP	+	EQ 10GM BASE/VIAL	N61395 006
	@ CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	N61936 005
	@	EQ 250MG BASE/VIAL	N61936 001
	@	EQ 500MG BASE/VIAL	N61936 002
	@	EQ 1GM BASE/VIAL	N61936 003
	@	EQ 2GM BASE/VIAL	N61936 004
	@ COPANOS	EQ 125MG BASE/VIAL	N61936 005
	@	EQ 250MG BASE/VIAL	N61936 001
	@	EQ 500MG BASE/VIAL	N61936 002
	@	EQ 1GM BASE/VIAL	N61936 003
	@	EQ 2GM BASE/VIAL	N61936 004
	PRINCIPEN		
AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001 FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002
AP		EQ 250MG BASE/VIAL	N62860 002 FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003 FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001 FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004 FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002 FEB 19, 1987

AMPICILLIN SODIUM

INJECTABLE; INJECTION

	PRINCIPEN			
AP	APOTHECON	EQ 2GM BASE/VIAL	N62860 005	
			FEB 05, 1988	
AP	+	EQ 10GM BASE/VIAL	N61395 006	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN TRIHYDRATE			
AB	BIOCHEMIE	EQ 250MG BASE	N64082 001	
			AUG 29, 1995	
AB		EQ 500MG BASE	N64082 002	
			AUG 29, 1995	
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	
AB	COPANOS	EQ 250MG BASE	N61602 001	
AB		EQ 500MG BASE	N61602 002	

POWDER FOR RECONSTITUTION; ORAL

	AMPICILLIN TRIHYDRATE			
AB	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
AB	COPANOS	EQ 125MG BASE/5ML	N61601 001	
AB		EQ 250MG BASE/5ML	N61601 002	
	POLYCILLIN			
AB	+ BRISTOL	EQ 125MG BASE/5ML	N50308 001	
AB	+	EQ 250MG BASE/5ML	N50308 002	
	+	EQ 500MG BASE/5ML	N50308 003	
	@	EQ 125MG BASE/5ML	N50308 001	
	@	EQ 250MG BASE/5ML	N50308 002	
	@	EQ 500MG BASE/5ML	N50308 003	

> ADD > ANASTROZOLE

> ADD > TABLET; ORAL

> ADD >	ARIMIDEX			
> ADD >	+ ZENECA	1MG	N20541 001	
> ADD >			DEC 27, 1995	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	VASOCON-A			
+	CIBA VISION	0.5%;0.05%	N18746 001	
			APR 30, 1990	

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE			
AB	WATSON LABS	325MG;50MG;40MG;30MG	N74359 001	
			AUG 31, 1995	
	FIORINAL W/CODEINE NO 3			
AB	+ SANDOZ	325MG;50MG;40MG;30MG	N19429 003	
			OCT 26, 1990	

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
AB	STEVENS J	325MG;400MG	N81145 001	
			JAN 31, 1995	

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	COPLEY PHARM	50MG	N74120 001	
			FEB 24, 1995	
AB		100MG	N74120 002	
			FEB 24, 1995	
AB	LEMMON	50MG	N74056 001	
			JAN 18, 1995	
AB		100MG	N74056 002	
			JAN 18, 1995	
AB	MARTEC	50MG	N74127 001	
			FEB 21, 1995	
AB		100MG	N74127 002	
			FEB 21, 1995	

ATOVAQUONE

SUSPENSION; ORAL
MEPRON
+ GLAXO WELLCOME 750MG/5ML N20500 001 FEB 08, 1995

ATROPINE

INJECTABLE; INJECTION
ATROPEN
AP + SURVIVAL TECH EQ 2MG SULFATE/0.7ML N17106 001
+ EQ 2MG SULFATE/0.7ML N17106 001
ATROPINE
AP KALI DUPHAR EQ 2MG SULFATE/0.7ML N71295 001 JAN 30, 1987
@ SOLVAY EQ 2MG SULFATE/0.7ML N71295 001 JAN 30, 1987

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DI-ATRO
AA MD PHARM 0.025MG;2.5MG N85266 001
@ 0.025MG;2.5MG N85266 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE SODIUM
AP BEDFORD EQ 100MG BASE/VIAL N74419 001 MAR 31, 1995
IMURAN
AP + GLAXO WELLCOME EQ 100MG BASE/VIAL N17391 001

AZELAIC ACID

CREAM; TOPICAL
AZELEX
+ ALLERGAN 20% N20428 001 SEP 13, 1995

AZITHROMYCIN DIHYDRATE

POWDER FOR RECONSTITUTION; ORAL
ZITHROMAX
+ PFIZER EQ 100MG BASE/5ML N50710 001 OCT 19, 1995
+ EQ 200MG BASE/5ML N50710 002 OCT 19, 1995

BACITRACIN

INJECTABLE; INJECTION
BACITRACIN
AP + PFIZER 50,000 UNITS/VIAL N60282 001
@ 50,000 UNITS/VIAL N60282 001
AP UPJOHN 50,000 UNITS/VIAL N60733 002
+ 50,000 UNITS/VIAL N60733 002

POWDER; FOR RX COMPOUNDING
BACITRACIN
> ADD > AA APOTHEKERNES 5,000,000 UNITS/BOT N61699 001
> DLT > AA BRAE 5,000,000 UNITS/BOT N61699 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN
AT + GLAXO WELLCOME 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50416 002
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE
AT BAUSCH AND LOMB 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N64068 001 OCT 30, 1995

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
AT BAUSCH AND LOMB 400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N64064 001 OCT 30, 1995

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN ZINC AND POLYMYXIN B SULFATE			
AT	ADV REMEDIES	500 UNITS/GM; 10,000 UNITS/GM	N64028 001	JAN 30, 1995
AT	BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001	JAN 26, 1995
	POLYSPORIN			
AT	+ GLAXO WELLCOME	500 UNITS/GM; 10,000 UNITS/GM	N61229 001	

BENDROFLUMETHIAZIDE

TABLET; ORAL

	NATURETIN-10		
	+ APOTHECON	10MG	N12164 003
	+ SQUIBB	10MG	N12164 003
	NATURETIN-2.5		
	@ APOTHECON	2.5MG	N12164 001
	@ SQUIBB	2.5MG	N12164 001
	NATURETIN-5		
	APOTHECON	5MG	N12164 002
	SQUIBB	5MG	N12164 002

BENTONITE; SULFUR

POWDER; TOPICAL

	BENSULFOID		
	@ POYTHRESS	66.64%;33.32%	N02918 001

BETAMETHASONE BENZOATE

GEL; TOPICAL

	UTICORT		
	+ PARKE DAVIS	0.025%	N17244 001
	@	0.025%	N17244 001

LOTION; TOPICAL

	UTICORT		
	+ PARKE DAVIS	0.025%	N17528 001
	@	0.025%	N17528 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	NMC	EQ 0.05% BASE	N74304 001	AUG 31, 1995
	DIPROLENE			
AB	+ SCHERING	EQ 0.05% BASE	N18741 001	JUL 27, 1983

BICALUTAMIDE

TABLET; ORAL

	CASODEX		
	+ ZENECA	50MG	N20498 001 OCT 04, 1995

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLOL			
AP	DUPONT MERCK	50MG/ML	N17954 001	
AP	FAULDING	50MG/ML	N17954 001	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	DIMETANE-DC			
AA	ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006	MAR 29, 1984
AA	+	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006	MAR 29, 1984

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	BEDFORD	0.25MG/ML	N74441 001	JAN 27, 1995

TABLET; ORAL

	BUMETANIDE			
AB	ZENITH LABS	0.5MG	N74225 001	APR 24, 1995

BUMETANIDE

TABLET; ORAL

		BUMETANIDE			
AB		ZENITH LABS	1MG	N74225 002	
				APR 24, 1995	
AB			2MG	N74225 003	
				APR 24, 1995	
		BUMEX			
AB		ROCHE	0.5MG	N18225 002	
				FEB 28, 1983	
AB			1MG	N18225 001	
				FEB 28, 1983	
AB	+		2MG	N18225 003	
				JUN 14, 1985	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

		MARCAINE HCL		
AP	+	SANOFI WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+	STERLING WINTHROP	0.25%	N16964 001
AP	+		0.5%	N16964 006
AP	+		0.75%	N16964 009
		MARCAINE HCL PRESERVATIVE FREE		
AP	+	SANOFI WINTHROP	0.25%	N16964 012
AP	+		0.5%	N16964 005
AP	+		0.75%	N16964 009

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

		MARCAINE HCL W/ EPINEPHRINE		
AP	+	SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+	STERLING WINTHROP	0.25%;0.0091MG/ML	N16964 004
AP	+		0.5%;0.0091MG/ML	N16964 008
AP	+		0.75%;0.0091MG/ML	N16964 010
		MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE		
AP	+	SANOFI WINTHROP	0.25%;0.0091MG/ML	N16964 013
AP	+		0.5%;0.0091MG/ML	N16964 007
AP	+		0.75%;0.0091MG/ML	N16964 010

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

		STADOL		
+		APOTHECON	1MG/ML	N17857 001
+			2MG/ML	N17857 002
+			2MG/ML	N17857 004
		STADOL PRESERVATIVE FREE		
+		APOTHECON	1MG/ML	N17857 001
+			2MG/ML	N17857 002

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

		CAPERGOT		
AA	+	SANDOZ	100MG;1MG	N06620 001
	@		100MG;1MG	N06620 001
		ERCATAB		
AA		GENEVA PHARMS	100MG;1MG	N84294 001
AA	+		100MG;1MG	N84294 001

CALCITONIN, SALMON

INJECTABLE; INJECTION

		CALCITONIN-SALMON		
AP		ASTRA	200 IU/ML	N73690 001
				APR 14, 1995

SPRAY, METERED; NASAL

		MIACALCIN		
	+	SANDOZ	200 IU/INH	N20313 002
				AUG 17, 1995

CAPTOPRIL

TABLET; ORAL

		CAPOTEN		
AB		BRISTOL MYERS SQUIBB	12.5MG	N18343 005
				JAN 17, 1985
AB	+		25MG	N18343 002
AB			50MG	N18343 001
AB			100MG	N18343 003
	+		150MG	N18343 004
> ADD >				JUN 13, 1995
> ADD >			75MG	N18343 007
> ADD >				JUN 13, 1995

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	APOTHECON	12.5MG	N74472 001	> DLT >	
			MAR 31, 1995	> DLT >	
AB		25MG	N74472 002	> ADD >	
			MAR 31, 1995	> ADD >	
AB		50MG	N74472 003		
			MAR 31, 1995		
AB		100MG	N74472 004		
			MAR 31, 1995		
AB	GENEVA PHARMS	12.5MG	N74363 001		
			NOV 09, 1995		
AB		25MG	N74363 002		
			NOV 09, 1995		
AB		50MG	N74363 003	> DLT >	
			NOV 09, 1995	> ADD >	
AB		100MG	N74363 004		
			NOV 09, 1995		

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPOZIDE 25/25

	SQUIBB	25MG;25MG	N18709 002
			OCT 12, 1984
+		25MG;25MG	N18709 002
			OCT 12, 1984

CAPOZIDE 50/15

	SQUIBB	50MG;15MG	N18709 004
			OCT 12, 1984
+		50MG;15MG	N18709 004
			OCT 12, 1984

CAPOZIDE 50/25

+	SQUIBB	50MG;25MG	N18709 003
			OCT 12, 1984
		50MG;25MG	N18709 003
			OCT 12, 1984

CARBACHOL

SOLUTION; INTRAOCULAR
CARBASTAT

AT	CIBA	0.01%	N73677 001
			APR 28, 1995

MIOSTAT

AT	+ ALCON	0.01%	N16968 001

CARBAMAZEPINE

SUSPENSION; ORAL
TEGRETOL

	+	BASEL PHARMS	100MG/5ML	N18927 001	
				DEC 18, 1987	
	+	CIBA GEIGY	100MG/5ML	N18927 001	
				DEC 18, 1987	

TABLET; ORAL
TEGRETOL

AB	+	BASEL PHARMS	200MG	N16608 001
AB	+	CIBA GEIGY	200MG	N16608 001

TABLET, CHEWABLE; ORAL
TEGRETOL

AB	+	BASEL PHARMS	100MG	N18281 001
AB	+	CIBA GEIGY	100MG	N18281 001

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	GENEVA PHARMS	10MG;100MG	N73586 001
			JUN 29, 1995
AB		25MG;100MG	N73587 001
			JUN 29, 1995
AB		25MG;250MG	N73620 001
			JUN 29, 1995

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

+	OTSUKA	1%	N19972 001
			MAY 23, 1990

OPTIPRESS

+	OTSUKA	1%	N19972 001
			MAY 23, 1990

CARVEDILOL

TABLET; ORAL
COREG

	SMITHKLINE BEECHAM	6.25MG	N20297 003
			SEP 14, 1995

CARVEDILOL

TABLET; ORAL
COREG

	SMITHKLINE BEECHAM	12.5MG	N20297 002 SEP 14, 1995		
+		25MG	N20297 001 SEP 14, 1995		

CEFACLOR

CAPSULE; ORAL
CECLOR

AB	+ LILLY	EQ 250MG BASE	N50521 001		
AB		EQ 250MG BASE	N62205 001		
AB	+	EQ 500MG BASE	N50521 002		
AB		EQ 500MG BASE	N62205 002		

CEFACLOR

AB	LEDERLE	EQ 250MG BASE	N64107 001 APR 27, 1995		
AB		EQ 500MG BASE	N64107 002 APR 27, 1995		
AB	ZENITH LABS	EQ 250MG BASE	N64061 001 APR 27, 1995	> DLT >	
AB		EQ 500MG BASE	N64061 002 APR 27, 1995	> ADD >	

POWDER FOR RECONSTITUTION; ORAL
CECLOR

AB	+ LILLY	EQ 125MG BASE/5ML	N50522 001		
AB		EQ 125MG BASE/5ML	N62206 001		
AB	+	EQ 187MG BASE/5ML	N62206 003 APR 20, 1988		
AB	+	EQ 250MG BASE/5ML	N50522 002		
AB		EQ 250MG BASE/5ML	N62206 002		
AB	+	EQ 375MG BASE/5ML	N62206 004 APR 20, 1988		

CEFACLOR

AB	LEDERLE	EQ 125MG BASE/5ML	N64114 001 APR 28, 1995		
AB		EQ 187MG BASE/5ML	N64115 001 APR 28, 1995		
AB		EQ 250MG BASE/5ML	N64116 001 APR 28, 1995		
AB		EQ 375MG BASE/5ML	N64110 001 APR 28, 1995		
AB	ZENITH LABS	EQ 125MG BASE/5ML	N64087 001 APR 28, 1995		

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL
CEFACLOR

AB	ZENITH LABS	EQ 187MG BASE/5ML	N64086 001 APR 28, 1995		
AB		EQ 250MG BASE/5ML	N64085 001 APR 28, 1995		
AB		EQ 375MG BASE/5ML	N64070 001 APR 28, 1995		

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL

+	LILLY	EQ 500MG BASE/VIAL	N50504 001		
@		EQ 500MG BASE/VIAL	N50504 001		

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF

AP	+ SMITHKLINE BEECHAM	EQ 250MG BASE/VIAL	N50461 001		
@		EQ 250MG BASE/VIAL	N50461 001		

CEFAZOLIN SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001 DEC 09, 1988		
AP		EQ 1GM BASE/VIAL	N62831 002 DEC 09, 1988		
AP		EQ 10GM BASE/VIAL	N62831 003 SEP 25, 1992		
AP	ELKINS SINN	EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988		
AP		EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988		
AP		EQ 1GM BASE/VIAL	N62807 003 JAN 12, 1988		
AP		EQ 5GM BASE/VIAL	N62807 004 JAN 12, 1988		
AP		EQ 10GM BASE/VIAL	N62807 005 JAN 12, 1988		
AP		EQ 20GM BASE/VIAL	N62807 006 JAN 12, 1988		
@		EQ 250MG BASE/VIAL	N62807 001 JAN 12, 1988		
@		EQ 500MG BASE/VIAL	N62807 002 JAN 12, 1988		

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

		@ ELKINS SINN	EQ 1GM BASE/VIAL	N62807 003	JAN 12, 1988
		@	EQ 5GM BASE/VIAL	N62807 004	JAN 12, 1988
		@	EQ 10GM BASE/VIAL	N62807 005	JAN 12, 1988
		@	EQ 20GM BASE/VIAL	N62807 006	JAN 12, 1988
		KEFZOL			
> DLT >	AP	LILLY	EQ 250MG BASE/VIAL	N61773 001	
> ADD >	AP	+	EQ 250MG BASE/VIAL	N61773 001	
> DLT >	AP		EQ 20GM BASE/VIAL	N61773 005	
> DLT >					SEP 08, 1987
> ADD >	AP	+	EQ 20GM BASE/VIAL	N61773 005	
> ADD >					SEP 08, 1987
		ZOLICEF			
	AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001	
					DEC 09, 1988
	AP		EQ 1GM BASE/VIAL	N62831 002	
					DEC 09, 1988
	AP		EQ 10GM BASE/VIAL	N62831 003	
					SEP 25, 1992

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

	PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995
		EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

	APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984
		1GM/VIAL	N62579 002	NOV 26, 1984
		2GM/VIAL	N62579 003	NOV 26, 1984

CEFORANIDE

INJECTABLE; INJECTION
PRECEF

	APOTHECON	10GM/VIAL	N62579 004	NOV 26, 1984
		20GM/VIAL	N62579 005	NOV 26, 1984
	BRISTOL	500MG/VIAL	N62579 001	NOV 26, 1984
		1GM/VIAL	N62579 002	NOV 26, 1984
		2GM/VIAL	N62579 003	NOV 26, 1984
		10GM/VIAL	N62579 004	NOV 26, 1984
		20GM/VIAL	N62579 005	NOV 26, 1984

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MERCK SHARP DOHME	EQ 20MG BASE/ML	N50581 002	SEP 20, 1984
+		EQ 40MG BASE/ML	N50581 001	SEP 20, 1984
	@	EQ 20MG BASE/ML	N50581 002	SEP 20, 1984
	@	EQ 40MG BASE/ML	N50581 001	SEP 20, 1984

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
PENTACEF

AP	SMITHKLINE BEECHAM	1GM/VIAL	N63322 001	NOV 07, 1995
AP		2GM/VIAL	N63322 002	NOV 07, 1995

> ADD > CEFTIBUTEN DIHYDRATE

> ADD > CAPSULE; ORAL
> ADD > CEDAX
> ADD > + SCHERING PLOUGH EQ 400MG BASE N50685 002 DEC 20, 1995
> ADD >

> ADD > CEFTIBUTEN DIHYDRATE

> ADD > POWDER FOR RECONSTITUTION; ORAL
> ADD > CEDAX
> ADD > + SCHERING PLOUGH EQ 90MG BASE/5ML N50686 001 DEC 20, 1995
> ADD >
> ADD > + EQ 180MG BASE/5ML N50686 002 DEC 20, 1995
> ADD >

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN
AP + ROCHE EQ 250MG BASE/VIAL N50585 001 DEC 21, 1984
AP + EQ 500MG BASE/VIAL N50585 002 DEC 21, 1984
AP + EQ 1GM BASE/VIAL N50585 003 DEC 21, 1984
+ EQ 250MG BASE/VIAL N50585 001 DEC 21, 1984
+ EQ 500MG BASE/VIAL N50585 002 DEC 21, 1984
+ EQ 1GM BASE/VIAL N50585 003 DEC 21, 1984

CEFUROXIME SODIUM

INJECTABLE; INJECTION
KEFUROX
AP + LILLY EQ 7.5GM BASE/VIAL N62591 003 DEC 17, 1987
AP EQ 7.5GM BASE/VIAL N62591 003 DEC 17, 1987

ZINACEF
AP GLAXO EQ 7.5GM BASE/VIAL N50558 004 OCT 23, 1986
AP + GLAXO WELLCOME EQ 7.5GM BASE/VIAL N50558 004 OCT 23, 1986

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN
AB APOTHECON EQ 125MG BASE/5ML N62986 001 APR 18, 1991

> ADD > CETIRIZINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ZYRTEC
> ADD > PFIZER 5MG N19835 001 DEC 08, 1995
> ADD >

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN
AB APOTHECON EQ 250MG BASE/5ML N62987 001 JUL 25, 1989
AB SQUIBB MARK EQ 125MG BASE/5ML N62986 001 APR 18, 1991
AB EQ 250MG BASE/5ML N62987 001 JUL 25, 1989

CEPHRADINE

CAPSULE; ORAL
VELOSEF
AB + APOTHECON 250MG N61764 001
AB + 500MG N61764 002
AB + ERSANA 250MG N61764 001
AB + 500MG N61764 002

INJECTABLE; INJECTION
VELOSEF
> DLT > + APOTHECON 250MG/VIAL N61976 001
> DLT > + 500MG/VIAL N61976 002
> DLT > + 1GM/VIAL N61976 004
> DLT > + 2GM/VIAL N61976 003
> DLT > + 4GM/VIAL N61976 005
> ADD > @ 250MG/VIAL N61976 001
> ADD > @ 500MG/VIAL N61976 002
> ADD > @ 1GM/VIAL N61976 004
> ADD > @ 2GM/VIAL N61976 003
> ADD > @ 4GM/VIAL N61976 005

POWDER FOR RECONSTITUTION; ORAL
VELOSEF '125'
AB + APOTHECON 125MG/5ML N61763 001
AB + ERSANA 125MG/5ML N61763 001
VELOSEF '250'
AB + APOTHECON 250MG/5ML N61763 002
AB + ERSANA 250MG/5ML N61763 002

> ADD > CETIRIZINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ZYRTEC
> ADD > + PFIZER 10MG N19835 002
> ADD > DEC 08, 1995

CHLORAMPHENICOL

CAPSULE; ORAL
> DLT > AMPHICOL
> ADD > @ FERRANTE 100MG N60058 001
> ADD > @ 250MG N60058 002
> DLT > AB MK LABS 100MG N60058 001
> DLT > AB 250MG N60058 002

CHLOROMYCETIN
> DLT > AB + PARKE DAVIS 100MG N60591 003
> ADD > + 100MG N60591 003

MYCHEL
AB ARMENPHARM 250MG N60851 001
AB RACHELLE 250MG N60851 001

SOLUTION/DROPS; OPHTHALMIC
OPTOMYCIN
AT OPTOPICS 0.5% N62171 001
MAR 31, 1982
@ 0.5% N62171 001
MAR 31, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
CHLORAMPHENICOL
AP ELKINS SINN EQ 1GM BASE/VIAL N62406 001
NOV 09, 1982
@ EQ 1GM BASE/VIAL N62406 001
NOV 09, 1982

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL
MENRIUM 10-4
ROCHE 10MG;0.4MG N14740 006
@ 10MG;0.4MG N14740 006
MENRIUM 5-2
ROCHE 5MG;0.2MG N14740 002

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL
MENRIUM 5-2
@ ROCHE 5MG;0.2MG N14740 002
MENRIUM 5-4
+ ROCHE 5MG;0.4MG N14740 004
@ 5MG;0.4MG N14740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
> ADD > CHLORHEXIDINE GLUCONATE
> ADD > AT BARRE 0.12% N74291 001
> ADD > DEC 28, 1995
> ADD > AT LEMMON 0.12% N74522 001
> ADD > DEC 15, 1995

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE
AP STERIS 10MG/ML N83593 001
100MG/ML N86095 001
@ 10MG/ML N83593 001
@ 100MG/ML N86095 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
AP STERIS 25MG/ML N85591 001
@ 25MG/ML N85591 001

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE
AB LEMMON 100MG N88768 001
OCT 11, 1984
@ 100MG N88768 001
OCT 11, 1984
GLUCAMIDE
AB LEMMON 250MG N88641 001
OCT 11, 1984

CHLORPROPAMIDE

TABLET; ORAL
GLUCAMIDE
@ LEMMON 250MG N88641 001 OCT 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL
TARACTAN
ROCHE 100MG/5ML N16149 002
@ 100MG/5ML N16149 002

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
AB MUTUAL PHARM 25MG N89738 001 SEP 19, 1988
AB 50MG N89739 001 SEP 19, 1988
@ 25MG N89738 001 SEP 19, 1988
@ 50MG N89739 001 SEP 19, 1988

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
AA AMIDE PHARM 500MG N40113 001 SEP 29, 1995

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR
+ PARKE DAVIS EQ 4GM RESIN/BAR N71621 001 MAY 26, 1988
EQ 4GM RESIN/BAR N71739 001 MAY 26, 1988
@ EQ 4GM RESIN/BAR N71621 001 MAY 26, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL
CHOLYBAR
@ PARKE DAVIS EQ 4GM RESIN/BAR N71739 001 MAY 26, 1988

TABLET; ORAL
QUESTRAN
+ BRISTOL MYERS SQUIBB EQ 1GM RESIN N73403 001 APR 28, 1994
@ EQ 1GM RESIN N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL
CIMETIDINE
AB BAKER NORTON 200MG N74424 001 JUL 28, 1995
AB 300MG N74424 002 JUL 28, 1995
AB 400MG N74424 003 JUL 28, 1995
AB 800MG N74424 004 JUL 28, 1995
AB GENEVA PHARMS 200MG N74100 001 JAN 31, 1995
AB 300MG N74100 002 JAN 31, 1995
AB 400MG N74100 003 JAN 31, 1995
AB 800MG N74100 004 JAN 31, 1995
AB LEK LJUBLJANA 200MG N74250 001 JUN 29, 1995
AB 300MG N74250 002 JUN 29, 1995
AB 400MG N74250 003 JUN 29, 1995
AB 800MG N74250 004 JUN 29, 1995
AB LEMMON 200MG N74365 001 FEB 28, 1995
AB 300MG N74365 002 FEB 28, 1995
AB 400MG N74365 003 FEB 28, 1995

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	800MG	N74365 004	
			FEB 28, 1995	
AB	MOVA	300MG	N74340 001	
			JUN 23, 1995	
AB		400MG	N74340 002	
			JUN 23, 1995	
AB		800MG	N74339 001	
			JUN 23, 1995	
AB	ZENITH LABS	200MG	N74401 001	
			MAY 30, 1995	
AB		300MG	N74401 002	
			MAY 30, 1995	
AB		400MG	N74401 003	
			MAY 30, 1995	> DLT >
AB		800MG	N74402 001	> DLT >
			MAY 30, 1995	> DLT >

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	ABBOTT	EQ 300MG BASE/2ML	N74344 001	
			JAN 31, 1995	
AP		EQ 300MG BASE/2ML	N74345 001	
			JAN 31, 1995	
AP		EQ 300MG BASE/2ML	N74422 001	
			JAN 31, 1995	

CIPROFLOXACIN

INJECTABLE; INJECTION

> DLT >	CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
> ADD >	@ BAYER	200MG/100ML	N19858 001	
> ADD >			DEC 26, 1990	
> DLT >	+ MILES	200MG/100ML	N19858 001	
> DLT >			DEC 26, 1990	

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID

	+ JANSSEN	EQ 1MG BASE/ML	N20398 001	
			SEP 15, 1995	

> ADD >

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
NIMBEX

> ADD >	+ GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 001	
> ADD >			DEC 15, 1995	

NIMBEX PRESERVATIVE FREE

> ADD >	+ GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 003	
> ADD >			DEC 15, 1995	
> ADD >	+	EQ 10MG BASE/ML	N20551 002	
> ADD >			DEC 15, 1995	

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TIMENTIN

> DLT >	+ SMITHKLINE BEECHAM	EQ 100MG ACID/VIAL;		
> DLT >		EQ 3GM BASE/VIAL	N50590 001	
> DLT >			APR 01, 1985	
> DLT >		EQ 100MG ACID/VIAL;		
> DLT >		EQ 3GM BASE/VIAL	N62691 001	
> DLT >			DEC 19, 1986	
> DLT >	+	EQ 200MG ACID/VIAL;		
> DLT >		EQ 3GM BASE/VIAL	N50590 002	
> DLT >			APR 01, 1985	
> DLT >	+	EQ 1GM ACID/VIAL;		
> DLT >		EQ 30GM BASE/VIAL	N50590 003	
> DLT >			AUG 18, 1987	
> ADD >	+	EQ 100MG BASE/VIAL;		
> ADD >		EQ 3GM BASE/VIAL	N50590 001	
> ADD >			APR 01, 1985	
> ADD >		EQ 100MG BASE/VIAL;		
> ADD >		EQ 3GM BASE/VIAL	N62691 001	
> ADD >			DEC 19, 1986	
> ADD >	+	EQ 200MG BASE/VIAL;		
> ADD >		EQ 3GM BASE/VIAL	N50590 002	
> ADD >			APR 01, 1985	
> ADD >	+	EQ 1GM BASE/VIAL;		
> ADD >		EQ 30GM BASE/VIAL	N50590 003	
> ADD >			AUG 18, 1987	

TIMENTIN IN PLASTIC CONTAINER

> DLT >	+ SMITHKLINE BEECHAM	EQ 100MG ACID/100ML;		
> DLT >		EQ 3GM BASE/100ML	N50658 001	
> DLT >			DEC 15, 1989	
> ADD >	+	EQ 100MG BASE/100ML;		
> ADD >		EQ 3GM BASE/100ML	N50658 001	
> ADD >			DEC 15, 1989	

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLEOCIN
UPJOHN — EQ 1% BASE — N50517 002 — FEB 22, 1994

CLINDAMYCIN PHOSPHATE
AT CLAY PARK — EQ 1% BASE — N64050 001 — NOV 30, 1995

SWAB; TOPICAL
CLEOCIN
UPJOHN — EQ 1% BASE — N50537 002 — FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL
TEMOVATE E
BX + GLAXO WELLCOME — 0.05% — N20340 001 — JUN 17, 1994

TEMOVATE EMOLLIENT
BX + GLAXO — 0.05% — N20340 001 — JUN 17, 1994

OINTMENT; TOPICAL
EMBELINE
AB DPT — 0.05% — N74221 001 — MAR 31, 1995

SOLUTION; TOPICAL
> ADD > CLOBETASOL PROPIONATE
> ADD > AT NMC — 0.05% — N74331 001 — DEC 15, 1995
> ADD > EMBELINE
> ADD > AT DPT — 0.05% — N74222 001 — DEC 06, 1995
> ADD > TEMOVATE
> ADD > AT + GLAXO WELLCOME — 0.05% — N19966 001 — FEB 22, 1990

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
AB GENEVA PHARMS — 500MG — N72191 001 — MAY 02, 1988

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
@ GENEVA PHARMS — 500MG — N72191 001 — MAY 02, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL
BASEL PHARMS — 50MG — N19906 002 — DEC 29, 1989
+ — 75MG — N19906 003 — DEC 29, 1989
+ — 50MG — N19906 002 — DEC 29, 1989
75MG — N19906 003 — DEC 29, 1989

CLOTRIMAZOLE

SOLUTION; TOPICAL
CLOTRIMAZOLE
AT LEMMON — 1% — N73306 001 — FEB 28, 1995

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM
AB + APOTHECON — EQ 250MG BASE — N61452 001
AB + — EQ 500MG BASE — N61452 002
TEGOPEN
AB + APOTHECON — EQ 250MG BASE — N61452 001
AB + — EQ 500MG BASE — N61452 002

POWDER FOR RECONSTITUTION; ORAL
TEGOPEN
@ APOTHECON — EQ 125MG BASE/5ML — N50192 001
AA BRISTOL — EQ 125MG BASE/5ML — N50192 001

CLOZAPINE

TABLET; ORAL
CLOZARIL
SANDOZ — 25MG — N19758 001 SEP 26, 1989
+ — 100MG — N19758 002 SEP 26, 1989
+ — 25MG — N19758 001 SEP 26, 1989
100MG — N19758 002 SEP 26, 1989

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
COLESTID
UPJOHN — 5GM/SCOOPFUL — N17563 003 SEP 22, 1995
+ — 5GM/PACKET — N17563 004 SEP 22, 1995

COLISTIN SULFATE

SUSPENSION, ORAL
COLY-MYCIN S
PARKE DAVIS — EQ 25MG BASE/5ML — N50355 001
@ — EQ 25MG BASE/5ML — N50355 001

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
AP PARKE DAVIS — 40 UNITS/VIAL — N08317 004
@ — 40 UNITS/VIAL — N08317 004

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROLOM
AT BAUSCH AND LOMB — 4% — N74443 001 JAN 30, 1995

OPTICROM
AT + FISONS — 4% — N18155 001 OCT 03, 1984

CUPRIC SULFATE

INJECTABLE, INJECTION
CUPRIC SULFATE
+ FUJISAWA — EQ 0.4MG COPPER/ML — N19350 001 MAY 05, 1987
@ — EQ 0.4MG COPPER/ML — N19350 001 MAY 05, 1987

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN
AP AKORN — 1MG/ML — N87969 001 NOV 10, 1983
@ — 1MG/ML — N87969 001 NOV 10, 1983
@ WARNER CHILCOTT — 1MG/ML — N07085 002
RUBRAMIN PC
AP + SQUIBB — 0.1MG/ML — N06799 002
@ — 0.1MG/ML — N06799 002
SYTOBEX
AP PARKE DAVIS — 1MG/ML — N07085 002

CYCLACILLIN

TABLET; ORAL
CYCLACILLIN
AB BIOCRAFT — 250MG — N62895 001 AUG 04, 1988
AB — 500MG — N62895 002 AUG 04, 1988
+ — 250MG — N62895 001 AUG 04, 1988
+ — 500MG — N62895 002 AUG 04, 1988
CYCLAPEN-W
AB + WYETH AYERST — 250MG — N50509 001
AB + — 500MG — N50509 002
@ — 250MG — N50509 001
@ — 500MG — N50509 002

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB	BARR	10MG	N73541 001	
			MAY 23, 1995	
AB	SIDMAK LABS NJ	10MG	N74421 001	
			SEP 29, 1995	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

> DLT >	AP	+	BRISTOL	100MG/VIAL	N12142 001	
> DLT >	AP	+		200MG/VIAL	N12142 002	
> DLT >	AP	+		500MG/VIAL	N12142 003	
> DLT >	AP	+		1GM/VIAL	N12142 004	
> DLT >					AUG 30, 1982	
> DLT >	AP	+		2GM/VIAL	N12142 005	
> DLT >					AUG 30, 1982	
> ADD >	AP	+	BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 001	
> ADD >	AP	+		200MG/VIAL	N12142 002	
> ADD >	AP	+		500MG/VIAL	N12142 003	
> ADD >	AP	+		1GM/VIAL	N12142 004	
> ADD >					AUG 30, 1982	
> ADD >	AP	+		2GM/VIAL	N12142 005	
> ADD >					AUG 30, 1982	

LYOPHILIZED CYTOXAN

> DLT >	AP	+	BRISTOL	100MG/VIAL	N12142 006	
> DLT >					DEC 05, 1985	
> DLT >	AP	+		200MG/VIAL	N12142 007	
> DLT >					DEC 10, 1985	
> DLT >	AP	+		500MG/VIAL	N12142 008	
> DLT >					JAN 04, 1984	
> DLT >	AP	+		1GM/VIAL	N12142 010	
> DLT >					SEP 24, 1985	
> DLT >	AP	+		2GM/VIAL	N12142 009	
> DLT >					DEC 10, 1984	
> ADD >	AP	+	BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 006	
> ADD >					DEC 05, 1985	
> ADD >	AP	+		200MG/VIAL	N12142 007	
> ADD >					DEC 10, 1985	
> ADD >	AP	+		500MG/VIAL	N12142 008	
> ADD >					JAN 04, 1984	
> ADD >	AP	+		1GM/VIAL	N12142 010	
> ADD >					SEP 24, 1985	
> ADD >	AP	+		2GM/VIAL	N12142 009	
> ADD >					DEC 10, 1984	

CYCLOPHOSPHAMIDE

TABLET; ORAL

CYTOXAN

> DLT >		BRISTOL	25MG	N12141 002	
> DLT >	+		50MG	N12141 001	
> ADD >		BRISTOL MYERS SQUIBB	25MG	N12141 002	
> ADD >	+		50MG	N12141 001	

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

BP		SANDOZ	25MG	N50715 001	
				JUL 14, 1995	
BP			50MG	N50715 003	
				JUL 14, 1995	
BP	+		100MG	N50715 002	
				JUL 14, 1995	
			25MG	N50715 001	
				JUL 14, 1995	
			50MG	N50715 003	
				JUL 14, 1995	
	+		100MG	N50715 002	
				JUL 14, 1995	

SANDIMMUNE

BP		SANDOZ	25MG	N50625 001	
				MAR 02, 1990	
BP			50MG	N50625 003	
				NOV 23, 1992	
BP	+		100MG	N50625 002	
				MAR 02, 1990	
			25MG	N50625 001	
				MAR 02, 1990	
			50MG	N50625 003	
				NOV 23, 1992	
	+		100MG	N50625 002	
				MAR 02, 1990	

SOLUTION; ORAL

NEORAL

BP	+	SANDOZ	100MG/ML	N50716 001	
				JUL 14, 1995	
	+		100MG/ML	N50716 001	
				JUL 14, 1995	

SANDIMMUNE

BP	+	SANDOZ	100MG/ML	N50574 001	
				NOV 14, 1983	

CYCLOSPORINE

SOLUTION; ORAL
SANDIMMUNE
\+ SANDOZ 100MG/ML N50574 001 NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
AA ASCOT **4MG** **N87685 001 OCT 25, 1982**
@ 4MG N87685 001 OCT 25, 1982

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL
AP CETUS BEN VENUE **EQ 20MG BASE/VIAL** **N64103 001 FEB 03, 1995**

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DDAVP
\+ RHONE POULENC 0.015MG/ML N18938 002 APR 25, 1995

SPRAY, METERED; NASAL
STIMATE
>ADD> \+ ARMOUR PHARM 0.15MG/INH N20355 001 >ADD> MAR 07, 1994
>DLT> \+ RHONE POULENC RORER 0.15MG/INH N20355 001 >DLT> MAR 07, 1994

TABLET; ORAL
DDAVP
RHONE POULENC RORER 0.1MG N19955 001 SEP 06, 1995
\+ 0.2MG N19955 002 SEP 06, 1995

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGEN
AB \+ ORGANON **0.15MG;0.03MG** **N20071 001 DEC 10, 1992**
@ 0.15MG;0.03MG N20071 001 DEC 10, 1992
ORTHO-CEPT
AB JOHNSON RW **0.15MG;0.03MG** **N20301 001 DEC 14, 1992**
0.15MG;0.03MG N20301 001 DEC 14, 1992

DEXAMETHASONE

AEROSOL; TOPICAL
DECASPRAY
\+ MERCK SHARP DOHME 0.4% N12731 002
\+ 0.04% N12731 002

TABLET; ORAL
HEXADROL
BP ORGANON 0.5MG N12675 004
BP 0.75MG N12675 007
BP 1.5MG N12675 009
@ 0.5MG N12675 004
@ 0.75MG N12675 007
@ 1.5MG N12675 009

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
DEXASPORIN
AT BAUSCH AND LOMB **0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML** **N64135 001 SEP 13, 1995**

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE
AP FUJISAWA **EQ 4MG PHOSPHATE/ML** **N88448 001 JAN 25, 1984**
@ EQ 4MG PHOSPHATE/ML N88448 001 JAN 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	AKORN	EQ 4MG PHOSPHATE/ML	N84493 001	> DLT >	
@		EQ 4MG PHOSPHATE/ML	N84493 001	> DLT >	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N64055 001 OCT 30, 1995	> ADD >	

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
ZINECARD

+	PHARMACIA	EQ 250MG BASE/VIAL	N20212 001 MAY 26, 1995	> ADD >	
+		EQ 500MG BASE/VIAL	N20212 002 MAY 26, 1995	> DLT >	

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 2.5% IN PLASTIC CONTAINER

	MCGAW	2.5GM/100ML	N19626 001 FEB 02, 1988	> DLT >	
@		2.5GM/100ML	N19626 001 FEB 02, 1988	> DLT >	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	DHL	5GM/100ML	N19971 001 SEP 28, 1995	> ADD >	

DEXTROSE 7.7% IN PLASTIC CONTAINER

	MCGAW	7.7GM/100ML	N19626 003 FEB 02, 1988	> DLT >	
@		7.7GM/100ML	N19626 003 FEB 02, 1988	> ADD >	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION
ANGIOVIST 282

AP	BERLEX	60%	N87726 001 SEP 23, 1982	> DLT >	
@		60%	N87726 001 SEP 23, 1982	> ADD >	

UROVIST MEGLUMINE DIU/CT

AP	BERLEX	30%	N87739 001 SEP 23, 1982	> DLT >	
@		30%	N87739 001 SEP 23, 1982	> ADD >	

SOLUTION; URETERAL
RENO-30

	BRACCO	30%	N10040 021	> ADD >	
AT	BRACCO DXS	30%	N10040 021	> DLT >	

UROVIST CYSTO

AT	BERLEX	30%	N87729 001 SEP 23, 1982	> DLT >	
@		30%	N87729 001 SEP 23, 1982	> ADD >	

UROVIST CYSTO PEDIATRIC

AT	BERLEX	30%	N87731 001 SEP 23, 1982	> DLT >	
@		30%	N87731 001 SEP 23, 1982	> ADD >	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
ANGIOVIST 292

AP	BERLEX	52%;8%	N87724 001 SEP 23, 1982	> DLT >	
@		52%;8%	N87724 001 SEP 23, 1982	> ADD >	

ANGIOVIST 370

AP	BERLEX	66%;10%	N87723 001 SEP 23, 1982	> DLT >	
@		66%;10%	N87723 001 SEP 23, 1982	> ADD >	

RENOGRAFIN-60

	BRACCO	52%;8%	N10040 006	> ADD >	
AP	BRACCO DXS	52%;8%	N10040 006	> DLT >	

SOLUTION; ORAL, RECTAL
GASTROVIST

AA	BERLEX	66%;10%	N87728 001 SEP 23, 1982	> DLT >	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL

> DLT >		GASTROVIST		
> ADD >		@ BERLEX	66%;10%	N87728 001
> ADD >				SEP 23, 1982

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

		HYPAQUE		
> DLT >	AP	NYCOMED	50%	N09561 001
> ADD >			50%	N09561 001
> DLT >		UROVIST SODIUM 300		
> DLT >	AP	BERLEX	50%	N87725 001
> DLT >				SEP 23, 1982
> ADD >		@	50%	N87725 001
> ADD >				SEP 23, 1982

DIAZEPAM

INJECTABLE; INJECTION

	DIAZEPAM		
AP	FUJISAWA	5MG/ML	N70662 001
			JUN 25, 1986
	@	5MG/ML	N70662 001
			JUN 25, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

	CATAFLAM		
	GEIGY	25MG	N20142 001
			NOV 24, 1993
	@	25MG	N20142 001
			NOV 24, 1993

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM		
AB	GENEVA PHARMS	25MG	N74376 001
			SEP 28, 1995
AB		50MG	N74376 002
			SEP 28, 1995

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM		
AB	GENEVA PHARMS	75MG	N74394 001
			NOV 30, 1995
AB	ROXANE	25MG	N74391 001
			JUN 29, 1995
AB		50MG	N74391 002
			JUN 29, 1995
AB		75MG	N74391 003
			JUN 29, 1995
	VOLTAREN		
AB +	GEIGY	25MG	N19201 001
			JUL 28, 1988
AB +		50MG	N19201 002
			JUL 28, 1988
AB +		75MG	N19201 003
			JUL 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DICLOXACILLIN SODIUM		
AB	APOTHECON	EQ 250MG BASE	N61454 001
AB		EQ 500MG BASE	N61454 003
		EQ 125MG BASE	N61454 002
	DYNAPEN		
AB	APOTHECON	EQ 250MG BASE	N61454 001
AB		EQ 500MG BASE	N61454 003
		EQ 125MG BASE	N61454 002

POWDER FOR RECONSTITUTION; ORAL

	DICLOXACILLIN SODIUM		
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
	DYNAPEN		
AB	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
	@	EQ 62.5MG BASE/5ML	N50337 002
	@ BRISTOL	EQ 62.5MG BASE/5ML	N50337 002

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL

	VIDEX		
	BRISTOL MYERS SQUIBB	250MG/PACKET	N20155 005
			OCT 09, 1991

DIDANOSINE

POWDER FOR RECONSTITUTION; ORAL

	VIDEX			
	+ BRISTOL MYERS SQUIBB	175MG/PACKET	N20155 006 OCT 09, 1991	
	+	250MG/PACKET	N20155 005 OCT 09, 1991	
	@	375MG/PACKET	N20155 006 OCT 09, 1991	

DIENESTROL

CREAM; VAGINAL

	DIENESTROL			
AT	+ JOHNSON RW	0.01%	N06110 005	
	+	0.01%	N06110 005	
	DV			
	@ HOECHST MARION RSSL	0.01%	N83518 001	
AT	MERRELL DOW	0.01%	N83518 001	

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
	@ UPJOHN	0.05%	N19259 001 AUG 28, 1985	
	FLORONE E			
BX	+ UPJOHN	0.05%	N19259 001 AUG 28, 1985	
	PSORCON			
BX	DERMIK	0.05%	N20205 001 NOV 20, 1992	
BX	+	0.05%	N20205 001 NOV 20, 1992	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD			
BC	+ CARDERM	300MG	N20062 004 DEC 27, 1991	
	DILACOR XR			
BC	RHONE POULENC RORER	120MG	N20092 001 MAY 29, 1992	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILACOR XR			
BC	+ RHONE POULENC RORER	120MG	N20092 001 MAY 29, 1992	
BC		180MG	N20092 002 MAY 29, 1992	
BC	+	180MG	N20092 002 MAY 29, 1992	
BC		240MG	N20092 003 MAY 29, 1992	
BC	+	240MG	N20092 003 MAY 29, 1992	
	TIAZAC			
BC	BIOVAIL	120MG	N20401 001 SEP 11, 1995	
BC		180MG	N20401 002 SEP 11, 1995	
BC		240MG	N20401 003 SEP 11, 1995	
BC		300MG	N20401 004 SEP 11, 1995	
	+	360MG	N20401 005 SEP 11, 1995	

INJECTABLE; INJECTION

	CARDIZEM			
	+ HOECHST MARION RSSL	25MG/VIAL	N20027 003 AUG 18, 1995	

TABLET; ORAL

	DILTIAZEM HCL			
AB	LEMMON	30MG	N74185 001 MAY 31, 1995	
AB		60MG	N74185 002 MAY 31, 1995	
AB		90MG	N74185 003 MAY 31, 1995	
AB		120MG	N74185 004 MAY 31, 1995	
AB	ZENITH LABS	30MG	N74168 001 MAR 03, 1995	
AB		60MG	N74168 002 MAR 03, 1995	
AB		90MG	N74168 003 MAR 03, 1995	
AB		120MG	N74168 004 MAR 03, 1995	

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
AP STERIS 50MG/ML N83531 001
@ 50MG/ML N83531 001

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL
+ CONTROLLED THERAP 10MG N20411 001
MAR 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
AA WEST WARD PHARM 50MG N83567 001
@ 50MG N83567 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AKPRO
AT AKORN 0.1% N74382 001
SEP 29, 1995

DIPIVEFRIN HCL
AT BAUSCH AND LOMB 0.1% N74188 001
MAY 19, 1995

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC
+ LILLY 250MG N50678 001
JUN 19, 1995

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE
+ ABBOTT EQ 125MG BASE N19680 001
SEP 12, 1989

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE
+ ABBOTT EQ 125MG VALPROIC ACID N19680 001
SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE
ABBOTT EQ 125MG BASE N18723 003
OCT 26, 1984
EQ 250MG BASE N18723 001
MAR 10, 1983
+ EQ 500MG BASE N18723 002
MAR 10, 1983
EQ 125MG VALPROIC ACID N18723 003
OCT 26, 1984
EQ 250MG VALPROIC ACID N18723 001
MAR 10, 1983
+ EQ 500MG VALPROIC ACID N18723 002
MAR 10, 1983

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL
AP ASTRA EQ 12.5MG BASE/ML N74098 001
FEB 21, 1995
AP SANOFI WINTHROP EQ 12.5MG BASE/ML N74292 001
FEB 16, 1995

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
> DLT > AP ABBOTT 40MG/ML N70656 001
> DLT > JAN 24, 1989
> DLT > AP 80MG/ML N70657 001
> DLT > JAN 24, 1989
> ADD > @ 40MG/ML N70656 001
> ADD > JAN 24, 1989
> ADD > @ 80MG/ML N70657 001
> ADD > JAN 24, 1989

DOPAMINE HCL IN DEXTROSE 5%
AP + ABBOTT 1.6MG/ML N20542 001
AUG 30, 1995

INTROPIN
AP + DUPONT MERCK 40MG/ML N17395 001

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		INTROPIN			
AP	+	DUPONT MERCK	80MG/ML	N17395 002	
AP	+		160MG/ML	N17395 003	
AP	+	FAULDING	40MG/ML	N17395 001	
AP	+		80MG/ML	N17395 002	
AP	+		160MG/ML	N17395 003	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

> DLT >		DOXIL			
> DLT >	+	SEQUUS PHARM	2MG/ML	N50718 001	
> DLT >				NOV 17, 1995	
		DOXORUBICIN HCL			
AP		FUJISAWA	2MG/ML	N63277 001	
				OCT 26, 1995	
AP		GENSIA	2MG/ML	N64140 001	
				JUL 28, 1995	
AP			200MG/100ML	N64140 002	
				JUL 28, 1995	
AP		PHARMACHEMIE (NL)	2MG/ML	N63336 001	
				FEB 28, 1995	
AP			200MG/100ML	N63336 004	
				FEB 28, 1995	

> ADD > INJECTABLE, LIPOSOMAL; INJECTION

> ADD >		DOXIL		
> ADD >	+	SEQUUS PHARM	2MG/ML	N50718 001
> ADD >				NOV 17, 1995

DOXYCYCLINE

CAPSULE; ORAL

		DOXYCYCLINE MONOHYDRATE		
	+	VINTAGE PHARMS	EQ 100MG BASE	N50641 001
				DEC 29, 1989
		MONODOX		
		OCLASSEN	EQ 50MG BASE	N50641 002
				FEB 10, 1992
	+		EQ 100MG BASE	N50641 001
				DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCYCLINE HYCLATE		
AB		HALSEY	EQ 50MG BASE	N62119 002
				MAY 24, 1985
AB			EQ 100MG BASE	N62119 001
				MAY 24, 1985
	@		EQ 50MG BASE	N62119 002
				MAY 24, 1985
	@		EQ 100MG BASE	N62119 001
				MAY 24, 1985
AB		PVT FORM	EQ 50MG BASE	N62631 001
				JUL 24, 1986
AB			EQ 100MG BASE	N62631 002
				JUL 24, 1986
	@		EQ 50MG BASE	N62631 001
				JUL 24, 1986
	@		EQ 100MG BASE	N62631 002
				JUL 24, 1986

DROPERIDOL

INJECTABLE; INJECTION

		DROPERIDOL		
AP		DUPONT MERCK	2.5MG/ML	N71645 001
				APR 07, 1988
AP		FAULDING	2.5MG/ML	N71645 001
				APR 07, 1988
AP		SANOFI WINTHROP	2.5MG/ML	N72272 001
				AUG 31, 1995

EDETATE DISODIUM

INJECTABLE; INJECTION

		SODIUM VERSENATE		
	+	3M	200MG/ML	N10573 001
	@		200MG/ML	N10573 001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

		VASERETIC		
		MERCK	5MG;12.5MG	N19221 003
				JUL 12, 1995

EPINEPHRINE

INJECTABLE; INJECTION

>_DLT_>		EPIPEN			
>_DLT_>	+	SURVIVAL TECH	1MG/ML	N19430 001	
>_DLT_>				DEC 22, 1987	
>_DLT_>		EPIPEN JR.			
>_DLT_>	+	SURVIVAL TECH	0.5MG/ML	N19430 002	
>_DLT_>				DEC 22, 1987	
>_ADD_>		INJECTABLE; INTRAMUSCULAR			
>_ADD_>		EPIPEN			
>_ADD_>	+	SURVIVAL TECH	0.3MG/DELIVERY	N19430 001	
>_ADD_>				DEC 22, 1987	
>_ADD_>		EPIPEN JR.			
>_ADD_>	+	SURVIVAL TECH	0.15MG/DELIVERY	N19430 002	
>_ADD_>				DEC 22, 1987	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

>_ADD_>		SOLUTION; IONTOPHORESIS			
>_ADD_>		IONTOCAINE			
>_ADD_>	+	IOMED	0.01MG/ML;2%	N20530 001	
>_ADD_>				DEC 21, 1995	

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

		FLOLAN			
	+	GLAXO WELLCOME	EQ 0.5MG BASE/VIAL	N20444 001	
				SEP 20, 1995	
	+		EQ 1.5MG BASE/VIAL	N20444 002	
				SEP 20, 1995	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

		ERYC			
AB		FAULDING	250MG	N50536 001	
AB	+		250MG	N50536 001	
AB	+	PARKE DAVIS	250MG	N62338 001	
AB	+		250MG	N62618 001	
				SEP 25, 1985	
	@		250MG	N62338 001	
	@		250MG	N62618 001	
				SEP 25, 1985	

ERYTHROMYCIN

SWAB; TOPICAL

>_DLT_>		C-SOLVE-2			
>_DLT_>	AT	SYOSSET	2%	N62751 001	
>_DLT_>				JUL 30, 1993	
>_ADD_>	AT	ZENITH GOLDLINE	2%	N62751 001	
>_ADD_>				JUL 30, 1993	

TABLET, DELAYED RELEASE; ORAL

	ROBIMYCIN			
AB	ROBINS AH	250MG	N61633 001	
@		250MG	N61633 001	

ERYTHROMYCIN ESTOLATE

DROPS; ORAL

	ILOSONE			
+	DISTA	EQ 100MG BASE/ML	N61894 003	

SUSPENSION/DROPS; ORAL

	ILOSONE		
+	DISTA	EQ 100MG BASE/ML	N61894 003

ERYTHROMYCIN ETHYLSUCCINATE

DROPS; ORAL

	PEDIAMYCIN		
+	ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

SUSPENSION; ORAL

	WYAMYCIN E		
AB	WYETH AYERST	EQ 200MG BASE/5ML	N62123 002
AB		EQ 400MG BASE/5ML	N62123 001
@		EQ 200MG BASE/5ML	N62123 002
@		EQ 400MG BASE/5ML	N62123 001

SUSPENSION/DROPS; ORAL

	PEDIAMYCIN		
+	ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ETHRIL 250		
AB	SQUIBB	EQ 250MG BASE	N61605 001

ERYTHROMYCIN STEARATE

TABLET; ORAL

		ETHRIL 250			
		@ SQUIBB	EQ 250MG BASE	N61605 001	
		ETHRIL 500			
AB		SQUIBB	EQ 500MG BASE	N61605 002	
		@	EQ 500MG BASE	N61605 002	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

		CLIMARA			
BX	+	3M	0.05MG/24HR	N20375 001 DEC 22, 1994	
BX	+		0.1MG/24HR	N20375 002 DEC 22, 1994	
BX	+	BERLEX	0.05MG/24HR	N20375 001 DEC 22, 1994	
BX	+		0.1MG/24HR	N20375 002 DEC 22, 1994	
		VIVELLE			
BX			0.05MG/24HR	N20323 002 OCT 28, 1994	
BX			0.1MG/24HR	N20323 004 OCT 28, 1994	
			0.0375MG/24HR	N20323 001 OCT 28, 1994	
			0.075MG/24HR	N20323 003 OCT 28, 1994	
BX	+	CIBA GEIGY	0.05MG/24HR	N20323 002 OCT 28, 1994	
BX	+		0.1MG/24HR	N20323 004 OCT 28, 1994	
	+		0.0375MG/24HR	N20323 001 OCT 28, 1994	
	+		0.075MG/24HR	N20323 003 OCT 28, 1994	

ESTRADIOL VALERATE

INJECTABLE; INJECTION

		DELESTROGEN			
AO	+	SQUIBB	10MG/ML	N09402 002	
	+		10MG/ML	N09402 002	
		ESTRADIOL VALERATE			
AO		STERIS	10MG/ML	N83546 001	

ESTRADIOL VALERATE

INJECTABLE; INJECTION

		ESTRADIOL VALERATE			
		@ STERIS	10MG/ML	N83546 001	

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

		PREMPHASE 14/14		
	+	WYETH AYERST	0.625MG,0.625MG;N/A,5MG	N20527 002 NOV 17, 1995
		PREMPRO 14/14		
	+	WYETH AYERST	0.625MG,0.625MG;2.5MG, 2.5MG	N20527 001 NOV 17, 1995

ESTRONE

INJECTABLE; INJECTION

		ESTROGENIC SUBSTANCE			
BP		WYETH AYERST	2MG/ML	N83488 001	
BP	+		2MG/ML	N83488 001	
		THEELIN			
BP	+	PARKE DAVIS	2MG/ML	N03977 002	
		@	2MG/ML	N03977 002	

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

		EDECRIN			
	+	MERCK SHARP DOHME	EQ 50MG ACID/VIAL	N16093 001	>DLT>
	+		EQ 50MG BASE/VIAL	N16093 001	>ADD>

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

		ETHAMOLIN		
	+	REED AND CARNRICK	50MG/ML	N19357 001 DEC 22, 1988
	+	SPKU	50MG/ML	N19357 001 DEC 22, 1988

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28
NORQUEST FE
@ SEARLE 0.035MG;75MG;1MG N18926 001 JUL 18, 1986
@ SYNTEX 0.035MG;75MG;1MG N18926 001 JUL 18, 1986

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
LEVORA 0.15/30-21
> ADD > AB SEARLE 0.03MG;0.15MG N73592 001 DEC 13, 1993
> DLT > AB SYNTEX 0.03MG;0.15MG N73592 001 DEC 13, 1993

TABLET; ORAL-28
LEVORA 0.15/30-28
> ADD > AB SEARLE 0.03MG;0.15MG N73594 001 DEC 13, 1993
> DLT > AB SYNTEX 0.03MG;0.15MG N73594 001 DEC 13, 1993

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BREVICON 21-DAY
AB SEARLE 0.035MG;0.5MG N17566 001
AB SYNTEX 0.035MG;0.5MG N17566 001
NORINYL 1+35 21-DAY
AB SEARLE 0.035MG;1MG N17565 001
AB SYNTEX 0.035MG;1MG N17565 001
OVCON-35
+ BRISTOL MYERS SQUIBB 0.035MG;0.4MG N18127 001
+ MEAD JOHNSON 0.035MG;0.4MG N18127 001
OVCON-50
@ BRISTOL MYERS SQUIBB 0.05MG;1MG N18128 001
+ MEAD JOHNSON 0.05MG;1MG N18128 001
TRI-NORINYL 21-DAY
+ SEARLE 0.035MG,0.035MG;0.5MG,1MG N18977 001 APR 13, 1984
+ SYNTEX 0.035MG,0.035MG;0.5MG,1MG N18977 001 APR 13, 1984

TABLET; ORAL-28
BREVICON 28-DAY
AB SEARLE 0.035MG;0.5MG N17743 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28
BREVICON 28-DAY
AB SYNTEX 0.035MG;0.5MG N17743 001
NORINYL 1+35 28-DAY
AB SEARLE 0.035MG;1MG N17565 002
AB SYNTEX 0.035MG;1MG N17565 002
OVCON-35
BRISTOL MYERS SQUIBB 0.035MG;0.4MG N17716 001
MEAD JOHNSON 0.035MG;0.4MG N17716 001
OVCON-50
BRISTOL MYERS SQUIBB 0.05MG;1MG N17576 001
MEAD JOHNSON 0.05MG;1MG N17576 001
TRI-NORINYL 28-DAY
SEARLE 0.035MG,0.035MG;0.5MG,1MG N18977 002 APR 13, 1984
SYNTEX 0.035MG,0.035MG;0.5MG,1MG N18977 002 APR 13, 1984

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL
PARSIDOL
PARKE DAVIS 10MG N09078 003
50MG N09078 006
+ 100MG N09078 008
@ 10MG N09078 003
@ 50MG N09078 006
@ 100MG N09078 008

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
AP ABBOTT 20MG/ML N74320 001 AUG 30, 1995
AP 20MG/ML N74351 001 AUG 30, 1995
AP BEN VENUE 20MG/ML N74290 001 JUL 17, 1995
AP GENSIA 20MG/ML N74510 001 JUN 29, 1995
TOPOSAR
AP PHARMACIA 20MG/ML N74166 001 FEB 27, 1995

FAMCICLOVIR

TABLET; ORAL
FAMVIR
> ADD > SMITHKLINE BEECHAM 125MG N20363 003
> ADD > DEC 11, 1995

FENOFIBRATE

CAPSULE; ORAL
LIPIDIL
+ LABS FOURNIER 100MG N19304 001
DEC 31, 1993
@ 100MG N19304 001
DEC 31, 1993

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL
FENTANYL
ANESTA EQ 0.1MG BASE N20195 007
OCT 30, 1995

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLORINEF
+ APOTHECON 0.1MG N10060 001
+ SQUIBB 0.1MG N10060 001

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE
BX + SYNTEX 0.025MG/INH N18148 001
NASAREL
BX + SYNTEX 0.025MG/INH N20409 001
MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA 0.01% N12787 004

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA 0.025% N12787 002
AT + 0.025% N12787 005
+ 0.2% N16161 002
SYNALAR
AT + SYNTEX 0.01% N12787 004
AT + 0.025% N12787 002
SYNALAR-HP
+ SYNTEX 0.2% N16161 002
SYNEMOL
AT + SYNTEX 0.025% N12787 005

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA 0.025% N13960 001
SYNALAR
AT + SYNTEX 0.025% N13960 001

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
AT + HAMILTON PHARMA CA 0.01% N15296 001
AT PHARMADERM 0.01% N88048 001
DEC 16, 1982
@ 0.01% N88048 001
DEC 16, 1982
SYNALAR
AT + SYNTEX 0.01% N15296 001

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA 0.05% N16908 002
FLUOCINONIDE EMOLLIENT BASE
AB HAMILTON PHARMA CA 0.05% N16908 003
FLUOCINONIDE EMULSIFIED BASE
AB NMC 0.05% N74204 001
JUN 13, 1995
LIDEX
AB + SYNTEX 0.05% N16908 002
LIDEX-E
AB SYNTEX 0.05% N16908 003

GEL; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA 0.05% N17373 001

FLUOCINONIDE

GEL; TOPICAL
LIDEX
AB + SYNTEX 0.05% N17373 001

OINTMENT; TOPICAL
FLUOCINONIDE
AB + HAMILTON PHARMA CA 0.05% N16909 002
LIDEX
AB + SYNTEX 0.05% N16909 002

SOLUTION; TOPICAL
FLUOCINONIDE
AT FOUGERA 0.05% N72934 001 FEB 27, 1995
AT + HAMILTON PHARMA CA 0.05% N18849 001 APR 06, 1984
LIDEX
AT + SYNTEX 0.05% N18849 001 APR 06, 1984

FLUOROURACIL

INJECTABLE; INJECTION
ADRUCIL
> DLT > AP PHARMACIA 50MG/ML N81222 001 JUN 28, 1991
> DLT > @ 50MG/ML N81222 001 JUN 28, 1991
> ADD >
> ADD >

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
PERMITIL
AA SCHERING 5MG/ML N16008 001
AA + 5MG/ML N16008 001

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
AB GENEVA PHARMS 50MG N74448 001 JUL 28, 1995
AB 100MG N74448 002 JUL 28, 1995

FLURBIPROFEN

TABLET; ORAL
FLURBIPROFEN
AB LEMMON 100MG N74431 001 MAY 31, 1995
AB NOVOPHARM 50MG N74405 002 MAY 24, 1995
AB 100MG N74405 001 MAY 24, 1995
AB ZENITH LABS 50MG N74411 001 MAY 31, 1995
AB 100MG N74411 002 MAY 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC
FLURBIPROFEN SODIUM
AT BAUSCH AND LOMB 0.03% N74447 001 JAN 04, 1995
OCUFEN
AT + ALLERGAN 0.03% N19404 001 DEC 31, 1986

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCAVIR
> DLT > + ASTRA 24MG/ML N20068 001 SEP 27, 1991
> DLT > + 2.4GM/100ML N20068 001 SEP 27, 1991
> ADD >
> ADD >

FOSINOPRIL SODIUM

TABLET; ORAL
MONOPRIL
+ BRISTOL MYERS SQUIBB 20MG N19915 003 MAY 16, 1991
20MG N19915 003 MAY 16, 1991
+ 40MG N19915 004 MAR 28, 1995

GALLIUM NITRATE

	INJECTABLE; INJECTION			
	GANITE			
	+ FUJISAWA	25MG/ML	N19961 002	JAN 17, 1991
	+ SOLOPAK	25MG/ML	N19961 002	JAN 17, 1991

GEMFIBROZIL

	CAPSULE; ORAL			
	GEMFIBROZIL			
AB	+ MYLAN	300MG	N73466 001	JAN 25, 1993
	@	300MG	N73466 001	JAN 25, 1993
AB	PUREPAC PHARM	300MG	N72929 001	JAN 29, 1993
	@	300MG	N72929 001	JAN 29, 1993
	LOPID			
AB	+ PARKE DAVIS	300MG	N18422 002	
	@	300MG	N18422 002	
	TABLET; ORAL			
	GEMFIBROZIL			
AB	CHELSEA LABS	600MG	N74442 001	APR 28, 1995
AB	INVAMED	600MG	N74615 001	SEP 29, 1995
AB	MYLAN	600MG	N74452 001	FEB 16, 1995

GENTAMICIN SULFATE

	INJECTABLE; INJECTION			
	GENTAFAIR			
AP	PHARMAFAIR	EQ 40MG BASE/ML	N62493 001	AUG 28, 1985
	@	EQ 40MG BASE/ML	N62493 001	AUG 28, 1985
	GENTAMICIN			
AP	INTL MEDICATION	EQ 1MG BASE/ML	N62325 003	JUN 23, 1982
AP		EQ 100MG BASE/100ML	N62325 004	JUN 23, 1982

GENTAMICIN SULFATE

	INJECTABLE; INJECTION			
	GENTAMICIN			
AP	INTL MEDICATION	EQ 40MG BASE/ML	N62325 001	
	@	EQ 1MG BASE/ML	N62325 003	JUN 23, 1982
	@	EQ 100MG BASE/100ML	N62325 004	JUN 23, 1982
	@	EQ 40MG BASE/ML	N62325 001	
	OINTMENT; OPHTHALMIC			
	GENTAMICIN SULFATE			
AT	ADV REMEDIES	EQ 0.3% BASE	N64093 001	AUG 31, 1995
	OINTMENT; TOPICAL			
	GENTAMICIN SULFATE			
AT	PHARMADERM	EQ 0.1% BASE	N62534 001	OCT 10, 1984
	@	EQ 0.1% BASE	N62534 001	OCT 10, 1984
	SOLUTION/DROPS; OPHTHALMIC			
	GENTAMICIN SULFATE			
AT	ALCON	EQ 0.3% BASE	N62196 001	

GLIMEPIRIDE

	TABLET; ORAL			
	AMARYL			
	HOECHST ROUSSEL	1MG	N20496 001	NOV 30, 1995
		2MG	N20496 002	NOV 30, 1995
	+	4MG	N20496 003	NOV 30, 1995

GLIPIZIDE

	TABLET; ORAL			
	GLIPIZIDE			
AB	ALPHAPHARM	5MG	N74438 001	JUN 20, 1995
AB		10MG	N74438 002	JUN 20, 1995

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE			
> DLT >	AB	BAKER NORTON	5MG	N74497 001	AUG 31, 1995
> DLT >	AB		10MG	N74497 002	AUG 31, 1995
> DLT >	AB	GENEVA PHARMS	5MG	N74305 001	APR 07, 1995
	AB		10MG	N74305 002	APR 07, 1995
	AB	INVAMED	5MG	N74542 001	JUN 20, 1995
	AB		10MG	N74542 002	JUN 20, 1995
	AB	WATSON LABS	5MG	N74223 001	FEB 27, 1995
	AB		10MG	N74223 002	FEB 27, 1995
> ADD >	AB	ZENITH GOLDLINE	5MG	N74497 001	AUG 31, 1995
> ADD >	AB		10MG	N74497 002	AUG 31, 1995

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

		GLUCAGON			
> DLT >		LILLY	EQ 10MG BASE/VIAL	N12122 002	
> ADD >		@	EQ 10MG BASE/VIAL	N12122 002	

GLYBURIDE

TABLET; ORAL

		GLUBATE			
		@ HOECHST ROUSSEL	1.5MG	N20055 001	APR 17, 1992
		@	3MG	N20055 002	APR 17, 1992
		GLYBURIDE			
	AB	NOVOPHARM	1.25MG	N74388 001	AUG 29, 1995
	AB		2.5MG	N74388 002	AUG 29, 1995
	AB		5MG	N74388 003	AUG 29, 1995

GLYBURIDE

TABLET; ORAL

		GLYBURIDE (MICRONIZED)			
	AB	HOECHST ROUSSEL	1.5MG	N20055 001	APR 17, 1992
	AB		3MG	N20055 002	APR 17, 1992
		GLYNASE			
	AB	UPJOHN	1.5MG	N20051 001	MAR 04, 1992
	AB		3MG	N20051 002	MAR 04, 1992
		MICRONASE			
	AB	UPJOHN	1.25MG	N17498 001	MAY 01, 1984
	AB		2.5MG	N17498 002	MAY 01, 1984
	AB	+	5MG	N17498 003	MAY 01, 1984

GLYCINE

SOLUTION; IRRIGATION

		GLYCINE 1.5% IN PLASTIC CONTAINER			
	AT	BAXTER	1.5GM/100ML	N18522 001	FEB 19, 1982
		@	1.5GM/100ML	N18522 001	FEB 19, 1982

GRANISETRON HYDROCHLORIDE

TABLET; ORAL

		KYTRIL			
		+ SMITHKLINE BEECHAM	EQ 1MG BASE	N20305 001	MAR 16, 1995

GUANABENZ ACETATE

TABLET; ORAL

		GUANABENZ ACETATE			
	AB	ZENITH LABS	EQ 4MG BASE	N74149 001	APR 07, 1995
	AB		EQ 8MG BASE	N74149 002	APR 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	WATSON LABS	EQ 1MG BASE	N74145 001	OCT 17, 1995
AB		EQ 2MG BASE	N74145 002	OCT 17, 1995
	TENEX			
AB	ROBINS AH	EQ 1MG BASE	N19032 001	OCT 27, 1986
AB	+	EQ 2MG BASE	N19032 002	NOV 07, 1988
		EQ 1MG BASE	N19032 001	OCT 27, 1986
	+	EQ 2MG BASE	N19032 002	NOV 07, 1988
	@	3MG	N19032 003	NOV 07, 1988
	@	EQ 3MG BASE	N19032 003	NOV 07, 1988

HALCINONIDE

CREAM; TOPICAL

	HALOG			
AT	+ WESTWOOD SQUIBB	0.1%	N17556 001	
	+	0.1%	N17556 001	
	HALOG-E			
AT	WESTWOOD SQUIBB	0.1%	N18234 001	
		0.1%	N18234 001	

HALOPERIDOL LACTATE

SOLUTION; ORAL

	HALOPERIDOL LACTATE			
	UDL	EQ 1MG BASE/ML	N74536 001	NOV 02, 1995

HALOPROGIN

SOLUTION; TOPICAL

	HALOTEX			
	+ WESTWOOD SQUIBB	1%	N16943 001	
	@	1%	N16943 001	

HEPARIN CALCIUM

INJECTABLE; INJECTION

	CALCIPARINE			
	+ CHOAY	25,000 UNITS/ML	N18237 001	
	@ SANOFI WINTHROP	25,000 UNITS/ML	N18237 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH			
AP	SANOFI WINTHROP	10 UNITS/ML	N40082 001	FEB 28, 1995
AP		100 UNITS/ML	N40082 002	FEB 28, 1995
	HEPARIN SODIUM			
AP	+ ABBOTT	2,500 UNITS/ML	N05264 014	APR 07, 1986
	+	2,000 UNITS/ML	N05264 013	APR 07, 1986
AP	ELKINS SINN	10,000 UNITS/ML	N17037 013	APR 07, 1986
AP		5,000 UNITS/0.5ML	N17037 013	APR 07, 1986
AP	MARSAM	1,000 UNITS/ML	N40008 001	OCT 10, 1995
AP	PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP	WYETH AYERST	2,500 UNITS/ML	N17007 007	
AP	+	2,500 UNITS/ML	N17007 007	
	HEPARIN SODIUM 1000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19130 001	DEC 31, 1984
	@	200 UNITS/100ML	N19130 001	DEC 31, 1984
	HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19042 001	MAR 29, 1985
	@	200 UNITS/100ML	N19042 001	MAR 29, 1985
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	ABBOTT	5,000 UNITS/100ML	N18916 006	JAN 31, 1984
		5,000 UNITS/100ML	N18916 006	JAN 31, 1984

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	MCGAW	5,000 UNITS/100ML	N19802 001 JUL 20, 1992	
@		5,000 UNITS/100ML	N19802 001 JUL 20, 1992	
	HEPARIN SODIUM 2000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19130 003 DEC 31, 1984	
@		200 UNITS/100ML	N19130 003 DEC 31, 1984	
	HEPARIN SODIUM 2000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	MCGAW	200 UNITS/100ML	N19042 002 MAR 29, 1985	
@		200 UNITS/100ML	N19042 002 MAR 29, 1985	
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	ABBOTT	5,000 UNITS/100ML	N18916 007 JAN 31, 1984	
AP		10,000 UNITS/100ML	N18916 008 JAN 31, 1984	
		5,000 UNITS/100ML	N18916 007 JAN 31, 1984	
		10,000 UNITS/100ML	N18916 008 JAN 31, 1984	
	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	MCGAW	5,000 UNITS/100ML	N19802 005 JUL 20, 1992	
AP		10,000 UNITS/100ML	N19802 002 JUL 20, 1992	
@		5,000 UNITS/100ML	N19802 005 JUL 20, 1992	
@		10,000 UNITS/100ML	N19802 002 JUL 20, 1992	
	HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	MCGAW	5,000 UNITS/100ML	N19802 003 JUL 20, 1992	
@		5,000 UNITS/100ML	N19802 003 JUL 20, 1992	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN SODIUM 5000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	1,000 UNITS/100ML	N19130 002 DEC 31, 1984	
@		1,000 UNITS/100ML	N19130 002 DEC 31, 1984	
	HEPARIN SODIUM PRESERVATIVE FREE			
AP +	ABBOTT	2,500 UNITS/ML	N05264 014 APR 07, 1986	
+		2,000 UNITS/ML	N05264 013 APR 07, 1986	
AP	FUJISAWA	1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP +		1,000 UNITS/ML	N17029 010 APR 28, 1986	
AP	PHARMA SERVE NY	1,000 UNITS/ML	N86129 001	
AP	STERLING WINTHROP	10,000 UNITS/ML	N89522 001 MAY 04, 1987	
AP +		10,000 UNITS/ML	N89522 001 MAY 04, 1987	
	LIQUAEMIN LOCK PLUSH			
AP	ORGANON	100 UNITS/ML	N00552 007	
@		100 UNITS/ML	N00552 007	
	LIQUAEMIN SODIUM			
AP	ORGANON	1,000 UNITS/ML	N00552 004	
AP		5,000 UNITS/ML	N00552 003	
AP		10,000 UNITS/ML	N00552 005	
@		1,000 UNITS/ML	N00552 004	
@		5,000 UNITS/ML	N00552 003	
@		10,000 UNITS/ML	N00552 005	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	DRALZINE		
AA	LEMMON	25MG	N84301 001
@		25MG	N84301 001
	HYDRALAZINE HCL		
AA	HALSEY	50MG	N89222 001 JAN 22, 1986
@		50MG	N89222 001 JAN 22, 1986

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
APRESOLINE-ESIDRIX

+	CIBA	25MG;15MG	N12026 002
@		25MG;15MG	N12026 002

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	ASCOT	50MG	N87540 001 FEB 03, 1982
@		50MG	N87540 001 FEB 03, 1982
AB	INWOOD LABS	25MG	N85067 001
@		25MG	N85067 001

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
HYZAAR

+	MERCK	12.5MG;50MG	N20387 001 APR 28, 1995

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	ZENITH LABS	15MG;250MG	N71458 001 MAR 08, 1988
AB		25MG;250MG	N71459 001 MAR 08, 1988
AB		30MG;500MG	N71460 001 MAR 08, 1988
AB		50MG;500MG	N71461 001 MAR 08, 1988
@		15MG;250MG	N71458 001 MAR 08, 1988
@		25MG;250MG	N71459 001 MAR 08, 1988
@		30MG;500MG	N71460 001 MAR 08, 1988
@		50MG;500MG	N71461 001 MAR 08, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR HCT

	CIBA	25MG;50MG	N18303 001 DEC 31, 1984
		25MG;100MG	N18303 002 DEC 31, 1984
+		50MG;100MG	N18303 003 DEC 31, 1984

LOPRESSOR HCT 100/25

	CIBA	25MG;100MG	N18303 002 DEC 31, 1984

LOPRESSOR HCT 100/50

+	CIBA	50MG;100MG	N18303 003 DEC 31, 1984

LOPRESSOR HCT 50/25

	CIBA	25MG;50MG	N18303 001 DEC 31, 1984

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	WARNER CHILCOTT	25MG;80MG	N71772 001 JAN 26, 1988
@		25MG;80MG	N71772 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE

	SMITHKLINE BEECHAM	25MG;37.5MG	N16042 003 MAR 03, 1994
+		25MG;37.5MG	N16042 003 MAR 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	ZENITH LABS	25MG;50MG	N74259 001 MAR 30, 1995

HYDROCORTISONE

CREAM; TOPICAL
FLEXICORT

AT	WESTWOOD SQUIBB	0.5%	N87136 003 APR 08, 1982

HYDROCORTISONE

CREAM; TOPICAL

		FLEXICORT			> ADD >
AT		WESTWOOD SQUIBB	1%	N87136 002 APR 08, 1982	> ADD >
AT			2.5%	N87136 001 APR 08, 1982	> ADD
	@		0.5%	N87136 003 APR 08, 1982	
	@		1%	N87136 002 APR 08, 1982	
	@		2.5%	N87136 001 APR 08, 1982	
		HYDROCORTISONE			
AT		CLAY PARK	0.5%	N84970 002	
AT			1%	N85026 001	
	@		0.5%	N84970 002	
	@		1%	N85026 001	

ENEMA; RECTAL

		CORTENEMA		
	+		100MG/60ML	N16199 001
BR	+	SOLVAY	100MG/60ML	N16199 001
		HYDROCORTISONE		
BR		COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994
	@		100MG/60ML	N74171 001 MAY 27, 1994

LOTION; TOPICAL

		HYDROCORTISONE		
AT		CLAY PARK	0.5%	N85662 001
	@		0.5%	N85662 001

OINTMENT; TOPICAL

		HYDROCORTISONE		
		CLAY PARK	0.5%	N84969 003
	@		0.5%	N84969 003

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN		
AT	+	BURROUGHS WELLCOME	10.1MG/ML;EQ 3.5MG BASE/ML; 12,000 UNITS/ML	N50479 001
AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE		
AT		BAUSCH AND LOMB	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N64053 001 DEC 29, 1995

HYDROCORTISONE; UREA

CREAM; TOPICAL

		ALPHADERM		
AT		VIVAN	1%;10%	N86008 001
	@		1%;10%	N86008 001
		CALMURID HC		
AT	+	PHARMACIA	1%;10%	N83947 001
	@		1%;10%	N83947 001

HYDROCORTISONE ACETATE

AEROSOL; RECTAL

		CORTIFOAM		
	+	REED AND CARNRICK	10%	N17351 001 FEB 10, 1982
	+	SPKU	10%	N17351 001 FEB 10, 1982

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

		EPIFOAM		
BX		REED AND CARNRICK	1%;1%	N86457 001
BX		SPKU	1%;1%	N86457 001
		PROCTOFOAM HC		
BX		REED AND CARNRICK	1%;1%	N86195 001
BX		SPKU	1%;1%	N86195 001

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

		LOCOID		
	@	YAMANOUCHI	0.1%	N18652 001 OCT 29, 1982
	+		0.1%	N18652 001 OCT 29, 1982

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		A-HYDROCORT			
> DLT >	AP	ABBOTT	EQ 100MG BASE/VIAL	N89577 001	
> DLT >				APR 11, 1989	
> ADD >		@	EQ 100MG BASE/VIAL	N89577 001	
> ADD >				APR 11, 1989	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
AP	+ KNOLL PHARM	10MG/ML	N19034 001	
			JAN 11, 1984	
	HYDROMORPHONE HCL			
AP	STERIS	10MG/ML	N74317 001	
			AUG 23, 1995	

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE			
AB	GENEVA PHARMS	200MG	N40104 001
			NOV 30, 1995
AB	ROYCE LABS	200MG	N40133 001
			NOV 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE			
+	AKORN	125MG/ML	N18004 001
@		125MG/ML	N18004 001

HYDROXYUREA

CAPSULE; ORAL

	HYDREA		
AB	+ SQUIBB	500MG	N16295 001
	HYDROXYUREA		
AB	ROXANE	500MG	N74476 001
			AUG 18, 1995

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
AP	PHARMAFAIR	50MG/ML	N88881 001	
			FEB 14, 1986	
@		50MG/ML	N88881 001	
			FEB 14, 1986	
AP	STERIS	25MG/ML	N87274 001	
AP		50MG/ML	N87274 002	
@		25MG/ML	N87274 001	
@		50MG/ML	N87274 002	

SYRUP; ORAL

	HYDROXYZINE HCL		
AA	BARRE	10MG/5ML	N88785 001
			FEB 03, 1988
@		10MG/5ML	N88785 001
			FEB 03, 1988

TABLET; ORAL

	HYDROXYZINE HCL		
AB	HALSEY	50MG	N89396 001
			MAY 02, 1988
@		50MG	N89396 001
			MAY 02, 1988
AB	SIDMAK LABS NJ	100MG	N81054 001
			SEP 25, 1995

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S MOTRIN		
BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001
			SEP 19, 1989
	PEDIA PROFEN		
BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001
			SEP 19, 1989

SUSPENSION/DROPS; ORAL

	MOTRIN		
	+ MCNEIL CONS PRODS	40MG/ML	N20476 001
			MAY 25, 1995

TABLET; ORAL

	IBU-TAB		
AB	ALRA	800MG	N71965 001
			AUG 11, 1988

IBUPROFEN

TABLET; ORAL

		IBU-TAB			
		@ ALRA	800MG	N71965 001	
				AUG 11, 1988	
		IBUPROFEN			
> DLT >	AB	LEMMON	400MG	N73343 001	
> DLT >				JUN 30, 1992	
> DLT >	AB		600MG	N73344 001	
> DLT >				JUN 30, 1992	
> DLT >	AB		800MG	N73345 001	
> DLT >				JUN 30, 1992	
> ADD >		@	400MG	N73343 001	
> ADD >				JUN 30, 1992	
> ADD >		@	600MG	N73344 001	
> ADD >				JUN 30, 1992	
> ADD >		@	800MG	N73345 001	
> ADD >				JUN 30, 1992	

> ADD > IBUTILIDE FUMARATE

> ADD > INJECTABLE; INJECTION

> ADD >		CORVERT			
> ADD >		+ UPJOHN	0.1MG/ML	N20491 001	
> ADD >				DEC 28, 1995	

INDAPAMIDE

TABLET; ORAL

		INDAPAMIDE			
	AB	ZENITH LABS	2.5MG	N74299 001	
				JUL 27, 1995	
		LOZOL			
	AB	+ RHONE POULENC RORER	2.5MG	N18538 001	
				JUL 06, 1983	

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	DECABID			
	LILLY	EQ 50MG BASE	N19693 001	
			DEC 29, 1989	
		EQ 75MG BASE	N19693 002	
			DEC 29, 1989	

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID			
+ LILLY	EQ 100MG BASE	N19693 003	
		DEC 29, 1989	
@	EQ 50MG BASE	N19693 001	
		DEC 29, 1989	
@	EQ 75MG BASE	N19693 002	
		DEC 29, 1989	
@	EQ 100MG BASE	N19693 003	
		DEC 29, 1989	

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE			
+ CYPROS	100MG/ML	N02282 001	
+ ISO TEX	100MG/ML	N02282 001	

IOCETAMIC ACID

TABLET, ORAL

CHOLEBRINE			
+ MALLINCKRODT	750MG	N17129 001	
@	750MG	N17129 001	

IOHEXOL

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350			
NYCOMED	75.5%	N20608 003	
		OCT 24, 1995	

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240			
NYCOMED	51.8%	N20608 001	
		OCT 24, 1995	
OMNIPAQUE 300			
NYCOMED	64.7%	N20608 002	
		OCT 24, 1995	

IOPAMIDOL

INJECTABLE; INTRAVASCULAR

ISOVUE-200			
@ BRACCO	41%	N20327 001	
		OCT 12, 1994	
BRACCO DXS	41%	N20327 001	
		OCT 12, 1994	

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST			
+ BERLEX	EQ 150MG IODINE/ML	N20220 004	
		MAY 10, 1995	
+	EQ 240MG IODINE/ML	N20220 003	
		MAY 10, 1995	
+	EQ 300MG IODINE/ML	N20220 002	
		MAY 10, 1995	
+	EQ 370MG IODINE/ML	N20220 001	
		MAY 10, 1995	
ULTRAVIST 150			
+ BERLEX	31.2%	N20220 004	
		MAY 10, 1995	
ULTRAVIST 240			
+ BERLEX	49.9%	N20220 003	
		MAY 10, 1995	
ULTRAVIST 300			
+ BERLEX	62.3%	N20220 002	
		MAY 10, 1995	
ULTRAVIST 370			
+ BERLEX	76.9%	N20220 001	
		MAY 10, 1995	

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY		
+ MALLINCKRODT	80%	N13319 001
@	80%	N13319 001

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION

GLOFIL-125		
CYPROS	250-300 uCi/ML	N17279 001

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION

GLOFIL-125		
ISO TEX	250-300 uCi/ML	N17279 001

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST		
BERLEX	EQ 190MG IODINE/ML	N19580 001
		DEC 07, 1989
	EQ 240MG IODINE/ML	N19580 002
		DEC 07, 1989
OSMOVIST 190		
BERLEX	40.6%	N19580 001
		DEC 07, 1989
OSMOVIST 240		
BERLEX	51.3%	N19580 002
		DEC 07, 1989

IOXILAN

INJECTABLE; INJECTION

OXILAN-300		
COOK IMAGING	62%	N20316 001
		DEC 21, 1995
OXILAN-350		
COOK IMAGING	73%	N20316 002
		DEC 21, 1995

IPODATE SODIUM

CAPSULE; ORAL

	BILIVIST		
AA	+ BERLEX	500MG	N87768 001
			AUG 11, 1982
	@	500MG	N87768 001
			AUG 11, 1982
	ORAGRAFIN SODIUM		
	+ BRACCO	500MG	N12967 001
AA	BRACCO DXS	500MG	N12967 001

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
ATROVENT

+	BOEHRINGER INGELHEIM	0.021MG/INH	N20393 001 OCT 20, 1995
+		0.042MG/INH	N20394 001 OCT 20, 1995

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F

AN	+	DEY	1%	N89252 001 SEP 15, 1986
	@		1%	N89252 001 SEP 15, 1986

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

AN	MARSAM	99.9%	N74393 001 MAY 12, 1995
AN	RHONE POULENC	99.9%	N74502 001 JUN 27, 1995

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

BC	REED AND CARNRICK	40MG	N19790 001 SEP 02, 1988
BC	SPKU	40MG	N19790 001 SEP 02, 1988

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

@	SCHERING	30MG	N20225 001 AUG 12, 1993
+		60MG	N20225 002 AUG 12, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
IMDUR

+	SCHERING	120MG	N20225 003 MAR 30, 1995
@	SCHERING PLOUGH	30MG	N20225 001 AUG 12, 1993
+		60MG	N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

AP	ELKINS SINN	EQ 75MG BASE/2ML	N62324 001
AP		EQ 500MG BASE/2ML	N62324 002
AP		EQ 1GM BASE/3ML	N62324 003
@		EQ 75MG BASE/2ML	N62324 001
@		EQ 500MG BASE/2ML	N62324 002
@		EQ 1GM BASE/3ML	N62324 003

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

> ADD > AB	GENEVA PHARMS	50MG	N74024 001 DEC 29, 1995
> ADD > AB		75MG	N74024 002 DEC 29, 1995

CAPSULE, EXTENDED RELEASE; ORAL
ORUVAIL

+	WYETH AYERST	100MG	N19816 003 FEB 08, 1995
+		150MG	N19816 002 FEB 08, 1995

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA	HI TECH PHARMA	10GM/15ML	N74076 001 JUL 03, 1995

LACTULOSE

SOLUTION; ORAL, RECTAL
LACTULOSE
AA HI TECH PHARMA 10GM/15ML N74077 001 JUL 03, 1995

LAMIVUDINE

SOLUTION; ORAL
EPIVIR
GLAXO WELLCOME 10MG/ML N20596 001 NOV 17, 1995 > ADD >

TABLET; ORAL
EPIVIR
+ GLAXO WELLCOME 150MG N20564 001 NOV 17, 1995

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID
TAP HOLDINGS 15MG N20406 001 MAY 10, 1995
+ 30MG N20406 002 MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
+ CETUS BEN VENUE EQ 200MG BASE/VIAL N40056 001 MAY 23, 1995

WELLCOVORIN
AP BURROUGHS WELLCOME EQ 50MG BASE/VIAL N89465 001 JAN 23, 1989
+ EQ 25MG BASE/VIAL N89833 001 JAN 23, 1989
@ GLAXO WELLCOME EQ 25MG BASE/VIAL N89833 001 JAN 23, 1989
@ EQ 50MG BASE/VIAL N89465 001 JAN 23, 1989

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON
TAP HOLDINGS 5MG/ML N20263 001 APR 16, 1993
+ 1MG/0.2ML N19010 001 APR 09, 1985
+ TAP PHARMS 5MG/ML N19010 001 APR 09, 1985

LUPRON DEPOT
+ TAP HOLDINGS 22.5MG/VIAL N20517 001 DEC 22, 1995 > ADD >

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP AKORN 1% N85037 001
AP 2% N85037 002
@ 1% N85037 001
@ 2% N85037 002
AP FUJISAWA 2% N80420 004
@ 2% N80420 004
AP SANOFI WINTHROP 1% N40013 001 JUN 23, 1995
AP 2% N40078 001 JUN 23, 1995

SOLUTION; ORAL
LIDOCAINE HCL
AT HI TECH PHARMA 2% N40014 001 JUL 10, 1995

LINDANE

LOTION; TOPICAL
SCABENE
AT STIEFEL 1% N86769 001
@ 1% N86769 001

SHAMPOO; TOPICAL
SCABENE
AT STIEFEL 1% N87940 001 APR 08, 1983
@ 1% N87940 001 APR 08, 1983

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MERCK	**2.5MG**	**N19558 006**	
			JAN 28, 1994	
		2.5MG	N19558 006	
			JAN 28, 1994	
	ZESTRIL			
AB	ZENECA	**2.5MG**	**N19777 005**	
			APR 29, 1993	
	@	2.5MG	N19777 005	
			APR 29, 1993	

LITHIUM CARBONATE

TABLET; ORAL

	LITHOTABS			
AB	SOLVAY	**300MG**	**N16980 001**	
AB	+	**300MG**	**N16980 001**	

TABLET, EXTENDED RELEASE; ORAL

	LITHOBID			
	@ SOLVAY	300MG	N18027 001	
		300MG	N18027 001	

LOSARTAN POTASSIUM

TABLET; ORAL

	COZAAR			
	MERCK	25MG	N20386 001	
			APR 14, 1995	
	+	50MG	N20386 002	
			APR 14, 1995	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOLYTE IN PLASTIC CONTAINER			
AT	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19024 001	
			JUN 08, 1984	

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

	PHYSIOLYTE IN PLASTIC CONTAINER			
	MCGAW	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19024 001	
			JUN 08, 1984	
	PHYSIOSOL IN PLASTIC CONTAINER			
AT	ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002	
			JUL 08, 1982	
		30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002	
			JUL 08, 1982	
	SYNOVALYTE IN PLASTIC CONTAINER			
AT	BAXTER	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001	
			JAN 25, 1985	
	@	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N19326 001	
			JAN 25, 1985	

MAGNESIUM SULFATE

INJECTABLE; INJECTION

	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
	ABBOTT	1GM/100ML	N20488 001	
			JUL 11, 1995	
	+	2GM/100ML	N20488 002	
			JUL 11, 1995	

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10%			
AP	ABBOTT	10GM/100ML	N16269 002	
	@	10GM/100ML	N16269 002	
	MANNITOL 15%			
AP	ABBOTT	15GM/100ML	N16269 003	
	@	15GM/100ML	N16269 003	
	MANNITOL 20%			
AP	ABBOTT	20GM/100ML	N16269 004	
	@	20GM/100ML	N16269 004	
	MANNITOL 25%			
AP	ABBOTT	12.5GM/50ML	N16269 005	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

AP	ABBOTT	12.5GM/50ML	N16269 006	
			AUG 25, 1994	
	@	12.5GM/50ML	N16269 005	

MANNITOL 5%

AP	ABBOTT	5GM/100ML	N16269 001	
	@	5GM/100ML	N16269 001	

MASOPROCOL

CREAM; TOPICAL

ACTINEX

+	BLOCK DRUG	10%	N19940 001	> DLT >	
			SEP 04, 1992	> ADD >	
+	SPKU	10%	N19940 001	> DLT >	
			SEP 04, 1992	> ADD >	

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

AB	COPLEY PHARM	100MG	N73580 001
			JAN 04, 1995

VERMOX

AB	+ JANSSEN	100MG	N17481 001

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+	UPJOHN	100MG/ML	N12541 002
@		100MG/ML	N12541 002

MEGESTROL ACETATE

TABLET; ORAL

MEGACE

AB	BRISTOL MYERS SQUIBB	20MG	N16979 001
AB	+	40MG	N16979 002
AB	MEAD JOHNSON	20MG	N16979 001
AB	+	40MG	N16979 002

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

AB	BARR	40MG	N74621 001
			NOV 30, 1995
AB	ROXANE	20MG	N74458 001
			SEP 29, 1995
AB		40MG	N74458 002
			SEP 29, 1995

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

DEMEROL

AA	STERLING WINTHROP	50MG	N05010 001	
AA	+	50MG	N05010 001	
AA		100MG	N05010 004	
AA	+	100MG	N05010 004	

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

@	SEARLE	0.1MG;2MG	N13625 004
@	SYNTEX	0.1MG;2MG	N13625 004

TABLET; ORAL-21

NORINYL 1+50 21-DAY

AB	SEARLE	0.05MG;1MG	N13625 002
AB	SYNTEX	0.05MG;1MG	N13625 002

NORINYL 1+80 21-DAY

@	SEARLE	0.08MG;1MG	N16724 001
@	SYNTEX	0.08MG;1MG	N16724 001

TABLET; ORAL-28

NORINYL 1+50 28-DAY

AB	SEARLE	0.05MG;1MG	N16659 001
AB	SYNTEX	0.05MG;1MG	N16659 001

NORINYL 1+80 28-DAY

@	SEARLE	0.08MG;1MG	N16725 001
@	SYNTEX	0.08MG;1MG	N16725 001

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

AN		BARRE	0.4%	N71855 001 JUL 14, 1988
AN			0.6%	N71726 001 JUL 14, 1988
AN		PACO	0.4%	N71855 001 JUL 14, 1988
AN			0.6%	N71726 001 JUL 14, 1988

SYRUP; ORAL
ALUPENT

AA		BOEHRINGER INGELHEIM	10MG/5ML	N17571 001
AA	+		10MG/5ML	N17571 001

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

		BRISTOL MYERS SQUIBB	500MG	N20357 001 DEC 29, 1994
	+		850MG	N20357 002 DEC 29, 1994
		LIPHA	500MG	N20357 001 DEC 29, 1994
	+		850MG	N20357 002 DEC 29, 1994

METHADONE HYDROCHLORIDE

POWDER; FOR RX COMPOUNDING
METHADONE HCL

	MALLINCKRODT	50GM/BOT	N06383 002
		100GM/BOT	N06383 003
		500GM/BOT	N06383 004

TABLET, DISPERSIBLE; ORAL
METHADONE HCL

AA	ROXANE	40MG	N74081 001 APR 28, 1995

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN

@	APOTHECON	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003
@	BRISTOL	EQ 900MG BASE/VIAL	N50117 001
@		EQ 3.6GM BASE/VIAL	N50117 002
@		EQ 5.4GM BASE/VIAL	N50117 003

METHOTRIMEPRAZINE

INJECTABLE; INJECTION
LEVOPROME

+	IMMUNEX	20MG/ML	N15865 001
+	LEDERLE	20MG/ML	N15865 001

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP		DUPONT MERCK	50MG/ML	N70691 001 JUN 19, 1987
AP			50MG/ML	N70849 001 JUN 19, 1987
AP		FAULDING	50MG/ML	N70691 001 JUN 19, 1987
AP			50MG/ML	N70849 001 JUN 19, 1987

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

BP		AKORN	40MG/ML	N86903 001 OCT 20, 1982
BP			80MG/ML	N86903 002 OCT 20, 1982
	@		40MG/ML	N86903 001 OCT 20, 1982
	@		80MG/ML	N86903 002 OCT 20, 1982

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	DUPONT MERCK	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989
AP	FAULDING	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	INVAMED	EQ 5MG BASE	N74478 001	OCT 05, 1995
AB		EQ 10MG BASE	N74478 002	OCT 05, 1995
> ADD > AB	SIDMAK LABS NJ	EQ 5MG BASE	N72750 001	DEC 28, 1995

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL
LOPRESSOR

GEIGY	EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
	EQ 200MG TARTRATE	N19786 002	DEC 27, 1989
	EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
+	EQ 400MG TARTRATE	N19786 004	DEC 27, 1989
@	EQ 100MG TARTRATE	N19786 001	DEC 27, 1989
@	EQ 200MG TARTRATE	N19786 002	DEC 27, 1989
@	EQ 300MG TARTRATE	N19786 003	DEC 27, 1989
@	EQ 400MG TARTRATE	N19786 004	DEC 27, 1989

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	LEMMON	50MG	N74141 001	JAN 31, 1995
AB		100MG	N74141 002	JAN 31, 1995
AB	PAR PHARM	50MG	N74453 001	APR 27, 1995
AB		100MG	N74453 002	APR 27, 1995

METRONIDAZOLE

CAPSULE; ORAL
FLAGYL

+	SEARLE	375MG	N20334 001 MAY 03, 1995

CREAM; TOPICAL
METROCREAM

+	GALDERMA	0.75%	N20531 001 SEP 20, 1995

METYRAPONE

TABLET; ORAL
METOPIRONE

+	CIBA	250MG	N12911 001
@		250MG	N12911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	NOVOPHARM	150MG	N74377 001	MAY 16, 1995
AB		200MG	N74377 002	MAY 16, 1995
AB		250MG	N74377 003	MAY 16, 1995

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	N18873 002	DEC 30, 1985

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXITIL

AB	BOEHRINGER INGELHEIM	200MG	N18873 003	DEC 30, 1985
AB +		250MG	N18873 004	DEC 30, 1985

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ABLE	200MG	N73509 001	NOV 19, 1993
AB	NMC	200MG	N73508 001	NOV 19, 1993

MINOXIDIL

TABLET; ORAL
MINOXIDIL

> ADD > > ADD >	AB	MUTUAL PHARM	2.5MG	N72708 001 DEC 14, 1995
> ADD > > ADD >	AB		10MG	N72709 001 DEC 14, 1995

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	CETUS BEN VENUE	5MG/VIAL	N64117 001	APR 19, 1995
AP		20MG/VIAL	N64117 002	APR 19, 1995
		20MG/VIAL	N64117 002	APR 19, 1995
AP	FAULDING	20MG/VIAL	N64106 001	NOV 29, 1995

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIVASC

	SPKU	7.5MG	N20312 001 APR 19, 1995

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
UNIVASC

+	SPKU	15MG	N20312 002 APR 19, 1995

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

BC	+ PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989

ORAMORPH SR

BC	ROXANE	15MG	N19977 004	NOV 23, 1994

MUPIROCIN CALCIUM

OINTMENT; NASAL
BACTROBAN

> DLT > > DLT >	+	SMITHKLINE BEECHAM	EQ 2% ACID	N50703 001 SEP 18, 1995
> ADD > > ADD >	+		EQ 2% BASE	N50703 001 SEP 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL
CELLCEPT

	+ SYNTEX	250MG	N50722 001	MAY 03, 1995

NADOLOL

TABLET; ORAL
NADOLOL

AB	INVAMED	20MG	N74501 001	NOV 09, 1995
AB		40MG	N74501 002	NOV 09, 1995
AB		80MG	N74501 003	NOV 09, 1995

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

+	SEARLE	EQ 0.2MG BASE/INH	N19886 001 FEB 13, 1990
+	SYNTEX	EQ 0.2MG BASE/INH	N19886 001 FEB 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984

NAFCILLIN SODIUM

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 4GM BASE/VIAL	N61984 005
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX

	OHMEDA	EQ 0.1MG BASE/ML	N20459 001 APR 17, 1995
+		EQ 1MG BASE/ML	N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	FUJISAWA	0.02MG/ML	N70648 001 NOV 17, 1986
AP		0.4MG/ML	N70649 001 NOV 17, 1986
@		0.02MG/ML	N70648 001 NOV 17, 1986
@		0.4MG/ML	N70649 001 NOV 17, 1986
AP	MARSAM	0.4MG/ML	N71811 001 JUL 19, 1988
@		0.4MG/ML	N71811 001 JUL 19, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO	AKORN	100MG/ML	N87519 001 SEP 28, 1983
@		100MG/ML	N87519 001 SEP 28, 1983

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	CHELSEA LABS	250MG	N74457 001 MAY 31, 1995
AB		375MG	N74457 002 MAY 31, 1995
AB		500MG	N74457 003 MAY 31, 1995

NAPROXEN

TABLET; ORAL
NAPROXEN

	AB	DANBURY PHARMA	250MG	N74163 001	FEB 10, 1995
	AB		375MG	N74163 002	FEB 10, 1995
	AB		500MG	N74163 003	FEB 10, 1995
> DLT >	AB	HAMILTON PHARMS	250MG	N74110 001	OCT 30, 1992
> DLT >	AB		375MG	N74110 002	OCT 30, 1992
> DLT >	AB		500MG	N74110 003	OCT 30, 1992
> ADD >	@		250MG	N74110 001	OCT 30, 1992
> ADD >	@		375MG	N74110 002	OCT 30, 1992
> ADD >	@		500MG	N74110 003	OCT 30, 1992
	AB	MOVA	250MG	N74410 001	APR 28, 1995
	AB		375MG	N74410 002	APR 28, 1995
	AB		500MG	N74410 003	APR 28, 1995
	AB	ZENITH LABS	250MG	N74111 001	FEB 28, 1995
	AB		375MG	N74111 002	FEB 28, 1995
	AB		500MG	N74111 003	FEB 28, 1995

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

	AB	CHELSEA LABS	EQ 250MG BASE	N74455 001	MAY 31, 1995
	AB		EQ 500MG BASE	N74455 002	MAY 31, 1995
> DLT >	AB	HAMILTON PHARMS	EQ 250MG BASE	N74106 001	AUG 31, 1993
> DLT >	AB		EQ 500MG BASE	N74106 002	AUG 31, 1993

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

> ADD >	@	HAMILTON PHARMS	EQ 250MG BASE	N74106 001	AUG 31, 1993
> ADD >	@		EQ 500MG BASE	N74106 002	AUG 31, 1993
	AB	PUREPAC PHARM	EQ 250MG BASE	N74319 001	MAR 20, 1995
	AB		EQ 500MG BASE	N74319 002	MAR 20, 1995
	AB	ZENITH LABS	EQ 250MG BASE	N74230 001	MAR 14, 1995
	AB		EQ 500MG BASE	N74230 002	MAR 14, 1995

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA	BIOCRAFT	EQ 350MG BASE	N60304 001	
		EQ 350MG BASE	N60304 001	
AA	LILLY	EQ 350MG BASE	N60385 001	
@		EQ 350MG BASE	N60385 001	

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	+	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991
BC	+	CIBA	7MG/24HR	N20076 001 NOV 27, 1991
BC	+		14MG/24HR	N20076 002 NOV 27, 1991
BC	+		21MG/24HR	N20076 003 NOV 27, 1991

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

		NICORETTE			
	+	MERRELL DOW	EQ 2MG BASE		N18612 001 JAN 13, 1984
	+	SMITHKLINE BEECHAM	EQ 2MG BASE		N18612 001 JAN 13, 1984
		NICORETTE DS			
	+	MERRELL DOW	EQ 4MG BASE		N20066 001 JUN 08, 1992
	+	SMITHKLINE BEECHAM	EQ 4MG BASE		N20066 001 JUN 08, 1992

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

		ADALAT CC			
BC	+	BAYER	30MG		N20198 001 APR 21, 1993
BC	+		60MG		N20198 002 APR 21, 1993
BC	+		90MG		N20198 003 APR 21, 1993
BC		MILES	30MG		N20198 001 APR 21, 1993
BC			60MG		N20198 002 APR 21, 1993
BC			90MG		N20198 003 APR 21, 1993

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

>DLT>		NISOCOR			
>DLT>	+	ZENECA	10MG		N20356 001
>DLT>	+		20MG		N20356 002
>DLT>	+		30MG		N20356 003
>DLT>	+		40MG		N20356 004
>ADD>		SULAR			
>ADD>	+	ZENECA	10MG		N20356 001 FEB 02, 1995
>ADD>	+		20MG		N20356 002 FEB 02, 1995
>ADD>	+		30MG		N20356 003 FEB 02, 1995
>ADD>	+		40MG		N20356 004 FEB 02, 1995

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

		SULAR			
	+	ZENECA	40MG		N20356 004 FEB 02, 1995

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

		NITROFURANTOIN			
AB		GENEVA PHARMS	25MG		N74336 001 JAN 25, 1995
AB			50MG		N74336 002 JAN 25, 1995
AB			100MG		N74336 003 JAN 25, 1995

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

		NITRO-DUR			
	+	KEY PHARMS	0.1MG/HR		N20145 001 APR 04, 1995
	+		0.2MG/HR		N20145 002 APR 04, 1995
	+		0.3MG/HR		N20145 003 APR 04, 1995
	+		0.4MG/HR		N20145 004 APR 04, 1995
	+		0.6MG/HR		N20145 005 APR 04, 1995
	+		0.8MG/HR		N20145 006 APR 04, 1995

INJECTABLE; INJECTION

		NITROGLYCERIN			
AP		FUJISAWA	5MG/ML		N70077 001 DEC 13, 1985
	@		5MG/ML		N70077 001 DEC 13, 1985
		NITROSTAT			
AP		PARKE DAVIS	5MG/ML		N18588 002 DEC 23, 1983
	+		0.8MG/ML		N18588 001
	@		0.8MG/ML		N18588 001

NITROGLYCERIN

INJECTABLE; INJECTION

	NITROSTAT			
	@ PARKE DAVIS	5MG/ML	N18588 002	DEC 23, 1983
	TRIDIL			
AP	DUPONT MERCK	5MG/ML	N18537 001	
	+	0.5MG/ML	N18537 002	JUN 16, 1983
AP	FAULDING	5MG/ML	N18537 001	
	+	0.5MG/ML	N18537 002	JUN 16, 1983

NORETHINDRONE

TABLET; ORAL

	NOR-Q.D.		
	SEARLE	0.35MG	N17060 001
	SYNTEX	0.35MG	N17060 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	LEMMON	EQ 10MG BASE	N74132 001	MAR 27, 1995
AB		EQ 25MG BASE	N74132 002	MAR 27, 1995
AB		EQ 50MG BASE	N74132 003	MAR 27, 1995
AB		EQ 75MG BASE	N74132 004	MAR 27, 1995

NYSTATIN

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	500,000 UNITS	N60574 001	
AA	+ SQUIBB	500,000 UNITS	N60574 001	

TABLET; VAGINAL

	NYSTATIN			
AT	LEMMON	100,000 UNITS	N62502 001	DEC 23, 1983

NYSTATIN

TABLET; VAGINAL

	NYSTATIN			
	@ LEMMON	100,000 UNITS	N62502 001	DEC 23, 1983

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	PHARMAFAIR	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986
	@	100,000 UNITS/GM;0.1%	N62656 001	JUL 30, 1986

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	PRILOSEC			
	+ ASTRA MERCK	10MG	N19810 003	OCT 05, 1995

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	ZOFRAN IN PLASTIC CONTAINER			
	+ GLAXO WELLCOME	EQ 0.64MG BASE/ML	N20403 001	JAN 31, 1995

OXACILLIN SODIUM

CAPSULE; ORAL

	OXACILLIN SODIUM			
AB	APOTHECON	EQ 250MG BASE	N61450 002	
AB	+	EQ 500MG BASE	N61450 001	
	PROSTAPHLIN			
AB	APOTHECON	EQ 250MG BASE	N61450 002	
AB	+	EQ 500MG BASE	N61450 001	
	@	EQ 500MG BASE	N50118 002	
	@ BRISTOL	EQ 500MG BASE	N50118 002	

INJECTABLE; INJECTION

	OXACILLIN SODIUM			
>ADD> AP	IBI	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995
>ADD>				

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

> ADD >	AP	IBI	EQ 500MG BASE/VIAL	N62798 005	
> ADD >				DEC 11, 1995	
> ADD >	AP		EQ 1GM BASE/VIAL	N62798 001	
> ADD >				DEC 11, 1995	
> ADD >	AP		EQ 2GM BASE/VIAL	N62798 002	
> ADD >				DEC 11, 1995	
> ADD >			EQ 125MG BASE/VIAL	N62798 003	
> ADD >				DEC 11, 1995	

POWDER FOR RECONSTITUTION; ORAL
OXACILLIN SODIUM

	AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
		PROSTAPHLIN		
	AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
		@	EQ 250MG BASE/5ML	N50194 001
		@ BRISTOL	EQ 250MG BASE/5ML	N50194 001

> ADD > OXYCODONE HYDROCHLORIDE

> ADD > TABLET, EXTENDED RELEASE; ORAL
> ADD > OXYCONTIN

> ADD >		+ PURDUE FREDERICK	10MG	N20553 001
> ADD >				DEC 12, 1995
> ADD >		+	20MG	N20553 002
> ADD >				DEC 12, 1995
> ADD >		+	40MG	N20553 003
> ADD >				DEC 12, 1995

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL
DARICON

		+ PFIZER	10MG	N11612 001
		@	10MG	N11612 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
> DLT > OXY-KESSO-TETRA

> ADD >		@ FERRANTE	EQ 250MG BASE	N60179 001
> DLT >	AB	MK LABS	EQ 250MG BASE	N60179 001

PENBUTOLOL SULFATE

TABLET; ORAL
LEVATOL

@ REED AND CARNRICK	10MG		N18976 001
			DEC 30, 1987
+	20MG		N18976 004
			JAN 05, 1989
@ SPKU	10MG		N18976 001
			DEC 30, 1987
+	20MG		N18976 004
			JAN 05, 1989

PENICILLAMINE

TABLET; ORAL
DEPEN

+ WALLACE	250MG		N19854 001
DEPEN 250			
+ WALLACE	250MG		N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

		@ CONSOLIDATED PHARM	500,000 UNITS/VIAL	N60806 001
		@	1,000,000 UNITS/VIAL	N60806 002
		@	5,000,000 UNITS/VIAL	N60806 003
		@	10,000,000 UNITS/VIAL	N60806 004
		@ COPANOS	500,000 UNITS/VIAL	N60806 001
		@	1,000,000 UNITS/VIAL	N60806 002
		@	5,000,000 UNITS/VIAL	N60806 003
		@	10,000,000 UNITS/VIAL	N60806 004
AP		+ LILLY	1,000,000 UNITS/VIAL	N60384 002
AP		+	5,000,000 UNITS/VIAL	N60384 001
AP		+	20,000,000 UNITS/VIAL	N60384 005
AP			20,000,000 UNITS/VIAL	N60601 001
		+	200,000 UNITS/VIAL	N60384 004
		+	500,000 UNITS/VIAL	N60384 003
		@	200,000 UNITS/VIAL	N60384 004
		@	500,000 UNITS/VIAL	N60384 003
		@	1,000,000 UNITS/VIAL	N60384 002
		@	5,000,000 UNITS/VIAL	N60384 001
		@	20,000,000 UNITS/VIAL	N60384 005
		@	20,000,000 UNITS/VIAL	N60601 001
		PFIZERPEN		
AP		PFIZER	1,000,000 UNITS/VIAL	N60657 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PFIZERPEN			
AP	+ PFIZER	1,000,000 UNITS/VIAL	N60657 001	
AP		5,000,000 UNITS/VIAL	N60657 002	
AP	+	5,000,000 UNITS/VIAL	N60657 002	
AP		20,000,000 UNITS/VIAL	N60657 003	
AP	+	20,000,000 UNITS/VIAL	N60657 003	

TABLET; ORAL

	PENICILLIN G POTASSIUM			
AB	DISTA	250,000 UNITS	N60403 001	
	@ LILLY	250,000 UNITS	N60403 001	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	PENICILLIN G PROCAINE			
	@ CONSOLIDATED PHARM	300,000 UNITS/ML	N60800 001	
	@	600,000 UNITS/1.2ML	N60800 002	
	@ COPANOS	300,000 UNITS/ML	N60800 001	
	@	600,000 UNITS/1.2ML	N60800 002	

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	PENICILLIN V POTASSIUM			
AA	CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61529 001	
AA		EQ 250MG BASE/5ML	N61529 002	
AA	COPANOS	EQ 125MG BASE/5ML	N61529 001	
AA		EQ 250MG BASE/5ML	N61529 002	

TABLET; ORAL

	BETAPEN-VK			
AB	APOTHECON	EQ 250MG BASE	N61411 001	
AB		EQ 500MG BASE	N61411 002	
	PENICILLIN V POTASSIUM			
AB	BIOCHEMIE	EQ 250MG BASE	N64071 001	
			NOV 30, 1995	
AB		EQ 500MG BASE	N64071 002	
			NOV 30, 1995	
AB	CONSOLIDATED PHARM	EQ 250MG BASE	N61528 001	
AB		EQ 500MG BASE	N61528 002	
AB	COPANOS	EQ 250MG BASE	N61528 001	
AB		EQ 500MG BASE	N61528 002	
	VEETIDS			
AB	APOTHECON	EQ 250MG BASE	N61411 001	

> ADD >
> ADD >

PENICILLIN V POTASSIUM

TABLET; ORAL

	VEETIDS		
AB	APOTHECON	EQ 500MG BASE	N61411 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTACARINAT		
AP	ARMOUR	300MG/VIAL	N73447 001
			APR 28, 1994
AP	RHONE POULENC RORER	300MG/VIAL	N73447 001
			APR 28, 1994
	PENTAMIDINE ISETHIONATE		
AP	ELKINS SINN	300MG/VIAL	N73617 001
			DEC 18, 1995
AP	STERIS	300MG/VIAL	N74303 001
			AUG 17, 1995

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON		
	AMARIC	2MG	N20184 001
			DEC 30, 1993
		4MG	N20184 002
			DEC 30, 1993
	+	8MG	N20184 003
			DEC 30, 1993
	JOHNSON RW	2MG	N20184 001
			DEC 30, 1993
		4MG	N20184 002
			DEC 30, 1993
	+	8MG	N20184 003
			DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	MELFIAT-105		
	@ NUMARK	105MG	N87487 001
			OCT 13, 1982
	@ SOLVAY	105MG	N87487 001
			OCT 13, 1982

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	SPRX-105		
	@ NUMARK	105MG	N88024 001 DEC 22, 1982
	@ SOLVAY	105MG	N88024 001 DEC 22, 1982

TABLET; ORAL

	MELFIAT		
	@ NUMARK	35MG	N83790 002
	@ SOLVAY	35MG	N83790 002
	PHENDIMETRAZINE TARTRATE		
	@ NUMARK	35MG	N83790 001
	@ SOLVAY	35MG	N83790 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL		
AA	LEMMON	30MG	N87777 001 NOV 01, 1985
	@	30MG	N87777 001 NOV 01, 1985

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN		
	FISONS	EQ 15MG BASE	N11613 004
+		EQ 30MG BASE	N11613 002
	IONAMIN-15		
	FISONS	EQ 15MG BASE	N11613 004
	IONAMIN-30		
+	FISONS	EQ 30MG BASE	N11613 002

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

	PINDAC		
+	LEO PHARM	12.5MG	N19456 001 DEC 28, 1989
+		25MG	N19456 002 DEC 28, 1989

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

	PINDAC		
	@ LEO PHARM	12.5MG	N19456 001 DEC 28, 1989
	@	25MG	N19456 002 DEC 28, 1989

PINDOLOL

TABLET; ORAL

	PINDOLOL		
AB	ROYCE LABS	5MG	N74437 001 FEB 27, 1995
AB		10MG	N74437 002 FEB 27, 1995

PIROXICAM

CAPSULE; ORAL

	PIROXICAM		
AB	ROYCE LABS	10MG	N74460 001 SEP 29, 1995
AB		20MG	N74460 002 SEP 29, 1995

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

POWDER FOR RECONSTITUTION; ORAL

	NULYTELY-FLAVORED		
	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT; 11.2GM/BOT	N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	COLYTE		
AA	KREMERS URBAN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 010 JAN 31, 1989

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

COLYTE

AA	KREMERS URBAN	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007 JUN 12, 1987
	@ REED AND CARNRICK	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005 OCT 26, 1984
	@	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004 OCT 26, 1984
	@	360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006 OCT 26, 1984
AA	SPKU	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 010 JAN 31, 1989
AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 007 JUN 12, 1987
	@	120GM/PACKET;1.49GM/PACKET; 3.36GM/PACKET;2.92GM/PACKET; 11.36GM/PACKET	N18983 005 OCT 26, 1984
	@	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N18983 004 OCT 26, 1984
	@	360GM/PACKET;4.47GM/PACKET; 10.08GM/PACKET;8.76GM/PACKET; 34.08GM/PACKET	N18983 006 OCT 26, 1984

COLYTE-FLAVORED

AA	KREMERS URBAN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008 NOV 14, 1991
AA		240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009 NOV 14, 1991
AA	SPKU	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N18983 008 NOV 14, 1991

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

COLYTE-FLAVORED

AA	SPKU	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT	N18983 009 NOV 14, 1991

GOLYTELY

AA	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N19011 002 JUN 02, 1992

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

	PFIZER	0.5MG;1MG	N17986 001
		0.5MG;2MG	N17986 002
	+	0.5MG;5MG	N17986 003
		0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
	+	0.5MG;EQ 5MG BASE	N17986 003

> ADD > PORFIMER SODIUM

> ADD > INJECTABLE; INJECTION

> ADD > PHOTOFRIN

> ADD > + QLT 75MG/VIAL N20451 001 DEC 27, 1995

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	AKORN	2MEQ/ML	N88286 001 SEP 05, 1985
	@	2MEQ/ML	N88286 001 SEP 05, 1985

TABLET, EXTENDED RELEASE; ORAL

KAON CL

	SAVAGE LABS	6.7MEQ	N17046 001
	@	6.7MEQ	N17046 001

KAON CL-10

BC	SAVAGE LABS	10MEQ	N17046 002

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
KAON CL-10
@ SAVAGE LABS 10MEQ N17046 002

PREDNISOLONE

TABLET; ORAL
CORTALONE
BX HALSEY 1MG N80304 003
BX 2.5MG N80304 002
BX 5MG N80304 001
@ 1MG N80304 003
@ 2.5MG N80304 002
@ 5MG N80304 001
PREDNISOLONE
>ADD< @ FERRANTE 2.5MG N80562 001
>ADD< @ 5MG N80562 002
>DLT< BX MARSHALL PHARMA 2.5MG N80562 001
>DLT< BX 5MG N80562 002
BX SPERTI 1MG N80358 001
1MG N80358 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS
AB ALCON **1%** **N17469 001**
EX 1% N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL
AP + MERCK SHARP DOHME EQ 20MG PHOSPHATE/ML N11583 002
+ EQ 20MG PHOSPHATE/ML N11583 002
PREDNISOLONE SODIUM PHOSPHATE
AP STERIS EQ 20MG PHOSPHATE/ML N80517 001
@ EQ 20MG PHOSPHATE/ML N80517 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
>ADD< >ADD< **AT** BAUSCH AND LOMB **EQ 0.23% PHOSPHATE;10%** N74449 001
DEC 29, 1995

PREDNISONE

TABLET; ORAL
CORTAN
BX HALSEY 20MG N87480 001
@ 20MG N87480 001

PROBUCOL

TABLET; ORAL
LORELCO
@ HOECHST MARION RSSL 250MG N17535 001
@ 500MG N17535 002
JUL 06, 1988
MERRELL DOW 250MG N17535 001
+ 500MG N17535 002
JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL
PRONESTYL
APOTHECON 250MG N17371 001
375MG N17371 002
+ 500MG N17371 003
SQUIBB 250MG N17371 001
375MG N17371 002
+ 500MG N17371 003

TABLET, EXTENDED RELEASE; ORAL
PROCAN SR
AB PARKE DAVIS 250MG N86468 001
@ 250MG N86468 001
PRONESTYL-SR
BC APOTHECON 500MG N87361 001
BC BRISTOL MYERS SQUIBB 500MG N87361 001

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	AKORN	25MG/ML	N83955 002	> ADD >	
AP		50MG/ML	N83955 001	> ADD >	
@		25MG/ML	N83955 002	> ADD >	
@		50MG/ML	N83955 001	> ADD >	

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

AA	DANBURY PHARMA	15MG	N83029 002
@		15MG	N83029 002
AA	GLOBAL PHARMS	15MG	N84541 002
@		15MG	N84541 002
AA	TABLICAPS	15MG	N84428 001
@		15MG	N84428 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPHTHAINE

AT	+ APOTHECON	0.5%	N08883 001	
AT	* SQUIBB	0.5%	N08883 001	

PROPARACAINE HCL

AT	BAUSCH AND LOMB	0.5%	N40074 001
			SEP 29, 1995

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

> DLT >	AB	INTERPHARM	10MG	N71368 001	
> DLT >				MAY 05, 1987	
> DLT >	AB		20MG	N71369 001	
> DLT >				MAY 05, 1987	
> DLT >	AB		40MG	N71370 001	
> DLT >				MAY 05, 1987	
> DLT >	AB		80MG	N71371 001	
> DLT >				MAY 05, 1987	
> ADD >	@		10MG	N71368 001	
> ADD >				MAY 05, 1987	
> ADD >	@		20MG	N71369 001	
> ADD >				MAY 05, 1987	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

@	INTERPHARM	40MG	N71370 001
			MAY 05, 1987
@		80MG	N71371 001
			MAY 05, 1987
AB	PARKE DAVIS	20MG	N70439 001
			SEP 15, 1986
AB		40MG	N70440 001
			SEP 15, 1986
AB		60MG	N70441 001
			SEP 24, 1986
AB		80MG	N70442 001
			SEP 15, 1986
AB	WARNER CHILCOTT	10MG	N70438 001
			SEP 15, 1986
@		10MG	N70438 001
			SEP 15, 1986
@		20MG	N70439 001
			SEP 15, 1986
@		40MG	N70440 001
			SEP 15, 1986
@		60MG	N70441 001
			SEP 24, 1986
@		80MG	N70442 001
			SEP 15, 1986

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	LILLY	50MG	N06213 001
@		50MG	N06213 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
PROTRIPTYLINE HCL

AB	SIDMAK LABS NJ	5MG	N73644 001
			AUG 24, 1995
AB		10MG	N73645 001
			AUG 24, 1995

VIVACTIL

AB	MERCK SHARP DOHME	5MG	N16012 001
AB +		10MG	N16012 002

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	AKORN	100MG/ML	N87967 001
			OCT 01, 1982
	@	100MG/ML	N87967 001
			OCT 01, 1982

QUINESTROL

TABLET; ORAL
ESTROVIS

	+ PARKE DAVIS	0.1MG	N16768 002
	@	0.1MG	N16768 002

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINALAN

BC	LANNETT	324MG	N88081 001
			FEB 10, 1986
	@	324MG	N88081 001
			FEB 10, 1986

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	PHOENIX LABS NY	200MG	N83963 001
	@ VINTAGE PHARMS	200MG	N83963 001

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUDIXIN

BP	APOTHECON	50MG	N08842 001
BP	+	100MG	N08842 002
	@	50MG	N08842 001
	@	100MG	N08842 002

RAUVAL

BP	VALE	100MG	N09108 004
BP	+	100MG	N09108 004

RAUWOLFIA SERPENTINA

BP	HALSEY	50MG	N80498 001

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUWOLFIA SERPENTINA

BP	HALSEY	100MG	N80498 002
	@	50MG	N80498 001
	@	100MG	N80498 002

> ADD >

RILUZOLE

> ADD >
TABLET; ORAL
> ADD >
RILUTEK
> ADD >

	+ RHONE POULENC	50MG	N20599 001
> ADD >			DEC 12, 1995

RITODRINE HYDROCHLORIDE

TABLET; ORAL
YUTOPAR

	+ ASTRA	10MG	N18555 001
	@	10MG	N18555 001

> ADD > SAQUINAVIR MESYLATE

> ADD >
CAPSULE; ORAL
> ADD >
INVIRASE
> ADD >

	+ ROCHE	EQ 200MG BASE	N20628 001
> ADD >			DEC 06, 1995

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM

AA	ZENITH LABS	100MG	N85869 001
	@	100MG	N85869 001

SEVOFLURANE

LIQUID; INHALATION
ULTANE

	ABBOTT	100%	N20478 001
			JUN 07, 1995

SILVER SULFADIAZINE

CREAM; TOPICAL
SSD AF

BX	KNOLL PHARM	1%	N18578 003	JUL 11, 1990

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	9MG/ML	N16677 004	OCT 30, 1985
AP	+	9MG/ML	N16677 004	OCT 30, 1985

SOLUTION; IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	BAXTER	450MG/100ML	N18497 001	FEB 19, 1982
	@	450MG/100ML	N18497 001	FEB 19, 1982

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

	BRACCO	200 uCi/ML	N13993 001	
	BRACCO DXS	250 uCi/VIAL	N13993 001	
		1mCi/VIAL	N13993 003	

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
BIO-TROPIN

+	BIO TECH GEN	4.8MG/VIAL	N19774 001	MAY 25, 1995

GENOTROPIN

+	PHARMACIA	1.5MG/VIAL	N20280 004	AUG 24, 1995
+		5.8MG/VIAL	N20280 006	AUG 24, 1995

NORDITROPIN

+	NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
NORDITROPIN

+	NOVO NORDISK	8MG/VIAL	N19721 002	MAY 08, 1995

> ADD >
NUTROPIN AQ

+	GENENTECH	5MG/ML	N20522 001	DEC 29, 1995

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

	BERLEX	120MG	N19865 005 APR 20, 1994
	@	120MG	N19865 005 APR 20, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP		LILLY	EQ 1GM BASE/VIAL	N60107 001
AP			EQ 5GM BASE/VIAL	N60107 002
			EQ 1GM BASE/2ML	N60404 001
	@		EQ 1GM BASE/2ML	N60404 001
	@		EQ 1GM BASE/VIAL	N60107 001
	@		EQ 5GM BASE/VIAL	N60107 002
AP	+	PFIZER	EQ 1GM BASE/VIAL	N60076 001
AP	+		EQ 5GM BASE/VIAL	N60076 002
	+		EQ 1GM BASE/VIAL	N60076 001
	+		EQ 5GM BASE/VIAL	N60076 002

SUCCIMER

CAPSULE; ORAL
CHEMET

+	BOCK PHARMA	100MG	N19998 002	JAN 30, 1991
+	MCNEIL CONS PRODS	100MG	N19998 002	JAN 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCOSTRIN

AP	APOTHECON	20MG/ML	N08847 001
@		100MG/ML	N08847 003
AP	SQUIBB	20MG/ML	N08847 001
@		100MG/ML	N08847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTA

> ADD >	AP	+ JANSSEN	EQ 0.05MG BASE/ML	N19050 001
> ADD >				MAY 04, 1984
> ADD >		**SUFENTANIL CITRATE**		
> ADD >	AP	ELKINS SINN	EQ 0.05MG BASE/ML	N74413 001
> ADD >				DEC 15, 1995
> ADD >	AP	STERIS	EQ 0.05MG BASE/ML	N74406 001
> ADD >				DEC 15, 1995

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULF-15

AT	CIBA	15%	N89047 001
			OCT 31, 1995

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

AB	BARRE	200MG/5ML;40MG/5ML	N72289 001
			MAY 23, 1988
@		200MG/5ML;40MG/5ML	N72289 001
			MAY 23, 1988

SULFUR

POWDER; TOPICAL
BENSULFOID

@ POYTHRESS	33.32%	N02918 001

SUMATRIPTAN SUCCINATE

TABLET; ORAL
IMITREX

	GLAXO WELLCOME	EQ 25MG BASE	N20132 002
			JUN 01, 1995
+		EQ 50MG BASE	N20132 003
			JUN 01, 1995
@		EQ 100MG BASE	N20132 001
			JUN 01, 1995

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
TECHNELITE

DUPONT	0.0083-2.7 CI/GENERATOR	N17771 001
TECHNETIUM TC 99M GENERATOR		
DUPONT	0.0083-2.7 CI/GENERATOR	N17771 001

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

+ THERATECH	2.5MG/24HR	N20489 001
		SEP 29, 1995

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

> ADD >	@ FERRANTE	125MG	N60173 001
> ADD >	@	250MG	N60173 002
> DLT > AB	MK LABS	250MG	N60173 002
> DLT >		125MG	N60173 001
AB	PVT FORM	250MG	N62686 001
			JUL 24, 1986
AB		500MG	N62686 002
			JUL 24, 1986
@		250MG	N62686 001
			JUL 24, 1986
@		500MG	N62686 002
			JUL 24, 1986

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

+ ON SITE	12.7MG/FIBER	N50653 001
		MAR 25, 1994

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

	ACTISITE			
	+ ON SITE ALZA	12.7MG/FIBER	N50653 001 MAR 25, 1994	

OINTMENT; OPHTHALMIC

	ACHROMYCIN			
	+ LEDERLE	10MG/GM	N50266 001	
	@ STORZ OPHTHALM	10MG/GM	N50266 001	

SUSPENSION; ORAL

	ACHROMYCIN V			
AB	+ LEDERLE	125MG/5ML	N50263 002	
	SUMYCIN			
AB	APOTHECON	125MG/5ML	N60400 001	
	TETRACYCLINE HCL			
AB	BARRE	125MG/5ML	N60633 001	
> ADD >	@ FERRANTE	125MG/5ML	N60174 001	
> DLT > AB	MK LABS	125MG/5ML	N60174 001	
	@ PROTER	125MG/5ML	N60446 001	
AB	PUREPAC PHARM	125MG/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	125MG/5ML	N60095 001	
	TETRAMED			
AB	ZENITH LABS	125MG/5ML	N61468 001	

SUSPENSION/DROPS, OPHTHALMIC

	ACHROMYCIN			
	+ LEDERLE	1%	N50268 001	
	@ STORZ OPHTHALM	1%	N50268 001	

SYRUP; ORAL

	ACHROMYCIN V			
AB	+ LEDERLE	125MG/5ML	N50263 002	
	SUMYCIN			
AB	SQUIBB	125MG/5ML	N60400 001	
	TETRACYCLINE HCL			
AB	BARRE	125MG/5ML	N60633 001	
AB	PUREPAC PHARM	125MG/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	125MG/5ML	N60095 001	
	TETRAMED			
AB	ZENITH LABS	125MG/5ML	N61468 001	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	THEOPHYLLINE			
BC	FAULDING	100MG	N89976 001 JAN 04, 1995	
BC		200MG	N89977 001 JAN 04, 1995	
BC		300MG	N89932 001 JAN 04, 1995	

TABLET, EXTENDED RELEASE; ORAL

	LABID			
BC	+ PROCTER AND GAMBLE	250MG	N87225 001	
	@	250MG	N87225 001	
	THEOLAIR-SR			
BC	3M	250MG	N86363 002 JUL 16, 1987	
		250MG	N86363 002 JUL 16, 1987	
	THEOPHYLLINE			
AB	INWOOD LABS	**450MG**	**N40034 001** APR 28, 1995	
	UNI-DUR			
BC	+ KEY PHARMS	400MG	N89822 001 JAN 04, 1995	
	+	600MG	N89823 001 JAN 04, 1995	
	UNIPHYL			
BC	PURDUE FREDERICK	400MG	N87571 001 SEP 01, 1982	

THEOPHYLLINE SODIUM GLYCINATE

TABLET, ORAL

ASBRON			
+ DORSEY	EQ 150MG BASE	N85148 001	
@ SANDOZ	EQ 150MG BASE	N85148 001	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL			
AP	AKORN	100MG/ML	N87968 001 OCT 01, 1982	
	@	100MG/ML	N87968 001 OCT 01, 1982	

THIOTEPA

INJECTABLE; INJECTION

	THIOPLEX			
	IMMUNEX	15MG/VIAL	N20058 001	
			DEC 22, 1994	
AP	LEDERLE	15MG/VIAL	N20058 001	
			DEC 22, 1994	
	THIOTEPA			
AP +	IMMUNEX	15MG/VIAL	N11683 001	
+		15MG/VIAL	N11683 001	

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

		THIOTHIXENE HCL			
>DLT>	AA	LEMMON	EQ 5MG BASE/ML	N71184 001	
>DLT>				JUN 22, 1987	
>ADD>		@	EQ 5MG BASE/ML	N71184 001	
>ADD>				JUN 22, 1987	

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TICAR		
+	SMITHKLINE BEECHAM	EQ 6GM BASE/VIAL	N50497 003
	@	EQ 6GM BASE/VIAL	N50497 003

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL			
+	LEIRAS	EQ 0.25% BASE	N20439 001	
			MAR 31, 1995	>DLT>
+		EQ 0.5% BASE	N20439 002	>DLT>
			MAR 31, 1995	>ADD>
				>ADD>

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	ALCON	**EQ 0.25% BASE**	**N74261 001**	
			APR 28, 1995	
AT		**EQ 0.5% BASE**	**N74262 001**	
			APR 28, 1995	

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOPTIC			
AT +	MERCK	**EQ 0.25% BASE**	**N18086 001**	
AT +		**EQ 0.5% BASE**	**N18086 002**	

TIOCONAZOLE

OINTMENT; VAGINAL

	VAGISTAT-1			
+	BRISTOL MYERS	6.5%	N19355 001	
			DEC 30, 1986	
+	BRISTOL MYERS SQUIBB	6.5%	N19355 001	
			DEC 30, 1986	

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

	TONOCARD			
	ASTRA MERCK	400MG	N18257 001	
			NOV 09, 1984	
+		600MG	N18257 002	
			NOV 09, 1984	
	MERCK SHARP DOHME	400MG	N18257 001	
			NOV 09, 1984	
+		600MG	N18257 002	
			NOV 09, 1984	

TOLMETIN SODIUM

CAPSULE; ORAL

		TOLMETIN SODIUM			
>DLT>	AB	BAKER NORTON	**EQ 400MG BASE**	**N73392 001**	
>DLT>				JAN 24, 1992	
>ADD>	AB	ZENITH GOLDLINE	**EQ 400MG BASE**	**N73392 001**	
>ADD>				JAN 24, 1992	

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	ULTRAM			
+	JOHNSON RW	50MG	N20281 002	
			MAR 03, 1995	

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
ULTRAM
@ JOHNSON RW 100MG N20281 001
MAR 03, 1995

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
> ADD > AB MUTUAL PHARM **150MG** N73138 001
> ADD > DEC 22, 1995
AB SIDMAK LABS NJ **150MG** N71525 001
MAR 09, 1988
TRAZON-150
AB SIDMAK LABS NJ **150MG** N71525 001
MAR 09, 1988

TRETINOIN

CAPSULE; ORAL
VESANOID
+ ROCHE 10MG N20438 001
NOV 22, 1995

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
KENALOG-H
AT APOTHECON **0.1%** N86240 001
AT WESTWOOD SQUIBB **0.1%** N86240 001

INJECTABLE; INJECTION
KENALOG-10
+ APOTHECON 10MG/ML N12041 001
+ WESTWOOD SQUIBB 10MG/ML N12041 001
KENALOG-40
BP APOTHECON 40MG/ML N14901 001
BP WESTWOOD SQUIBB 40MG/ML N14901 001

LOTION; TOPICAL
KENALOG
AT APOTHECON **0.025%** N84343 001
AT + **0.1%** N84343 002
@ 0.025% N11602 003

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
KENALOG
@ APOTHECON 0.1% N11602 001
AT WESTWOOD SQUIBB **0.025%** N84343 001
AT + **0.1%** N84343 002
@ 0.025% N11602 003
@ 0.1% N11602 001
TRIAMCINOLONE ACETONIDE
AT BARRE **0.025%** N87191 001
SEP 08, 1982
@ 0.025% N87191 001
SEP 08, 1982

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE IN ABSORBASE
+ CAROLINA MEDCL 0.05% N89595 001
MAR 23, 1995

PASTE; DENTAL
KENALOG IN ORABASE
AT + APOTHECON **0.1%** N12097 001
AT + SQUIBB **0.1%** N12097 001

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT
BP + LEDERLE 25MG/ML N11685 003
+ 25MG/ML N11685 003
TRIAMCINOLONE DIACETATE
BP AKORN 25MG/ML N85122 001
BP 40MG/ML N86394 001
@ 25MG/ML N85122 001
@ 40MG/ML N86394 001

TRIAZOLAM

TABLET; ORAL
TRIAZOLAM
AB CHELSEA LABS **0.125MG** **N74445 001**
OCT 20, 1995
AB **0.25MG** **N74445 002**
OCT 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL
NAQUA

BP		SCHERING	2MG	N12265 001
	@		2MG	N12265 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC
TRIFLURIDINE

AT		STERIS	1%	N74311 001 OCT 06, 1995

VIROPTIC

AT	+	GLAXO WELLCOME	1%	N18299 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
ARTANE

AA		LEDERLE	2MG/5ML	N06773 009
AA	+		2MG/5ML	N06773 009

TRILOSTANE

CAPSULE; ORAL
MODRASTANE

		SANOFI WINTHROP	30MG	N18719 002 DEC 31, 1984
	+		60MG	N18719 001 DEC 31, 1984
	@		30MG	N18719 002 DEC 31, 1984
	@		60MG	N18719 001 DEC 31, 1984

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

		ASCENT	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995

TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
TRIPROLIDINE HCL

	+	DANBURY PHARMA	2.5MG	N85094 001
	@		2.5MG	N85094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL
TERFONYL

	+	SQUIBB	167MG/5ML;167MG/5ML; 167MG/5ML	N06904 002
	@		167MG/5ML;167MG/5ML; 167MG/5ML	N06904 002

TABLET; ORAL
SULFA-TRIPLE #2

AB		GLOBAL PHARMS	167MG;167MG;167MG	N80079 001
AB	+		167MG;167MG;167MG	N80079 001

TERFONYL

AB	+	SQUIBB	167MG;167MG;167MG	N06904 001
	@		167MG;167MG;167MG	N06904 001

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

AP	+	APOTHECON	3MG/ML	N05657 001
AP	+	SQUIBB	3MG/ML	N05657 001

UROFOLLITROPIN

INJECTABLE; INJECTION
METRODIN

		SERONO	150 IU/AMP	N19415 003 SEP 18, 1986

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX

	+	GLAXO WELLCOME	EQ 500MG BASE	N20487 001 JUN 23, 1995

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX

	@	GLAXO WELLCOME	EQ 1GM BASE	N20487 002 JUN 23, 1995

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

AA		HIGH TECH PHARMA	**250MG/5ML**	**N74060 001** JAN 13, 1995

VANCOMYCIN HYDROCHLORIDE

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL

AA		LILLY	**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
AA	*		**EQ 500MG BASE/6ML**	**N61667 001**
AB			**EQ 250MG BASE/5ML**	**N61667 002** JUL 13, 1983
	+		EQ 500MG BASE/6ML	N61667 001

VANCOLED

AA		LEDERLE	**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
AA			**EQ 500MG BASE/6ML**	**N63321 003** OCT 15, 1993
AB			**EQ 250MG BASE/5ML**	**N63321 002** OCT 15, 1993
	@		EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON

AP	+	ORGANON	**10MG/VIAL**	**N18776 002** APR 30, 1984
AP	+		**20MG/VIAL**	**N18776 003** JAN 03, 1992

VECURONIUM BROMIDE

AP		STERIS	**10MG/VIAL**	**N74334 001** AUG 31, 1995

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP		STERIS	**20MG/VIAL**	**N74334 002** AUG 31, 1995

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
VERAPAMIL HCL

AP		BEDFORD	**2.5MG/ML**	**N72888 001** JUL 28, 1995

VITAMIN A

CAPSULE; ORAL
VITAMIN A

AA		BANNER PHARMACAPS	**50,000 USP UNITS**	**N83973 001**
	@		50,000 USP UNITS	N83973 001

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A

AA		BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N80702 001**
	@		EQ 50,000 UNITS BASE	N80702 001

VITAMIN A PALMITATE

AA		BANNER PHARMACAPS	**EQ 50,000 UNITS BASE**	**N83948 001**
	@		EQ 50,000 UNITS BASE	N83948 001

WARFARIN SODIUM

INJECTABLE; INJECTION
COUMADIN

	+	DUPONT MERCK	5MG/VIAL	N09218 024 FEB 07, 1995

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP		FUJISAWA	**100%**	**N89099 001** DEC 29, 1987

WATER FOR INJECTION, STERILE

LIQUID; N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	FUJISAWA	100%	N89100 001 DEC 29, 1987
	@	100%	N89099 001 DEC 29, 1987
	@	100%	N89100 001 DEC 29, 1987

ZIDOVUDINE

> ADD >
> ADD >
> ADD >
> ADD >

TABLET; ORAL
RETROVIR

@ GLAXO WELLCOME	200MG	N20518 001 DEC 19, 1995

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACETAMINOPHEN

ABLE	120MG	N73106 001 FEB 27, 1995
	325MG	N73107 001 FEB 27, 1995
	650MG	N73108 001 FEB 27, 1995

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A

+ CIBA	0.5%;0.05%	N18746 002 JUL 11, 1994

AVOBENZONE; PADIMATE O

> ADD >
> ADD >

LOTION; TOPICAL
PHOTOPLEX

+ ALLERGAN HERBERT	3%;7%	N19459 001 SEP 30, 1988
@	3%;7%	N19459 001 SEP 30, 1988

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL; TOPICAL
POLYSPORIN

@ GLAXO WELLCOME	10,000 UNITS/GM; 2,000,000 UNITS/GM	N50167 002 MAR 01, 1985

> ADD > BUTOCONAZOLE NITRATE

> ADD > CREAM; VAGINAL
> ADD > FEMSTAT 3
> ADD > + SYNTEX 2% N20421 001
> ADD > DEC 21, 1995

CIMETIDINE

TABLET; ORAL
TAGAMET HB

+ SMITHKLINE BEECHAM	100MG	N20238 001 JUN 19, 1995

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

PERRIGO	1.34MG	N74512 001 NOV 22, 1995

CLOTRIMAZOLE

CREAM; VAGINAL
CLOTRIMAZOLE

TARO	1%	N72641 001 DEC 04, 1995

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
DISOBRON

GENEVA PHARMS	6MG;120MG	N70770 001 SEP 30, 1991
@	6MG;120MG	N70770 001 SEP 30, 1991

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
ANTITUSSIVE

PERRIGO	12.5MG/5ML	N71292 001 APR 10, 1987
@	12.5MG/5ML	N71292 001 APR 10, 1987

BELDIN

HALSEY	12.5MG/5ML	N89179 001 JUN 05, 1986
@	12.5MG/5ML	N89179 001 JUN 05, 1986

BENYLIN

+ PARKE DAVIS	12.5MG/5ML	N065514 004

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

BENYLIN			
@ PARKE DAVIS	12.5MG/5ML	N06514 004	
DIPHEN			
@ MORTON GROVE	12.5MG/5ML	N70118 001 OCT 01, 1985	
PENNEX	12.5MG/5ML	N70118 001 OCT 01, 1985	
DIPHENHYDRAMINE HCL			
CUMBERLAND SWAN	12.5MG/5ML	N73611 001 AUG 20, 1992	
@	12.5MG/5ML	N73611 001 AUG 20, 1992	
HI TECH PHARMA	12.5MG/5ML	N72416 001 SEP 28, 1990	
@	12.5MG/5ML	N72416 001 SEP 28, 1990	
HYDRAMINE			
BARRE	12.5MG/5ML	N70205 001 JAN 28, 1986	> ADD >
@	12.5MG/5ML	N70205 001 JAN 28, 1986	> ADD > > ADD > > ADD >
SILPHEN			
SILARX	12.5MG/5ML	N72646 001 FEB 27, 1992	
@	12.5MG/5ML	N72646 001 FEB 27, 1992	
VICKS FORMULA 44			
@ PROCTER AND GAMBLE	12.5MG/5ML	N70524 001 JAN 14, 1987	
VICKS HLTH CARE	12.5MG/5ML	N70524 001 JAN 14, 1987	

FAMOTIDINE

TABLET; ORAL

PEPCID AC			> DLT > > DLT >
+ MERCK	10MG	N20325 001 APR 28, 1995	> DLT > > ADD >

IBUPROFEN

CAPSULE; ORAL

MIDOL			
WINTHROP	200MG	N71002 001 SEP 02, 1987	
@	200MG	N70626 001 SEP 02, 1987	
@	200MG	N71002 001 SEP 02, 1987	
PROVEL			
+ SANDOZ	200MG	N20402 001 APR 20, 1995	

SUSPENSION; ORAL

CHILDREN'S MOTRIN		
+ MCNEIL CONS PRODS	100MG/5ML	N20516 001 JUN 16, 1995

TABLET; ORAL

IBUPROFEN			
INVAMED	200MG	N74525 001 DEC 15, 1995	
	200MG	N74533 001 DEC 15, 1995	
MIDOL			
WINTHROP	200MG	N70591 001 SEP 02, 1987	
	200MG	N71001 001 SEP 02, 1987	
@	200MG	N70591 001 SEP 02, 1987	
@	200MG	N71001 001 SEP 02, 1987	

IBUPROFEN

CAPSULE; ORAL

MIDOL		
+ WINTHROP	200MG	N70626 001 SEP 02, 1987

INSULIN PORK

INJECTABLE; INJECTION

REGULAR INSULIN		
NOVO NORDISK	100 UNITS/ML	N17926 003
@	100 UNITS/ML	N17926 003

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

VELOSULIN		
NOVO NORDISK	100 UNITS/ML	N18193 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION		
VELOSULIN		
@ NOVO NORDISK	100 UNITS/ML	N18193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION		
INSULIN NORDISK MIXTARD (PORK)		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N18195 001
@	30 UNITS/ML;70 UNITS/ML	N18195 001

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
NOVOLIN R		
+ NOVO NORDISK	100 UNITS/ML	N18778 001 AUG 30, 1983
@	100 UNITS/ML	N18778 001 AUG 30, 1983

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
MIXTARD HUMAN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
@	30 UNITS/ML;70 UNITS/ML	N19585 001 MAR 11, 1988
NOVOLIN 70/30		
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986
@	30 UNITS/ML;70 UNITS/ML	N19441 001 JUL 11, 1986

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION		
NPH ILETIN II		
+ LILLY	100 UNITS/ML	N18479 001
@	100 UNITS/ML	N18479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION		
INSULIN INSULATARD NPH NORDISK		
+ NOVO NORDISK	100 UNITS/ML	N18194 001
@	100 UNITS/ML	N18194 001
NPH ILETIN II (PORK)		
@ LILLY	100 UNITS/ML	N18345 001
+	100 UNITS/ML	N18345 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
INSULATARD NPH HUMAN		
+ NOVO NORDISK	100 UNITS/ML	N19449 001 MAY 30, 1986
@	100 UNITS/ML	N19449 001 MAY 30, 1986

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION		
PROTAMINE ZINC AND ILETIN II		
+ LILLY	100 UNITS/ML	N18476 001
@	100 UNITS/ML	N18476 001
PROTAMINE ZINC INSULIN		
SQUIBB	100 UNITS/ML	N17928 003
+	100 UNITS/ML	N17928 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION		
ULTRALENTE INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17997 003
@	100 UNITS/ML	N17997 003

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION		
SEMILENTE INSULIN		
+ NOVO NORDISK	100 UNITS/ML	N17996 003
@	100 UNITS/ML	N17996 003

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION		
NOVOLIN L		
+ NOVO NORDISK	100 UNITS/ML	N18777 001 AUG 30, 1983
@	100 UNITS/ML	N18777 001 AUG 30, 1983

KETOPROFEN

TABLET; ORAL		
ACTRON		
BAYER	12.5MG	N20499 001 OCT 06, 1995
ORUDIS KT		
+ WHITEHALL ROBINS	12.5MG	N20429 001 OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL		
LOPERAMIDE HCL		
HI TECH PHARMA	1MG/5ML	N74352 001 NOV 17, 1995
LEMMON	1MG/5ML	N73478 001 JUN 23, 1995

MICONAZOLE NITRATE

CREAM; VAGINAL		
MICONAZOLE NITRATE		
LEMMON	2%	N74136 001 JAN 04, 1995
SUPPOSITORY; VAGINAL		
MICONAZOLE NITRATE		
ABLE	100MG	N73507 001 NOV 19, 1993
NMC	100MG	N73507 001 NOV 19, 1993

NAPROXEN SODIUM

TABLET; ORAL		
ALEVE		
HAMILTON PHARMS	EQ 200MG BASE	N20204 002 JAN 11, 1994
+	EQ 200MG BASE	N20204 002 JAN 11, 1994

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL		
NEOSPORIN		
@ GLAXO WELLCOME	EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50176 002 JAN 14, 1985

NONOXYNOL-9

AEROSOL; VAGINAL		
DELFEN		
@ ORTHO	12.5%	N14349 002
SPONGE; VAGINAL		
TODAY		
@ WHITEHALL LABS	1GM	N18683 001 APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001 APR 01, 1983

POTASSIUM IODIDE

SOLUTION; ORAL		
POTASSIUM IODIDE		
+ ROXANE	1GM/ML	N18551 001 FEB 19, 1982
@	1GM/ML	N18551 001 FEB 19, 1982

PYRITHIONE ZINC

LOTION; TOPICAL		
HEAD & SHOULDERS CONDITIONER		
+ PROCTER AND GAMBLE	0.3%	N19412 002 MAR 10, 1986

PYRITHIONE ZINC

LOTION; TOPICAL
HEAD & SHOULDERS CONDITIONER
@ PROCTER AND GAMBLE 0.3% N19412 002
MAR 10, 1986

> ADD > RANITIDINE HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > ZANTAC 75
> ADD > + GLAXO WELLCOME EQ 75MG BASE N20520 001
> ADD > DEC 19, 1995

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT 6GM/100ML;0.9GM/100ML N74193
JAN 30, 1995

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January - December, 1995]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ADENO-AS'TED VIRAL-BASED VECTOR CYSTIC FIBROSIS GENE THERAPY TN=	TREATMENT OF CYSTIC FIBROSIS.	TARGETED GENETICS CORPORATION 1100 OLIVE WAY, SUITE 100 SEATTLE WA 98101 DD 02/15/95 MA / /
ALGLUCERASE INJECTION TN= CEREDASE	REPLACEMENT THERAPY IN PATIENTS WITH TYPE II AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139-1562 DD 07/21/95 MA / /
AMINOCAPROIC ACID TN=	FOR THE TOPICAL TREATMENT OF TRAUMATIC HYPHEMA OF THE EYE.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 01/06/95 MA / /
APL 400-020 TN=	TREATMENT OF CUTANEOUS T CELL LYMPHOMA.	APOLLON, INC. ONE GREAT VALLEY PARKWAY MALVERN PA 19355 DD 03/08/95 MA / /
APOMORPHINE HCL TN=	TREATMENT OF ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	PENTECH PHARMACEUTICALS, INC. 417 HARVESTER COURT WHEELING IL 60090 DD 07/17/95 MA / /
BROMODEOXYURIDINE TN=	RADIATION SENSITIZER IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	NEOPHARM, INC. 225 EAST DEERPATH, SUITE 250 LAKE FOREST IL 60045 DD 09/18/95 MA / /
CHIMERIC A2 (HUMAN-MURINE) IGG MONOCLONAL ANTI-TNF ANTIBODY (CA2) TN=	TREATMENT OF CROHN'S DISEASE.	CENTOCOR, INC 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 DD 11/14/95 MA / /
CHONDROITINASE TN=	TREATMENT OF PATIENTS UNDERGOING VITRECTOMY.	STORZ OPHTHALMICS AMERICAN CYANAMID COMPANY PEARL RIVER NY 10965 DD 02/09/95 MA / /
CLOTRIMIDAZOLE TN=	TREATMENT OF SICKLE CELL DISEASE.	BRUGNARA, CARLO M.D. THE CHILDREN'S HOSPITAL BOSTON MA 02115 DD 04/24/95 MA / /
CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS) TN= ADgvCFTR.10	TREATMENT OF CYSTIC FIBROSIS.	GENVAC, INCORPORATED 12111 PARKLAWN DRIVE ROCKVILLE MD 20852 DD 03/09/95 MA / /
ELCATONIN TN=	INTRATHECAL TREATMENT OF INTRACTABLE PAIN.	INNAPHARMA,INCORPORATED 75 MONTEBELLO ROAD SUFFERN NY 10901 DD 09/25/95 MA / /
ENCAPSULATED PORCINE ISLET PREPARATION TN= BETARX	TREATMENT OF TYPE I DIABETIC PATIENTS WHO ARE ALREADY ON IMMUNOSUPPRESSION.	VIVORX 3212 NEBRASKA AVENUE SANTA MONICA CA 90404 DD 07/05/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ETIOCHOLANEDIONE TN=	TREATMENT OF APLASTIC ANEMIA.	SUPERGEN, INC 3158 DES PLAINES AVENUE SUITE 10 DES PLAINES, IL 60018 DD 11/03/95 MA / /
FIBRINOGEN (HUMAN) TN=	FOR THE CONTROL OF BLEEDING AND PROPHYLACTIC TREATMENT OF PATIENTS DEFICIENT IN FIBRINOGEN.	ALPHA THERAPEUTIC CORPORATION 5555 VALLEY BOULEVARD LOS ANGELES CA 90032 DD 08/23/95 MA / /
FILGRASTIM TN= NEUPOGEN	FOR USE IN THE MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS FOR COLLECTION IN PATIENTS WHO WILL RECEIVE MYELOABLATIVE OR MYELOSUPPRESSIVE CHEMOTHERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/17/95 MA / /
GABAPENTIN TN= NEURONTIN	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	WARNER-LAMBERT COMPANY PARKE-DAVIS PHARMACEUTICAL RESEARCH DIV. ANN ARBOR MI 48105-2430 DD 07/05/95 MA / /
GLUTAMINE TN=	FOR USE WITH HUMAN GROWTH HORMONE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
GLYCERYL TRIOLEATE AND GLYCERYL TRIERUCATE TN= LORENZO'S OIL	TREATMENT OF ADRENOLEUKODYSTROPHY.	MOSER, HUGO W. M.D. JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21205 DD 02/14/95 MA / /
HEPATITIS B IMMUNE GLOBULIN, INTRAVENOUS TN= H-BIGIV	PROPHYLAXIS AGAINST HEPATITIS B VIRUS REINFECTION IN LIVER TRANSPLANT PATIENTS.	NORTH AMERICAN BIOLOGICS, INC. 16500 N.W. 15th AVENUE MIAMI FL 33169 DD 03/08/95 MA / /
HUMAN GROWTH HORMONE TN=	FOR USE WITH GLUTAMINE IN THE TREATMENT OF SHORT BOWEL SYNDROME (NUTRIENT MALABSORPTION FROM THE GASTROINTESTINAL TRACT RESULTING FROM AN INADEQUATE ABSORPTIVE SURFACE).	RESEARCH TRIANGLE PHARMACEUTICALS 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 DD 03/06/95 MA / /
HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TN= HIVIG	TREATMENT OF HIV-INFECTED PEDIATRIC PATIENTS.	NORTH AMERICAN BIOLOGICALS, INC. 16500 N.W. 15TH AVENUE MIAMI FL 33169 DD 01/04/95 MA / /
INTERFERON GAMMA-1B TN=ACTIMMUNE	TREATMENT OF RENAL CELL CARCINOMA.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO, CA 94080 DD 12/04/95 MA / /
INTRAVITREAL GANCICLOVIR FREE ACID IMPLANT TN= VITRASERT IMPLANT	TREATMENT OF CYTOMEGALOVIRUS RETINITIS.	CHIRON VISION 500 IOLAB DRIVE CLAREMONT CA 91711 DD 06/07/95 MA / /
KL4-SURFACTANT TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 07/17/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
KL4-SURFACTANT TN=	TREATMENT OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	COCHRANE, CHARLES G. M.D. THE SCRIPPS RESEARCH INSTITUTE 10666 NORTH TORREY PINES ROAD IMM 12 LA JOLLA, CA 92037 DD 10/18/95 MA / /
LAMOTRIGINE TN= LAMICTAL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	BURROUGHS-WELLCOME COMPANY 3030 CORNWALLIS ROAD, P.O. BOX 12700 RESEARCH TRIANGLE PK NC 27709 DD 08/23/95 MA / /
LIDOCAINE PATCH 5% TN=LIDOCAINE PATCH	TREATMENT OF POST-HERPETIC NEURALGIA RESULTING FROM HERPES ZOSTER INFECTIONS.	HIND HEALTH CARE, INC 165 GIBRALTAR COURT SUNNYVALE, CA 94089 DD 10/24/95 MA / /
MECASERMIN TN=	TREATMENT OF GROWTH HORMONE INSUFFICIENCY SYNDROME.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO, CA 94080 DD 12/12/95 MA / /
MITOLACTOL TN=	AS ADJUVANT THERAPY IN THE TREATMENT OF PRIMARY BRAIN TUMORS.	BIOPHARMACEUTICS, INC. 990 STATION ROAD BELLPORT NY 11713 DD 07/12/95 MA / /
MYCOBACTERIUM AVIUM SENSITIN RS-10 TN=	FOR USE IN THE DIAGNOSIS OF INVASIVE MYCOBACTERIUM AVIUM DISEASE IN IMMUNOCOMPETENT INDIVIDUALS.	STATENS SERUMINSTITUT 5 ARTILLERIVEJ DK-2300 COPENHAGEN S DENMARK DD 10/11/95 MA / /
NITRIC OXIDE TN=	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN ADULTS.	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION 110 ALLEN ROAD LIBERTY CORNER NJ 07938-0804 DD 07/10/95 MA / /
NTBC TN=	TREATMENT OF TYROSINEMIA TYPE 1.	SWEDISH ORPHAN AB ORPHAN PHARMACEUTICAL, USA, INC. NASHVILLE TN 37217 DD 05/16/95 MA / /
OMEGA-3 (N-3) POLYUNSATURATED FATTY ACID WITH ALL DOUBLE BONDS IN THE CIS CONFIGURATION TN=	PREVENTION OF ORGAN GRAFT REJECTION.	RESEARCH TRIANGLE PHARMACEUTICAL 4364 SOUTH ALSTON AVENUE DURHAM, NC 27713 DD 11/22/95 MA / /
PHENYLALANINE AMMONIA-LYASE TN= PHENYLASE	TREATMENT OF HYPERPHENYLALANINEMIA.	IBEX TECHNOLOGIES, INC. 5485 PARE MONTREAL, QUEBEC DD 03/08/95 MA / /
PORFIROMYCIN TN=	TREATMENT OF HEAD AND NECK CANCER.	ONCORX INC. 4 SCIENCE PARK NEW HAVEN CT 06511 DD 09/19/95 MA / /
PURIFIED TYPE II COLLAGEN TN= COLLORAL	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	AUTOIMMUNE, INCORPORATED 128 SPRING STREET LEXINGTON MA 02173 DD 02/09/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF ACUTE AND CHRONIC RESPIRATORY SYMPTOMS OF BRONCHIECTASIS.	BIOGEN, INCORPORATED 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 03/06/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN=	TREATMENT OF POST-POLIOMYELITIS SYNDROME.	CEPHALON, INC 145 BRANDYWINE PARKWAY WEST CHESTER, PA 19380 DD 10/13/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF GROWTH HORMONE RECEPTOR DEFICIENCY.	PHARMACIA, INC. PO BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR I TN= IGEF	TREATMENT OF ANTIBODY-MEDIATED GROWTH HORMONE RESISTANCE IN PATIENTS WITH ISOLATED GROWTH HORMONE DEFICIENCY IA.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 06/07/95 MA / /
RECOMBINANT HUMAN RELAXIN TN=	TREATMENT OF PROGRESSIVE SYSTEMIC SCLEROSIS.	CONNECTIVE THERAPEUTICS, INC. 3400 WEST BAYSHORE ROAD PALO ALTO, CA 94303 DD 11/03/95 MA / /
RECOMBINANT METHIONYL HUMAN STEM CELL FACTOR TN=	FOR USE IN COMBINATION WITH FILGRASTIM TO DECREASE THE NUMBER OF PHERESES REQUIRED TO COLLECT PERIPHERAL BLOOD PROGENITOR CELLS CAPABLE OF PROVIDING RAPID MULTI-LINEAGE HEMATOPOIETIC RECONSTITUTION FOLLOWING MYELOSUPPRESSIVE OR MYELOABLATIVE THERAPY.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 07/05/95 MA / /
RECOMBINANT METHIONYL HUMAN STEM CELL FACTOR TN=	TREATMENT OF PRIMARY BONE MARROW FAILURE.	AMGEN, INCORPORATED 1840 DEHAVILLAND DRIVE THOUSAND OAKS CA 91320-1789 DD 11/22/95 MA / /
RGG0853, E1A LIPID COMPLEX TN=	TREATMENT OF ADVANCED OVARIAN CANCER THAT OVEREXPRESSES THE HER-2/neu ONCOGENE.	RGENE THERAPEUTICS, INC. 2170 BUCKTHORNE PLACE, SUITE 230 THE WOODLANDS TX 77380 DD 09/19/95 MA / /
RIFAPENTINE TN=	TREATMENT OF PULMONARY TUBERCULOSIS.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 94137 DD 06/09/95 MA / /
RIFAPENTINE TN=	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	MARION MERRELL DOW INC. PO BOX 9627 (PARK A) KANSAS CITY MO 64137 DD 06/09/95 MA / /
SARGRAMOSTIM TN= LEUKINE	TO REDUCE NEUTROPENIA AND LEUKOPENIA AND DECREASE THE INCIDENCE OF DEATH DUE TO INFECTION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101 DD 03/06/95 MA / /
SORIVUDINE TN= BRAVAVIR	TREATMENT OF HERPES ZOSTER (SHINGLES) IN IMMUNOCOMPROMISED PATIENTS.	BRISTOL MYERS SQUIBB 5 RESEARCH PARKWAY P.O. BOX 5100 WALLINGFORD, CT 06492 DD 11/09/95 MA / /
STERILE AEROSOL TALC TN=	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRYAN CORPORATION 4 PLYMPTON STREET WOBURN MA 01801 DD 09/18/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
SU-101 TN=	TREATMENT OF MALIGNANT GLIOMA.	SUGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY CA 94063-4720 DD 05/25/95 MA / /
SYNSORB PK TN=	TREATMENT OF VEROCYTOTOXOGENIC E. COLI INFECTIONS.	SYNSORB BIOTECH INC. FOURTH FLOOR, 140 4TH AVENUE SW CALGARY, ALBERTA DD 07/17/95 MA / /
THALIDOMIDE TN=	TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN SEVERELY, TERMINALLY IMMUNOCOMPROMISED PATIENTS.	CELGENE CORPORATION P.O. BOX 4914 WARREN NJ 07059 DD 05/01/95 MA / /
THALIDOMIDE TN=	TREATMENT AND PREVENTION OF RECURRENT APHTHOUS ULCERS IN SEVERELY, TERMINALLY IMMUNOCPOMPROMISED PATIENTS.	ANDRULIS RESEARCH CORPORATION 11800 BALTIMORE AVENUE, SUITE 113 BELTSVILLE MD 20705 DD 05/15/95 MA / /
THALIDOMIDE TN= SYNOVIR	TREATMENT OF ERYTHEMA NODOSUM LEPROSUM.	CELGENE CORPORATION 7 POWDER HORN DRIVE, PO BOX 4914 WARREN NJ 07059 DD 07/26/95 MA / /
TRISODIUM CITRATE CONCENTRATION TN= HEMOCITRATE	FOR USE IN LEUKAPHERESIS PROCEDURES.	HEMOTEC MEDICAL PRODUCTS, INC. BOX 19255 JOHNSTON RI 02919 DD 06/15/95 MA / /
TYLOXAPOL TN=	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs 50 NORTH MEDICAL DRIVE, U OF UTAH SALT LAKE CITY UT 84132 DD 03/08/95 MA / /
URIDINE 5'-TRIPHOSPHATE TN=	TREATMENT OF CYSTIC FIBROSIS.	INSPIRE PHARMACEUTICALS, INC P.O. BOX 14285 RESEARCH TRIANGLE PARK, NC 27709 DD 12/04/95 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Approved Orphan Products in 1995		
AMIFOSTINE TN= ETHYOL	FOR USE AS A CHEMOPROTECTIVE AGENT FOR CISPLATIN IN THE TREATMENT OF ADVANCED OVARIAN CARCINOMA.	U.S. BIOSCIENCE, INC. ONE TOWER BRIDGE 100 FRONT STREET WEST CONSHOHOCKEN, PA 19428 DD 05/30/90 MA 12/08/95
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA 08/03/95
DEXRAZOXANE TN= ZINECARD	FOR THE PREVENTION OF CARDIOMYOPATHY ASSOCIATED WITH DOXORUBICIN ADMINISTRATION.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 12/17/91 MA 05/26/95
EPOPROSTENOL TN= FLOLAN	LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION IN NEW YORK HEART ASSOCIATION CLASS III AND CLASS IV PATIENTS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 09/25/85 MA 09/20/95
INTERFERON ALPHA-2A TN= ROFERON	TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML).	HOFFMAN-LA ROCHE 340 KINGSLAND STREET NUTLEY, NJ 07110-1199 DD 06/06/89 MA 10/19/95
PORFIMER SODIUM TN= PHOTOFRIN	FOR THE PHOTODYNAMIC THERAPY OF PATIENTS WITH PRIMARY OR RECURRENT OBSTRUCTING (EITHER PARTIALLY OR COMPLETELY) ESOPHAGEAL CARCINOMA.	QLT PHOTOTHERAPEUTICS, INC LEDERLE LABORATORIES 401 NORTH MIDDLETOWN ROAD PEARL RIVER, NY 10965 DD 06/06/89 MA 12/27/95
Rho (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= WinRho SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA 03/24/95
RILUZOLE TN=RILUTEK	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA 12/12/95
TRETINOIN TN= VESANOID	INDUCTION OF REMISSION IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA WHO ARE REFRACTORY TO OR UNABLE TO TOLERATE ANTHRACYCLINE BASED CYTOTOXIC CHEMOTHERAPEUTIC REGIMENS.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 10/24/90 MA 11/22/95

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1995 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
CLOZAPINE *IN VITRO* AND *IN VIVO* INTERIM (TABLET)	NOV 15, 1995	
CORTICOSTEROIDS, DERMATOLOGIC *IN VIVO* (TOPICAL)	JUN 02, 1995	
FLURBIPROFEN (TABLET)	DEC 24, 1992	JUN 08, 1995
HYDROXYCHLOROQUINE SULFATE (TABLET)	DEC 28, 1995	
NAPROXEN (TABLET)	JUN 12, 1992	JUN 08, 1995
PENTOXIFYLLINE (EXTENDED-RELEASE TABLET)	DEC 22, 1995	
SELEGILINE HYDROCHLORIDE (TABLET)	DEC 22, 1995	
TERFENADINE (TABLET)	JUN 12, 1992	SEP 11, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 15MG	94 P-0212/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 30MG	94 P-0211/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE TABLET; ORAL	150MG 180MG 60MG	94 P-0210/ CP1	MIKART	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE TABLET; ORAL	712.8MG 60MG 32MG	93 P-0484/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET, CHEWABLE; ORAL	120MG 12MG	94 P-0182/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ACETAMINOPHEN HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	95 P-0222/ CP2	MIKART	NEW STRENGTH	APPROVED NOV 21, 1995
ALBUTEROL SULFATE TABLET, CHEWABLE; ORAL	EQ 2MG BASE EQ 4MG BASE	92 P-0335/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
ATRACURIUM BESYLATE INJECTABLE; INJECTION	25MG/ML	94 P-0314/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAY 02, 1995
CALCITONIN, SALMON INJECTABLE; INJECTION	100 IU/ML (0.5ML/AMP) 1ML/AMP)	95 P-0080/ CP1	FERRING	NEW STRENGTH	APPROVED AUG 07, 1995
CAPTOPRIL SOLUTION; ORAL	25MG/ML	95 P-0008/ CP1	ROXANE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
FLUOROURACIL GEL; TOPICAL	5%	94 P-0263/ CP1	BRADLEY PHARMS	NEW DOSAGE FORM	APPROVED SEP 12, 1995
IOPAMIDOL INJECTABLE; INJECTION	61% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995
IOPAMIDOL INJECTABLE; INJECTION	76% (250ML/CONTAINER) (500ML/CONTAINER)	95 P-0073/ CP1	ABBOTT	NEW STRENGTH	APPROVED AUG 23, 1995

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (5ML/VIAL)	94 P-0433/ CP2	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (20ML/VIAL)	94 P-0433/ CP3	LEDERLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	10MG/ML (35ML/VIAL)	94 P-0433/ CP1	LEDERLE	NEW DOSAGE FORM	APPROVED AUG 07, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (100MG/VIAL)	93 P-0427/ CP3	ABBOTT	NEW DOSAGE FORM	APPROVED JAN 19, 1995
LEUCOVORIN CALCIUM INJECTABLE; INJECTION	EQ 10MG BASE/ML (250MG/VIAL)	93 P-0427/ CP2	ABBOTT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JAN 19, 1995
LORAZEPAM SOLUTION; ORAL	0.5MG/5ML	94 P-0199/ CP1	ROXANE	NEW DOSAGE FORM	APPROVED FEB 07, 1995
MEDROXYPROGESTERONE ACETATE TABLET; ORAL	2MG 4MG 8MG	92 P-0452/ CP1	CARNRICK	NEW STRENGTH	APPROVED AUG 07, 1995
METHYLPREDNISOLONE TABLET, CHEWABLE; ORAL	4MG 16MG 24MG 32MG	94 P-0432/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED AUG 07, 1995
SULFAMETHOXAZOLE; TRIMETHOPRIM TABLET, CHEWABLE; ORAL	200MG 40MG	94 P-0186/ CP1	DURA PHARMS	NEW DOSAGE FORM	APPROVED JAN 19, 1995
THIORIDAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0283/ CP1	UDL LABS	NEW STRENGTH	APPROVED JAN 19, 1995

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROMORPHONE HYDROCHLORIDE INJECTABLE; INJECTION	0.2MG/ML (50ML PREFILLED SYRINGE)	95 P-0022/ CP1	ASTRA	NEW INDICATION NEW ROUTE OF ADMINISTRATION NEW STRENGTH	DENIED SEP 07, 1995
MEFLOQUINE HYDROCHLORIDE TABLET; ORAL	275MG	94 P-0329/ CP1	LACASSE	NEW DOSING REGIMEN NEW STRENGTH	DENIED SEP 07, 1995
NICOTINE POLACRILEX LOLLIPOP; ORAL	2MG	93 P-0414/ CP1	SAVAGE	NEW DOSAGE FORM	DENIED MAY 02, 1995
NORETHINDRONE ACETATE TABLET; ORAL	1MG 2.5MG	94 P-0446/ CP1	APOTHECON	NEW INGREDIENT NEW STRENGTH	DENIED SEP 07, 1995
SELEGILINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL	10MG	94 P-0387/ CP1	PHARMAVENE	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 08, 1995
TERFENADINE TABLET, CHEWABLE; ORAL	60MG	94 P-0119/ CP1	DURA PHARMS	NEW DOSAGE FORM	DENIED AUG 23, 1995

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 15TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-26 ONCE WEEKLY APPLICATION
D-27 BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-28 USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300

REFERENCES
NEW INDICATION

I-117 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, FOLLOWING KNEE REPLACEMENT SURGERY
I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121 EXPANDED PATIENT POPULATION - USE IN ICU PATIENTS
I-122 PSORIASIS OF THE SCALP
I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126 ADJUNCT TO THALLIUM-201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128 IN PATIENTS WITH CORONARY HEART DISEASE AND HYPERCHOLESTEROLEMIA: TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE THE RISK OF NON-FATAL MYOCARDIAL INFARCTION; REDUCE THE RISK FOR UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (TYPES IIA AND IIB)
I-129 TREATMENT OF ALCOHOL DEPENDENCE
I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131 PERIPHERAL ARTERIOGRAPHY
I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136 IDIOPATHIC CHRONIC URTICARIA
I-137 PREVENTION OF MEAL-INDUCED HEARTBURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE

REFERENCES
PATENT USE CODE

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103 TREATMENT OF OCULAR HYPERTENSION
U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105 EMESIS
U-106 TREATMENT OF EPILEPSY
U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-109	USE AS AN ADJUNCT TO DIET IN THE TREATMENT OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SATURATED FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING A RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASAR SURGICAL PROCEDURES

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20482 001	ACARBOSE; PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	20482 002	ACARBOSE; PRECOSE	4904769	FEB 27, 2007		NCE	SEP 06, 2000
	19872 001	ACETAMINOPHEN; TYLENOL	5004613	JUL 27, 2007			
			4968509	NOV 06, 2007			
			4820522	JUL 27, 2007		NDF	JUN 08, 1997
	19806 001	ACRIVASTINE; SEMPREX-D	4501893	FEB 01, 2003			
	20059 001	ADENOSINE; ADENOSCAN	5070877	DEC 10, 2008	U-116	I-126	MAY 18, 1998
	18062 001	ALBUTEROL SULFATE; PROVENTIL	4499108	JUN 08, 2003			
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4353365	APR 24, 1998			
			4206758	APR 24, 1998			
	18702 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	18707 001	ALCLOMETASONE DIPROPIONATE; ACLOVATE	4124707	DEC 12, 1996			
	20560 001	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
			4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
	20560 002	ALENDRONATE SODIUM; FOSAMAX	5358941	DEC 02, 2012			
			4621077	NOV 04, 2003	U-114	NCE	SEP 29, 2000
	19353 001	ALFENTANIL HYDROCHLORIDE; ALFENTA	4167574	MAY 05, 1999			
	20379 001	ALPROSTADIL; CAVERJECT	4127118	MAR 16, 1997	U-115	NP	JUL 06, 1998
	20379 002	ALPROSTADIL; CAVERJECT	4127118	MAR 16, 1997	U-115	NP	JUL 06, 1998
>ADD>	20221 001	AMIFOSTINE; ETHYOL				ODE	DEC 08, 2002
>ADD>						NCE	DEC 08, 2000
	20377 001	AMIODARONE HYDROCHLORIDE; CORDARONE				ODE	AUG 03, 2002
						NDF	AUG 03, 1998
	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007			
	20364 002	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	20364 003	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	20364 004	AMLODIPINE BESYLATE; LOTREL	4879303	MAR 25, 2007		NC	MAR 03, 1998
			4572909	AUG 01, 2006		NCE	JUN 25, 1996
			4410520	AUG 11, 2003		NCE	JUL 31, 1997
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	4105783	JAN 15, 1997			
>ADD>	20541 001	ANASTROZOLE; ARIMIDEX				NCE	DEC 27, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19779 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	5212196	MAY 18, 2010	U-120		
	19402 001	ASTEMIZOLE; HISMANAL	4219559	APR 03, 2000			
	20259 001	ATOVAQUONE; MEPRON	4981874	AUG 15, 2009	U-69		
	20500 001	ATOVAQUONE; MEPRON	5053432	OCT 01, 2008		NCE	NOV 25, 1997
			4981874	AUG 15, 2009	U-69	NDF	FEB 08, 1998
	20428 001	AZELAIC ACID; AZELEX				NCE	SEP 13, 2000
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	AUG 11, 2003			
	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	AUG 11, 2003			
	18827 001	BETAMETHASONE DIPROPIONATE; LOTRISONE	4298604	OCT 06, 2000			
	19555 001	BETAMETHASONE DIPROPIONATE; DIPROLENE AF	4489071	DEC 09, 2003			
	19716 001	BETAMETHASONE DIPROPIONATE; DIPROLENE	4775529	MAY 21, 2007			
>ADD>	19270 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC	4342783	JUN 30, 2000			
>DLT>	~~19270 001~~	~~BETAXOLOL HYDROCHLORIDE; BETOPTIC~~	~~4342783~~	~~AUG 03, 1999~~			
>ADD>	19845 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC S	4342783	JUN 30, 2000			
>DLT>	~~19845 001~~	~~BETAXOLOL HYDROCHLORIDE; BETOPTIC S~~	~~4342783~~	~~AUG 03, 1999~~			
	20498 001	BICALUTAMIDE; CASODEX				NCE	OCT 04, 2000
	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	JUL 25, 2004			
			4438138	DEC 06, 2002			
			4435449	MAY 14, 2001			
			4425363	MAY 14, 2001			
			4393078	MAR 15, 2002			
			4347257	OCT 09, 1999			
	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000			
	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000			
	19215 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
	19359 001	BUTOCONAZOLE NITRATE; FEMSTAT	4078071	JUL 28, 1997			
	20313 002	CALCITONIN, SALMON; MIACALCIN				NDF	AUG 17, 1998
>ADD>	18469 001	CALCIUM CHLORIDE; BSS PLUS	4443432	OCT 05, 2001			
>DLT>	~~18469 001~~	~~CALCIUM CHLORIDE; BSS PLUS~~	~~4443432~~	~~APR 07, 2001~~			
	18343 001	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 002	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 003	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>ADD>	18343 004	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92		
>ADD>			4258027	MAR 26, 1999			
>ADD>			4215104	MAR 26, 1999			
>ADD>			4105776	FEB 13, 1996			
	18343 005	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
	18343 006	CAPTOPRIL; CAPOTEN	4105776	FEB 13, 1996			
>ADD>	18343 007	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92		
>ADD>			4258027	MAR 26, 1999			
>ADD>			4215104	MAR 26, 1999			
>ADD>			4105776	FEB 13, 1996			
	18709 001	CAPTOPRIL; CAPOZIDE 25/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 002	CAPTOPRIL; CAPOZIDE 25/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 003	CAPTOPRIL; CAPOZIDE 50/25	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	18709 004	CAPTOPRIL; CAPOZIDE 50/15	4217347	DEC 27, 1997			
			4105776	FEB 13, 1996			
	19856 001	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19856 002	CARBIDOPA; SINEMET CR	4900755	JUN 16, 2006			
			4832957	JUN 16, 2006			
>ADD>	20297 001	CARVEDILOL; COREG	4503067	MAR 05, 2002	U-3	NCE	SEP 14, 2000
>ADD>	20297 002	CARVEDILOL; COREG	4503067	MAR 05, 2002	U-3	NCE	SEP 14, 2000
>ADD>	20297 003	CARVEDILOL; COREG	4503067	MAR 05, 2002	U-3	NCE	SEP 14, 2000
>ADD>	19835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC				NCE	DEC 08, 2000
>ADD>	19835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC				NCE	DEC 08, 2000
	20044 001	CETYL ALCOHOL; EXOSURF NEONATAL	5110806	MAY 02, 2006			
			4312860	AUG 20, 2003			
	18663 001	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	18663 002	CHYMOPAPAIN; CHYMODIACTIN	4439423	MAY 13, 2001			
	20238 001	CIMETIDINE; TAGAMET HB				NS	JUN 19, 1998
						I-137	NOV 15, 1998
	19847 001	CIPROFLOXACIN; CIPRO	4670444	DEC 09, 2003			
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5286754	FEB 15, 2011			
			4670444	DEC 09, 2003	U-36		
>ADD>	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	DEC 09, 2003			
>DLT>	~~19992 001~~	~~CIPROFLOXACIN HYDROCHLORIDE; CILOXAN~~	~~4670444~~	~~OCT 01, 2002~~			
	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID				NCE	JUL 29, 1998
>ADD>	20551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012		NE	DEC 15, 1998
>ADD>	20551 002	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012		NE	DEC 15, 1998
>ADD>	20551 003	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012		NE	DEC 15, 1998
	18891 001	CLONIDINE; CATAPRES-TTS-1	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 002	CLONIDINE; CATAPRES-TTS-2	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	18891 003	CLONIDINE; CATAPRES-TTS-3	4559222	MAY 04, 2003			
			4201211	JUL 12, 1997			
	20222 001	COLESTIPOL HYDROCHLORIDE; COLESTID				NDF	JUL 19, 1997
	12142 006	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
	12142 007	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
12142 008	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
12142 009	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
12142 010	CYCLOPHOSPHAMIDE; LYOPHILIZED CYTOXAN	4537883	NOV 12, 2002			
20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2000		NCE	DEC 22, 1999
19849 001	DAPIPRAZOLE HYDROCHLORIDE; REV-EYES	4252721	FEB 07, 2003			
20071 001	DESOGESTREL; DESOGEN	3927046	NOV 06, 1996			
20071 002	DESOGESTREL; DESOGEN	3927046	NOV 06, 1996			
20301 001	DESOGESTREL; ORTHO-CEPT	3927046	NOV 06, 1996			
20301 002	DESOGESTREL; ORTHO-CEPT	3927046	NOV 06, 1996			
20212 001	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
					ODE	MAY 26, 2002
20212 002	DEXRAZOXANE HYDROCHLORIDE; ZINECARD				NCE	MAY 26, 2000
					ODE	MAY 26, 2002
20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		5286497	MAY 20, 2011			
20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		5286497	MAY 20, 2011			
20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		5286497	MAY 20, 2011			
20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5470584	MAY 20, 2011			
		5439689	AUG 08, 2012	U-107		
		5286497	MAY 20, 2011			
20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	DEC 09, 2006		I-133	OCT 15, 1995
20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC				NS	SEP 11, 1998
20411 001	DINOPROSTONE; CERVIDIL	5269321	DEC 14, 2010	U-110		
		4931288	JAN 16, 2007		NDF	MAR 30, 1998
18723 001	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
18723 002	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
18723 003	DIVALPROEX SODIUM; DEPAKOTE	4988731	JAN 29, 2008		I-132	MAY 26, 1998
20408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	DEC 12, 2004	U-103	NCE	DEC 09, 1999
		4619939	OCT 28, 2003	U-104		
19946 001	DOXACURIUM CHLORIDE; NUROMAX				I-121	DEC 08, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19668 001	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 002	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 003	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	19668 004	DOXAZOSIN MESYLATE; CARDURA	4188390	OCT 18, 2000		I-96	FEB 06, 1998
	20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	DEC 09, 2001	U-95		
	19221 003	ENALAPRIL MALEATE; VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000		NS	JUL 12, 1998
	19616 004	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
	19616 005	ENOXACIN; PENETREX	4442101	FEB 04, 2002			
	20164 001	ENOXAPARIN SODIUM; LOVENOX				I-118	MAR 09, 1998
>ADD>	20530 001	EPINEPHRINE; IONTOCAINE				NP	DEC 21, 1998
	20444 001	EPOPROSTENOL SODIUM; FLOLAN				NCE	SEP 20, 2000
>ADD>						ODE	SEP 20, 2002
	20444 002	EPOPROSTENOL SODIUM; FLOLAN				NCE	SEP 20, 2000
>ADD>						ODE	SEP 20, 2002
	18418 001	ERGOLOID MESYLATES; HYDERGINE	4138565	MAY 26, 1996			
	18706 001	ERGOLOID MESYLATES; HYDERGINE LC	4366145	JUN 24, 2001			
	19081 002	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
	19081 003	ESTRADIOL; ESTRADERM	4379454	FEB 17, 2001			
	20323 001	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 002	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 003	ESTRADIOL; VIVELLE	5300291	APR 05, 2011		NS	OCT 28, 1997
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20323 004	ESTRADIOL; VIVELLE	5300291	APR 05, 2011			
			4994278	MAR 04, 2008			
			4994267	MAR 04, 2008			
			4814168	MAR 04, 2008			
	20375 001	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997
	20375 002	ESTRADIOL; CLIMARA	5223261	JUN 29, 2010		D-26	DEC 22, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	86069 001	ESTRADIOL; ESTRACE	4436738	MAR 15, 2002			
	20303 001	ESTROGENS, CONJUGATED; PREMPRO (PREMARIN;CYCRIN 14/14)	4826831	MAY 02, 2006	U-102	NP	DEC 30, 1997
	20527 001	ESTROGENS, CONJUGATED; PREMPRO 14/14	4826831	MAY 02, 2006	U-102		
	18977 001	ETHINYL ESTRADIOL; TRI-NORINYL 21-DAY	4390531	AUG 10, 2001			
	18977 002	ETHINYL ESTRADIOL; TRI-NORINYL 28-DAY	4390531	AUG 10, 2001			
	18985 001	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-21	4628051	SEP 26, 2003			
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003			
			4530839	SEP 26, 2003			
	18985 002	ETHINYL ESTRADIOL; ORTHO-NOVUM 7/7/7-28	4628051	SEP 26, 2003			
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003			
			4530839	SEP 26, 2003			
	19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003	U-66		
			4530839	SEP 26, 2003	U-112		
	19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	SEP 26, 2003	U-66		
			4616006	SEP 26, 2003			
			4544554	SEP 26, 2003	U-66		
			4530839	SEP 26, 2003	U-112		
>ADD>	20363 003	FAMCICLOVIR; FAMVIR				I-138	DEC 11, 1998
>ADD>						NCE	JUN 29, 1999
	19462 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
	19462 002	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
	19510 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
	19527 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
	20249 001	FAMOTIDINE; PEPCID	4283408	OCT 15, 2000			
	20325 001	FAMOTIDINE; PEPCID AC	4283408	OCT 15, 2000		NS	APR 28, 1998
	20189 001	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
			4978680	SEP 26, 2009	U-83		
	20189 002	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
			4978680	SEP 26, 2009	U-83		
	20189 003	FELBAMATE; FELBATOL	5082861	SEP 26, 2009	U-83		
			4978680	SEP 26, 2009	U-83		
	19834 001	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
			4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19834 002	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996
19834 004	FELODIPINE; PLENDIL	4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3	NCE	JUL 25, 1996
19813 001	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 002	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 003	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19813 004	FENTANYL; DURAGESIC	4588580	JUL 23, 2004	U-43		
19960 001	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 002	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 003	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19960 004	FLOSEQUINAN; MANOPLAX	4302460	MAR 24, 2000			
19949 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
19949 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
19949 003	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
19950 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
20090 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
20090 002	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
20322 001	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
20073 001	FLUMAZENIL; ROMAZICON	4316839	OCT 10, 2004			
18148 001	FLUNISOLIDE; NASALIDE	4933168	JUN 12, 2007			
18340 001	FLUNISOLIDE; AEROBID	4933168	JUN 12, 2007			
20409 001	FLUNISOLIDE; NASAREL	4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
		4782047	MAY 22, 2006			
19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				I-122	FEB 16, 1998
19957 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	NOV 14, 2003			
19958 001	FLUTICASONE PROPIONATE; CUTIVATE	4335121	NOV 14, 2003			
20121 001	FLUTICASONE PROPIONATE; FLONASE	4335121	NOV 14, 2003		NCE	DEC 14, 1995
					NDF	OCT 19, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20261 001	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-109	NCE	DEC 31, 1998
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4339445	JUL 29, 1997	U-64	I-127	JUN 16, 1998
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002			
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002			
	19915 004	FOSINOPRIL SODIUM; MONOPRIL	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000		I-92	MAY 02, 1998
			4337201	DEC 04, 2002		NCE	MAY 16, 1996
	20286 001	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
			4337201	DEC 04, 2002			
	20286 002	FOSINOPRIL SODIUM; MONOPRIL-HCT	5006344	JUL 10, 2009			
			4384123	DEC 04, 2000			
			4337201	DEC 04, 2002			
	20235 001	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	20235 002	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	20235 003	GABAPENTIN; NEURONTIN	4087544	MAY 02, 1996	U-86		
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	5362475	NOV 08, 2011			
	20460 001	GANCICLOVIR; CYTOVENE	4507305	OCT 19, 1999	U-64	NDF	DEC 22, 1997
>ADD>			4355032	JUN 23, 2003	U-64	I-140	OCT 27, 1998
	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4507305	MAY 21, 2001	U-35		
			4423050	MAY 21, 2001	U-34		
			4355032	JUN 23, 2003	U-64		
>ADD>	20496 001	GLIMEPIRIDE; AMARYL	4379785	DEC 17, 2000	U-118	NCE	NOV 30, 2000
>ADD>	20496 002	GLIMEPIRIDE; AMARYL	4379785	DEC 17, 2000	U-118	NCE	NOV 30, 2000
>ADD>	20496 003	GLIMEPIRIDE; AMARYL	4379785	DEC 17, 2000	U-118	NCE	NOV 30, 2000
	20329 001	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20329 002	GLIPIZIDE; GLUCOTROL XL	5091190	JUN 18, 2008	U-111		
			5082668	SEP 16, 2003			
			5024843	SEP 05, 2009			
			4612008	SEP 16, 2003			
			4327725	NOV 25, 2000		NDF	APR 26, 1997
>ADD>	19726 001	GOSERELIN ACETATE; ZOLADEX	4100274	APR 22, 1999		I-139	DEC 18, 1998
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-105	NCE	DEC 29, 1998
						NDF	MAR 16, 1998
	19059 001	HYDROCHLOROTHIAZIDE; INDERIDE LA 80/50	4138475	SEP 14, 1997			
	19059 002	HYDROCHLOROTHIAZIDE; INDERIDE LA 120/50	4138475	SEP 14, 1997			
	19059 003	HYDROCHLOROTHIAZIDE; INDERIDE LA 160/50	4138475	SEP 14, 1997			
	19129 001	HYDROCHLOROTHIAZIDE; MAXZIDE	4444769	JUL 27, 2002			
	19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25	4444769	JUL 27, 2002			
	20387 001	HYDROCHLOROTHIAZIDE; HYZAAR	5153197	OCT 06, 2009	U-3	NC	APR 28, 1998
			5138069	AUG 11, 2009		NCE	APR 14, 2000
	19842 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		I-123	MAR 24, 1998
	20135 001	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20135 002	IBUPROFEN; MOTRIN	5320855	JUN 14, 2011		I-123	MAR 24, 1998
			5215755	JUN 01, 2010		NDF	NOV 16, 1997
	20418 001	IBUPROFEN; MOTRIN				I-123	MAR 24, 1998
	20516 001	IBUPROFEN; CHILDREN'S MOTRIN	5374659	DEC 20, 2011		NP	JUN 16, 1998
>ADD>	20491 001	IBUTILIDE FUMARATE; CORVERT	5155268	OCT 13, 2009		NCE	DEC 28, 2000
	18185 001	INDOMETHACIN; INDOCIN SR	4173626	DEC 11, 1998			
	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131				ODE	MAR 25, 2001
	18956 007	IOHEXOL; OMNIPAQUE 70	4396597	JUL 14, 1998			
			4250113	DEC 26, 1999			
	18735 001	IOPAMIDOL; ISOVUE-M 200	4001323	NOV 24, 1997			
	18735 002	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
	18735 003	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997		D-28	MAY 15, 1998
	18735 004	IOPAMIDOL; ISOVUE-M 300	4001323	NOV 24, 1997			
	18735 007	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
	20327 001	IOPAMIDOL; ISOVUE-200	4001323	NOV 24, 1997			
	20327 002	IOPAMIDOL; ISOVUE-250	4001323	NOV 24, 1997			
	20327 003	IOPAMIDOL; ISOVUE-300	4001323	NOV 24, 1997			
	20327 004	IOPAMIDOL; ISOVUE-370	4001323	NOV 24, 1997			
	20220 001	IOPROMIDE; ULTRAVIST 370	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20220 002	IOPROMIDE; ULTRAVIST 300	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	20220 003	IOPROMIDE; ULTRAVIST 240	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	20220 004	IOPROMIDE; ULTRAVIST 150	4364921	DEC 21, 1999	U-113	NCE	MAY 10, 2000
	19710 005	IOVERSOL; OPTIRAY 350				I-131	JUN 21, 1998
	18905 002	IOXAGLATE MEGLUMINE; HEXABRIX	4014986	MAY 20, 1997			
>ADD>	20316 001	IOXILAN; OXILAN-300				NCE	DEC 21, 2000
>ADD>	20316 002	IOXILAN; OXILAN-350				NCE	DEC 21, 2000
>ADD>	20393 001	IPRATROPIUM BROMIDE; ATROVENT	4385048	MAY 24, 2000	U-119	NDF	OCT 20, 1998
>ADD>	20394 001	IPRATROPIUM BROMIDE; ATROVENT	4385048	MAY 24, 2000	U-119	NDF	OCT 20, 1998
	20225 003	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
						NCE	DEC 30, 1996
	20336 001	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	4816263	OCT 02, 2007	U-3		
	20083 001	ITRACONAZOLE; SPORANOX	4267179	JUN 23, 2000			
	19816 002	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	19816 003	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
>ADD>	20429 001	KETOPROFEN; ORUDIS KT				NS	OCT 06, 1998
>ADD>	20499 001	KETOPROFEN; ACTRON				NS	OCT 06, 1998
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55		
	19698 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
	19698 002	KETOROLAC TROMETHAMINE; TORADOL	4089969	JUL 14, 1998	U-55	NR	DEC 07, 1997
	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4454151	MAR 22, 2002	U-75		
			4089969	JUL 14, 1998	U-55		
	18686 001	LABETALOL HYDROCHLORIDE; NORMODYNE	4328213	NOV 28, 1999			
	20564 001	LAMIVUDINE; EPIVIR				NCE	NOV 17, 2000
	20596 001	LAMIVUDINE; EPIVIR				NCE	NOV 17, 2000
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2003	U-106	NCE	DEC 27, 1999
	20406 001	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20406 002	LANSOPRAZOLE; PREVACID	5093132	SEP 03, 2008			
			5045321	SEP 03, 2008			
			5026560	JUN 25, 2008			
			4689333	JUL 29, 2005			
			4628098	JUL 29, 2005		NCE	MAY 10, 2000
>ADD>	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
			4005063	JAN 25, 1996		I-119	MAR 30, 1998
>ADD>	20263 001	LEUPROLIDE ACETATE; LUPRON	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>	20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
>ADD>	20263 005	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4849228	JUL 18, 2006			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
			4005063	JAN 25, 1996			
>ADD>	20263 006	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	5476663	APR 17, 2007			
			5330767	NOV 01, 2004			
			4917893	NOV 01, 2004			
			4849228	JUL 18, 2006			
			4728721	MAY 01, 2006			
			4677191	JUL 03, 2005			
			4652441	NOV 01, 2004			
			4005063	JAN 25, 1996			
>ADD>	20517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5476663	APR 17, 2007		NP	DEC 22, 1998
>ADD>			5330767	NOV 01, 2004			
>ADD>			4954298	NOV 01, 2004			
>ADD>			4917893	NOV 01, 2004			
>ADD>			4849228	JUL 18, 2006			
>ADD>			4728721	MAY 01, 2006			
>ADD>			4677191	JUL 03, 2005			
>ADD>			4652441	NOV 01, 2004			
	18027 001	LITHIUM CARBONATE; LITHOBID	4264573	MAY 21, 1999			
>ADD>	20191 001	LODOXAMIDE TROMETHAMINE; ALOMIDE	5457126	OCT 10, 2012	U-117	NCE	SEP 23, 1998
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	FEB 21, 2006	U-36		
	19658 001	LORATADINE; CLARITIN	4282233	JUN 19, 2002	U-77	I-136	SEP 20, 1998
	19670 001	LORATADINE; CLARITIN-D	4282233	JUN 19, 2002		NCE	APR 12, 1998
	20386 001	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009		NCE	APR 14, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20386 002	LOSARTAN POTASSIUM; COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009		NCE	APR 14, 2000
19643 002	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19643 003	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19643 004	LOVASTATIN; MEVACOR	4231938	JUN 15, 2001		I-117	FEB 08, 1998
19940 001	MASOPROCOL; ACTINEX	4695590	SEP 04, 2006		NCE	SEP 04, 1997
19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM	4579855	OCT 01, 2004			
20207 001	MELPHALAN HYDROCHLORIDE; ALKERAN	4997651	NOV 18, 2008			
19884 001	MESNA; MESNEX	4220660	MAR 06, 2001			
19600 001	METHOXSALEN; OXSORALEN-ULTRA	4454152	DEC 21, 2001			
18029 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN-SR	4137300	AUG 20, 1996			
19962 001	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
19962 002	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
19962 003	METOPROLOL SUCCINATE; TOPROL-XL	5081154	JAN 14, 2009			
		5001161	MAR 19, 2008			
		4957745	SEP 18, 2007	U-107	NE	JAN 10, 1995
20531 001	METRONIDAZOLE; METROCREAM				NDF	SEP 20, 1998
18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		I-125	APR 26, 1997
19268 001	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
19268 003	MISOPROSTOL; CYTOTEC	4301146	JUL 29, 2000			
20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
20312 002	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4743450	FEB 24, 2007		NCE	APR 19, 2000
19625 001	MOMETASONE FUROATE; ELOCON	4808610	OCT 02, 2006			
19796 001	MOMETASONE FUROATE; ELOCON	4775529	MAY 21, 2007			
20459 001	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
20459 002	NALMEFENE HYDROCHLORIDE; REVEX				NCE	APR 17, 2000
18932 001	NALTREXONE HYDROCHLORIDE; REVIA				I-129	DEC 30, 1997
20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2001			
19488 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	FEB 15, 1996			
19488 002	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	FEB 15, 1996			
19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	5164405	NOV 17, 2009			
		4880823	NOV 14, 2006			
		3985758	FEB 15, 1996			
20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
		3985758	FEB 15, 1996			
20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
		3985758	FEB 15, 1996			
20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	5198226	MAR 30, 2010			
		3985758	FEB 15, 1996			
20076 001	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20076 002	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20076 003	NICOTINE; HABITROL	4597961	JAN 23, 2005	U-56		
20150 001	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20150 002	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20150 003	NICOTINE; NICOTROL	4915950	FEB 12, 2008			
20165 001	NICOTINE; NICODERM	5462745	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
20165 002	NICOTINE; NICODERM	5462745	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
20165 003	NICOTINE; NICODERM	5462745	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5004610	JUN 14, 2008			
19684 001	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 002	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			
19684 003	NIFEDIPINE; PROCARDIA XL	4327725	NOV 25, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20198 001	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20198 002	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20198 003	NIFEDIPINE; ADALAT CC	5264446	NOV 23, 2010			
		4892741	JUN 08, 2008			
20356 001	NISOLDIPINE; SULAR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 002	NISOLDIPINE; SULAR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 003	NISOLDIPINE; SULAR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20356 004	NISOLDIPINE; SULAR	4892741	JUN 08, 2008			
		4154839	NOV 02, 1996		NCE	FEB 02, 2000
20064 001	NITROFURANTOIN; MACROBID	4798725	JUN 16, 2006			
		4772473	JUN 16, 2006			
20145 001	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 002	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 003	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 004	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 005	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
20145 006	NITROGLYCERIN; NITRO-DUR	5186938	FEB 16, 2010			
19508 001	NIZATIDINE; AXID	4375547	APR 12, 2002			
19508 002	NIZATIDINE; AXID	4375547	APR 12, 2002			
19384 002	NORFLOXACIN; NOROXIN	4639458	JAN 22, 2005			
		4146719	FEB 16, 2000			
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 14, 2003			
		4146719	FEB 16, 2000			
19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	OCT 21, 2002			
19735 001	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			
19735 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			
19735 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2003			
20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20087 002	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
	20087 003	OFLOXACIN; FLOXIN	4382892	SEP 02, 2001			
	20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
	20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	SEP 02, 2001			
	19810 001	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
			4786505	APR 20, 2007	U-108	I-130	JUN 22, 1998
			4255431	APR 05, 2001	U-108		
	19810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108		
			4786505	APR 20, 2007	U-108		
			4255431	APR 05, 2001	U-108		
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44		
			4695578	JAN 25, 2005		D-20	FEB 02, 1996
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
			4695578	JAN 25, 2005		NCE	JAN 04, 1996
						I-9	APR 19, 1998
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-27	APR 10, 1998
			4695578	JAN 25, 2005		NCE	JAN 04, 1996
						I-9	APR 19, 1998
	20403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U-44	D-20	FEB 02, 1996
			4695578	JAN 25, 2005		NCE	JAN 04, 1996
						I-9	AUG 13, 1996
	19828 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
	20209 001	OXICONAZOLE NITRATE; OXISTAT	4124767	DEC 27, 1996			
>ADD>	20553 001	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5266331	FEB 05, 2008			
>ADD>			4970075	NOV 13, 2007			
>ADD>			4861598	AUG 29, 2006			
>ADD>	20553 002	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5266331	FEB 05, 2008			
>ADD>			4970075	NOV 13, 2007			
>ADD>			4861598	AUG 29, 2006			
>ADD>	20553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5266331	FEB 05, 2008			
>ADD>			4970075	NOV 13, 2007			
>ADD>			4861598	AUG 29, 2006			
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
>ADD>			3962432	JAN 09, 1998	U-53	NCE	OCT 31, 1996
>DLT>			~~3962432~~	~~JUL 16, 1996~~	~~U-53~~	~~NCE~~	~~OCT 31, 1996~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
>ADD>			3962432	JAN 09, 1998	U-53	NCE	OCT 31, 1996
>DLT>			~~3962432~~	~~JUL 16, 1996~~	~~U-53~~	~~NCE~~	~~OCT 31, 1996~~
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	JUL 29, 2005		I-135	SEP 01, 1998
>ADD>			3962432	JAN 09, 1998	U-53	NCE	OCT 31, 1996
>DLT>			~~3962432~~	~~JUL 16, 1996~~	~~U-53~~	~~NCE~~	~~OCT 31, 1996~~
	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	SEP 24, 2008	U-12		
	19385 001	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
			4166182	FEB 08, 2000			
	19385 002	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
			4166182	FEB 08, 2000			
	19385 003	PERGOLIDE MESYLATE; PERMAX	4797405	OCT 26, 2007			
			4166182	FEB 08, 2000			
>ADD>	20451 001	PORFIMER SODIUM; PHOTOFRIN				NCE	DEC 27, 2000
	17850 001	POTASSIUM CHLORIDE; KLOTRIX	4140756	JUN 10, 1996			
	18238 001	POTASSIUM CHLORIDE; MICRO-K	4259315	JUN 13, 2000			
	18238 002	POTASSIUM CHLORIDE; MICRO-K 10	4259315	JUN 13, 2000			
	19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4259315	JUN 13, 2000			
	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005			
	19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
	19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	4327725	NOV 25, 2000			
	19627 001	PROPOFOL; DIPRIVAN	4798846	MAR 19, 1997			
			4056635	MAR 19, 1997			
	18553 001	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 002	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 003	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	18553 004	PROPRANOLOL HYDROCHLORIDE; INDERAL LA	4138475	SEP 14, 1997			
	19536 001	PROPRANOLOL HYDROCHLORIDE; INDERAL	4600708	JUL 19, 2005			
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4929605	OCT 07, 2007	U-81		
			4254129	APR 10, 1999	U-81		
	20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAR 14, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	FEB 24, 2007			
			4344949	AUG 17, 2001	U-3		
	19901 001	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 002	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 003	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	19901 004	RAMIPRIL; ALTACE	5061722	OCT 29, 2008	U-3	I-134	AUG 22, 1998
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4880636	MAY 13, 2008			
			4128658	JUL 25, 1997		I-120	MAR 29, 1998
	19090 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4128658	JUL 25, 1997			
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4128658	JUL 25, 1997			
	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	APR 29, 2003			
			4521431	JUN 04, 2002			
			4128658	JUL 25, 1997			
>ADD>	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	5068249	NOV 26, 2008			
			4585790	MAY 11, 2004		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	FEB 22, 2010		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
	20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	JUN 23, 2009		I-120	MAR 29, 1998
			4128658	JUL 25, 1997			
>ADD>	20520 001	RANITIDINE HYDROCHLORIDE; ZANTAC 75				NS	DEC 19, 1998
>ADD>	20599 001	RILUZOLE; RILUTEK				ODE	DEC 12, 2002
>ADD>						NCE	DEC 12, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20474 001	RIMEXOLONE; VEXOL	4686214	OCT 30, 2005	U-100	NCE	DEC 30, 1999
>DLT>	~~20474 001~~	~~RIMEXOLONE; VEXOL~~	~~4686214~~	~~AUG 11, 2004~~	~~U-100~~	~~NCE~~	~~DEC 30, 1999~~
	20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	APR 13, 2008			
	20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	APR 13, 2008			
	20236 001	SALMETEROL XINAFOATE; SEREVENT	5380922	MAY 14, 2013			
>ADD>	20628 001	SAQUINAVIR MESYLATE; INVIRASE				NCE	DEC 06, 2000
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012	U-12		
			4962128	NOV 02, 2009	U-12		
	20478 001	SEVOFLURANE; ULTANE				NCE	JUN 07, 2000
	19766 001	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 002	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 003	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19766 004	SIMVASTATIN; ZOCOR				I-128	JUN 30, 1998
	19721 001	SOMATROPIN, BIOSYNTHETIC; NORDITROPIN				NS	MAY 08, 1998
	19721 002	SOMATROPIN, BIOSYNTHETIC; NORDITROPIN				NS	MAY 08, 1998
>ADD>	20522 001	SOMATROPIN, BIOSYNTHETIC; NUTROPIN AQ				NP	DEC 29, 1998
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2001	U-3	NCE	DEC 29, 1999
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U-72		
	20132 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
			4816470	DEC 28, 2006	U-72		
	20132 002	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
			4816470	DEC 28, 2006	U-72		
	20132 003	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U-72		
			4816470	DEC 28, 2006	U-72		
>DLT>	~~19387 001~~	~~SUPROFEN; PROFENAL~~	~~4035376~~	~~JUL 12, 1994~~			
>DLT>	~~19387 001~~	~~SUPROFEN; PROFENAL~~	~~4035376~~	~~JUL 12, 1996~~			
	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
			4631286	OCT 25, 2004	U-97		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	OCT 01, 2006	U-82		
		4631286	OCT 25, 2004	U-97		
19829 001	TECHNETIUM TC-99M EXAMETAZIME KIT; CERETEC	4789736	DEC 06, 2005		I-124	APR 07, 1998
		4615876	OCT 07, 2003			
19981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; ULTRATAG	4755375	JUL 05, 2005	U-51		
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997	U-3		
20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			
20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
		5294615	APR 29, 2013			
		5212176	JUN 29, 2010			
		4112097	JAN 21, 1997			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5412095	APR 29, 2013			
			5294615	APR 29, 2013			
			5212176	JUN 29, 2010			
			4112097	JAN 21, 1997			
	18949 001	TERFENADINE; SELDANE	4254129	APR 10, 1999	U-81		
	20489 001	TESTOSTERONE; ANDRODERM				NS	SEP 29, 1998
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	MAY 27, 2003			
	20439 001	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
	20439 002	TIMOLOL; BETIMOL	5231095	JUL 27, 2010		NP	MAR 31, 1998
	20136 001	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
	20136 002	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
	20136 003	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
	20136 004	TORSEMIDE; DEMADEX	RE34672	AUG 11, 2006			
	20137 002	TORSEMIDE; DEMADEX	4861786	JUL 08, 2007			
			RE34672	AUG 11, 2006			
	20281 001	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
	20281 002	TRAMADOL HYDROCHLORIDE; ULTRAM				NCE	MAR 03, 2000
	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
			4215104	MAR 26, 1999			
	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 26, 1999			
			4215104	MAR 26, 1999			
>ADD>	20438 001	TRETINOIN; VESANOID				ODE	NOV 22, 2002
	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	JAN 23, 2007	U-85		
	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	MAY 20, 2006	U-91		
			4376858	OCT 31, 2000			
	20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
	20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924	SEP 18, 2007		NE	JUN 23, 1998
	18776 002	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
			4237126	AUG 20, 1999			
	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	AUG 20, 1999			
			4237126	AUG 20, 1999			
	20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
	20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
	20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
	20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
	20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2002			
	19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
	19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
	19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	JUN 19, 2007	U-3		
	20388 001	VINORELBINE TARTRATE; NAVELBINE	4307100	AUG 20, 1999		NCE	DEC 23, 1999
	19655 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
			4833130	SEP 17, 2005			
			4828838	SEP 17, 2005			
			4818538	SEP 17, 2005			
			4724232	SEP 17, 2005			
	19910 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
			4833130	SEP 17, 2005			
			4818538	SEP 17, 2005			
			4724232	SEP 17, 2005			
	19951 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
			4833130	SEP 17, 2005			
			4818538	SEP 17, 2005			
			4724232	SEP 17, 2005			
>ADD>	20518 001	ZIDOVUDINE; RETROVIR	4837208	SEP 17, 2005			
>ADD>			4833130	SEP 17, 2005			
>ADD>			4828838	SEP 17, 2005			
>ADD>			4818538	SEP 17, 2005			
>ADD>			4724232	SEP 17, 2005			
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	OCT 21, 2006	U-74		
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	OCT 21, 2006	U-74		

*U.S. Government Printing Office: 1996 - 404-907/20006

New 16th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7809

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $72.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature)

(10/95)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.